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Abstract 
In the past decade several candidate malaria vaccines have undergone clinical trials in artificial challenge studies 
and studies of natural infection under field conditions. GlaxoSmithKline’s RTS,S vaccine against Plasmodium 
falciparum infection has taken the lead, with Phase III trials in African children demonstrating 55.8% (97.5% CI, 
51.3% - 59.8%) efficacy against clinical malaria and 34.8% (95% CI, 16.2% – 49.2%) efficacy against severe malaria. 
Mathematical models can contribute to multiple stages of malaria vaccine development, from measuring efficacy 
in clinical trials, understanding the relationship between naturally acquired and vaccine-induced immunity, 
identifying correlates of protection, and predicting the likely impact of vaccination programs in the field. 
When measuring vaccine efficacy in field trials under natural exposure to malaria, there are many factors which 
can bias estimates of efficacy. We demonstrate how heterogeneity in exposure can cause efficacy to be 
underestimated and heterogeneity in vaccine response can cause efficacy to be overestimated. 
Most infection-blocking vaccines rely on boosting some element of the pre-erythrocytic immune response, 
however the relationship between the naturally acquired pre-erythrocytic responses and protection from 
infection remains poorly understood. By analysing studies from a systematic of the published literature, I 
demonstrate that although many studies report a statistically significant relationship between cellular pre-
erythrocytic immune responses and protection from infection, many studies do not have sufficient statistical 
power to evaluate the effects of the pre-erythrocytic immune response. 
Mathematical models are developed for investigating the relationship between pre-erythrocytic antibodies and 
protection from infection, and fitted to data from a longitudinal study of malaria infection in Kenyan adults. The 
relationship between antibodies to the antigens circumsporozoite protein (CSP) and thrombospondin-related 
adhesion protein (TRAP) and protection from infection is characterised using dose-response curves.  
Using data from an artificial challenge trial of the RTS,S malaria vaccine, I demonstrate that vaccine-induced 
protection from infection depends on both anti-CSP antibodies and CSP-specific T cells. I estimate that RTS,S 
causes a 97.7% (95% CI, 96.3% – 98/7%) reduction in the number of parasites entering the blood from the liver. 
The immune effector mechanisms determining the duration of vaccine-induced protection from infection are 
likely to be similar to those involved in naturally acquired immunity. Models of antibody kinetics were fitted to 
data from longitudinal studies of the antibody response to P. falciparum infection in Ghanaian and Gambian 
children, and the parameters determining the duration of antibody response are estimated. 
Upon licensure, a successful malaria vaccine is likely to be administered to young African children. A model of 
malaria transmission, extensively fitted to clinical data, is used to investigate the impact of vaccination in different 
transmission settings; the interaction between vaccines and other interventions such as insecticide treated nets; 
and the interaction between vaccination and naturally acquired immunity. Finally, the potential cost-effectiveness 
of vaccination is explored. 
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Chapter 1. Introduction 
 
1.1. Background 
In 1967 Nussenzweig et al [1] reported that mice immunized with radiation-attenuated Plasmodium berghei 
sporozoites developed sterile immunity against further infection, a finding subsequently repeated by Vanderberg 
et al [2]. Buoyed by these early successes, the challenge of developing an effective vaccine for malaria in humans 
appeared to lie in translating these findings from animal models to appropriate technology for the immunisation 
of humans, as had been done for other human pathogens. Studies followed demonstrating that following 
exposure to the bites of large numbers of infectious irradiated mosquitoes, sterile immunity to infection could be 
induced in humans challenged with either Plasmodium falciparum [3-5] or Plasmodium vivax [6]. An effective 
malaria vaccine appeared to be just around the corner. However progressing from immunity induced by the bites 
of infectious mosquitoes to immunity induced by vaccination proved to be an unexpectedly challenging hurdle. A 
similar pattern of optimism followed by failure was repeated in the 1990’s with the development of the SPf66 
malaria vaccine where initial indications of efficacy in South American trials [7] were followed by disappointing 
results in Africa and Asia [8, 9]. 
The successes and failures in the malaria vaccine development effort were mirrored by those in the wider malaria 
control effort. In the 1950’s the World Health Organisation (WHO) launched the Global Malaria Elimination 
Project (GMEP) with the laudable aim of eliminating malaria from many of the world’s endemic countries [10]. 
Based on indoor residual spraying with the recently discovered insecticide DDT and effective treatment with 
chloroquine, the program experienced early successes eliminating malaria from several countries including Spain 
and Italy [11]. Unfortunately these early successes were followed by failure as resistance to both DDT and 
chloroquine emerged. Notably, the GMEP made no serious attempt to tackle malaria in sub-Saharan Africa where 
transmission was at its most intense. The early optimism for widespread malaria elimination was replaced by a 
resigned acceptance that malaria was here to stay. Following this disappointment the problem of malaria 
elimination was reduced to waiting for a vaccine [12], arguably to the detriment of innovative research into other 
tools for malaria control. 
In the past decade there has been renewed enthusiasm for widespread control of malaria, and even elimination 
in some settings, built upon advances in malaria control tools, in particular insecticide treated nets [13] and 
effective treatment with artemisinin combination therapies (ACTs) [14]. Against this background of increased 
research into more traditional malaria control tools targeting the vector with insecticides and the parasite with 
drugs, there has finally been substantial progress towards an effective vaccine, with several promising candidates 
under development [15-17]. The most advanced candidate is GlaxoSmithKline’s RTS,S vaccine which has 
demonstrated 55% efficacy against clinical malaria and 47% efficacy against severe malaria [15]. Phase III trials are 
15 
 
scheduled for completion in 2014 after which the vaccine is likely to become licensed and available as a tool for 
protecting young African children from malaria. 
 
1.2. Epidemiology of malaria 
1.2.1. Burden of malaria 
Malaria, caused by the Plasmodium parasite, inflicts an enormous burden of morbidity and mortality on the 
world’s population, the bulk of which is borne by young children and pregnant women living in P. falciparum 
endemic regions of sub-Saharan Africa (Figure 1.1). The annual number of deaths attributable to malaria was 
estimated to be 655,000 in 2010 [18], although this number has been in steady decline for the past decade [19]. 
P. falciparum is just one of the five species of parasite responsible for malaria in humans, the others being P. 
vivax, P. ovale, P. malariae and P. knowlesei. Often neglected in the past, P. vivax is increasingly being recognised 
as a major public health problem with an estimated 132 – 391 million cases per year [20]. Approximately 2.6 
billion people live in P. vivax endemic areas, predominantly in South and East Asia and parts of South America 
[21]. P. vivax is rare in most parts of Africa due to very high prevalence of the Duffy-negative phenotype which 
confers resistance to P. vivax infection [22]. P. malariae and P. ovale are usually found at low prevalence 
throughout Africa, Asia and South America [23, 24] and give rise to mild illness, although the full range of clinical 
outcomes remain poorly understood [24]. P. knowlesei was thought to only infect old world monkeys but has 
recently been diagnosed in humans in Malaysian Borneo [25] and is increasingly being recognised as potentially 
life threatening [26].   
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Figure 1.1: Estimated number of malaria cases per 1,000 population in 99 endemic countries in 2009. Figure reproduced from Cibulskis et 
al [19]. 
 
1.2.2. The lifecycle of the Plasmodium falciparum parasite 
The lifecycle of the Plasmodium falciparum parasite begins when an infectious Anopheles mosquito takes a blood 
meal from a human host (Figure 1.2). As the mosquito feeds, sporozoites (the infectious stage of the parasite) are 
inoculated into the skin through the mosquito’s proboscis. Sporozoites migrate through the skin until they reach a 
blood vessel and travel to the liver in the blood circulation. Once in the liver a sporozoite will invade a hepatocyte 
and transform into a trophozoite [27]. The trophozoite undergoes schizogonic development and differentiates 
into approximately 20,000 merozoites [28] over a period of approximately 6.5 days [29]. The combined skin and 
liver stage of the parasite lifecycle is termed the pre-erythrocytic stage. Hepatic merozoites enter the blood from 
the liver to begin the erythrocytic stage of the lifecycle. Merozoites rapidly invade red blood cells, typically on a 
time scale of less than 10 minutes, where they replicate and differentiate into 8 – 32 merozoites over a period of 
two days after which the infected blood cell ruptures releasing the next generation of merozoites into the blood 
stream [30]. The rupturing of infected red blood cells every two days results in the periodic cycle of fever 
characteristic of clinical malaria. A proportion of merozoites will differentiate into male or female gametocytes – 
the sexual stage of the parasite. Gametocytes circulate in the blood stream until they are ingested by another 
mosquito taking a blood meal.  
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The parasites’ multiplication in the mosquito is known as the sporogonic cycle. In the mosquito’s midgut, male 
microgametes penetrate female macrogametes generating zygotes. The zygotes in turn become motile ookinetes 
which invade the midgut wall where they develop into oocysts. The oocysts grow, rupture and release sporozoites 
which migrate to the mosquito’s salivary glands [30]. When the mosquito next takes a blood meal from a human, 
sporozoites are inoculated as the mosquito salivates, thus completing the parasites’ lifecycle.   
 
 
Figure 1.2: The lifecycle of the malaria parasite in humans and mosquitoes. Figure reproduced from Johns Hopkins Open Courseware: "Life 
cycle of the malaria parasite" from Epidemiology of Infectious Diseases. © Johns Hopkins Bloomberg School of Public Health. Creative 
Commons BY-NC-SA. 
 
 
1.2.3. Malaria transmission 
Ever since Ronald Ross and Giovanni Grassi first demonstrated that malaria was transmitted from mosquitoes to 
humans [31], malariologists have been measuring the transmission of malaria and the effects of malaria on 
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exposed populations. Malaria transmission can be quantified using measurements from epidemiological studies. 
The entomological inoculation rate (EIR) measures the average number of infectious bites per person per year 
(ibppy). The EIR is usually estimated from the number of mosquitoes taking a blood meal on a human adult over a 
day and the proportion of mosquitoes testing positive for sporozoites. Not all infectious mosquito bites progress 
to blood-stage malaria, either due to chance [32] or due to an infection-blocking immune response [33]. The 
number of infectious bites that progress to blood stage malaria is termed the force of infection. The proportion of 
a population infected with malaria is measured by the parasite prevalence or parasite rate (PfPR for P. falciparum) 
– defined to be the proportion of a cross-sectional cohort testing positive for parasites. The parasite prevalence 
will depend on the method used for parasite detection, with parasite prevalences measured by PCR generally 
being higher than those measured by slide microscopy [34]. Malaria infection can either be asymptomatic with no 
detectable clinical symptoms, or progress to an episode of clinical malaria – usually defined as fever plus parasite 
density above a given threshold. The average number of episodes of clinical malaria per person per year is termed 
the clinical incidence. A proportion of episodes of clinical malaria will progress to severe malaria. Severe malaria 
can be measured on a population level as the number of cases per person year at risk, but in practice is often 
measured via the number of cases presenting to hospital [35]. There are several manifestations of severe malaria, 
including but not limited to, severe anemia, cerebral malaria and respiratory distress. Variation in the diagnosis of 
severe malaria can lead to variation in estimates of severe malaria incidence [36, 37]. The relationship between 
these epidemiological measures is shown in Figure 1.3. 
A number of malariological quantities derived from entomological data on vector behaviour are also of 
importance for malaria transmission. The stability index gives a measure of an environments capacity to sustain 
malaria transmission and is defined to be the expected number of human bites taken by a vector over its lifetime 
[38]. The vectorial capacity estimates the number of infectious bites on humans that arise from all the mosquitoes 
that are infected by a single person on a single day [39]. The human blood index measures the proportion of 
mosquito blood meals that are taken from humans. The basic reproductive number (R0) is defined as the expected 
number of human cases that would arise from a typical malaria case in an otherwise uninfected population with 
no immunity and no control [40].  
 
Figure 1.3: Schematic diagram of the relationship between epidemiological measurements of malaria transmission and clinical outcomes. 
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In addition to its average intensity, malaria transmission can also be characterised by its variation. Heterogeneity 
in malaria transmission exists on all spatial scales, from large scale variation between geographic regions to 
micro-heterogeneity within a single household. Large scale variation in transmission is primarily due to 
differences in climate [41], vector species distribution [42] and economic development. On a community or village 
level, heterogeneity in transmission can arise due to proximity to larval breeding sites [43] or variation in the 
quality of housing [44]. Mosquito biting is heterogeneous even between members of the same household due to 
different sleeping patterns or olfactory cues [45, 46].  
Malaria transmission also shows substantial temporal variation, primarily driven by seasonal changes in mosquito 
densities, which are in turn regulated by climatic factors [47]. Most malaria endemic regions experience some 
degree of seasonality dependent on their rainfall patterns [48], with transmission at its highest during the rainy 
season and at its lowest during the dry season. 
  
1.2.4. The Anopheles mosquito 
Although there are thousands of species of mosquito belonging to several genera, only one genus, Anopheles, is 
capable of transmitting malaria to humans. The genus Anopheles contains around 430 known species, but only 40 
of these are competent malaria vectors [49]. The most important vectors in sub-Saharan Africa are An. gambiae 
sensu stricto, An. arabiensis and An. funestus. The Anopheles mosquito begins its life upon emergence from a 
pupa in a larval breeding site. Both male and female mosquitoes feed on sugar from nearby plants and mate in 
swarms. Female mosquitoes must take a blood meal from an animal host to facilitate egg production – hence only 
female mosquitoes are responsible for malaria transmission. After feeding, a mosquito must rest while the blood 
meal is digested and eggs develop in the abdomen. After a period of 2 – 3 days [50], the mosquito will search for a 
suitable breeding site and oviposit 50 – 200 eggs [51]. The duration between consecutive blood meals is termed 
the gonotrophic cycle, and is a key quantity for malaria control as it determines the expected number of bites a 
mosquito will make in her lifetime. Oviposited eggs develop into larvae which feed on bacteria, yeasts, protozoa 
and particulate organic matter in the water. Growth takes place via a series of moults through four 
morphologically distinct larval instars. Fourth instar larvae moult to become non-feeding pupae which develop 
into adult mosquitoes. The duration of the larval period depends mainly on temperature and, in tropical areas, 
lasts 7-15 days [52].   
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1.3. Immunity to malaria 
1.3.1. Naturally acquired immunity to malaria 
Children and adults living in malaria-endemic areas acquire substantial protection from malaria, but rarely, if ever, 
achieve sterile immunity. The rate of acquisition of immunity is both age [53] and exposure [54] dependent, 
leading to non-linear patterns of immunity across a population. Effective immunity to malaria is acquired in a 
sequential manner, with rapid development of immunity to severe malaria, followed by immunity to episodes of 
clinical malaria, and finally the acquisition of immune tolerance to blood-stage parasites [55].  
Young children are particularly vulnerable to episodes of severe malaria after maternally acquired immunity has 
waned and before the acquisition of effective immunity [56]. The acquisition of immunity to severe malaria is 
believed to be rapid, requiring only one or two infections [57], however there is substantial variation in the rates 
of acquisition of immunity to different forms of severe malaria, with cerebral malaria manifesting in older children 
[35]. Immunity to episodes of clinical malaria is acquired at a slower rate than immunity to severe malaria with a 
peak in clinical incidence occurring in children between 1 – 10 years of age depending on the intensity of 
transmission (Figure 1.4). 
 
Figure 1.4: Annual clinical incidence of malaria in the Senegalese villages of Dielmo (EIR = 200 ibppy) and Ndiop (EIR = 20 ibppy). The 
patterns demonstrate that clinical incidence peaks earlier in high transmission settings. Figure reproduced from Smith et al [58] based on 
data from Trape and Rogier [59].  
 
Patterns of immunity to asymptomatic parasite infection are observable in studies of age-stratified parasite 
prevalence [60-62] with the highest prevalence rates typically being in younger children before the acquisition of 
effective immunity (Figure 1.5). These patterns can be explained by two types of immune response: a blood-stage 
immune response controlling parasite densities, a pre-erythrocytic immune response that prevents infections, or 
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a combination of the two. The relative contribution of these two types of immune response to protection from 
parasites has been difficult to estimate from epidemiological data [63, 64]. 
 
Figure 1.5: Prevalence of P. falciparum parasites by age stratified by altitude band and region. Triangles, Tanga < 600m; circles, Tanga 600 – 
1200m; squares, Kilimanjaro 600 – 1200m; plus signs, Tanga > 1200m; crosses, Kilimanjaro > 1200m. Figure reproduced from Drakeley et al 
[60]. 
 
1.3.2. Immunology of malaria 
Upon entering a host, the malaria parasite must first invade and replicate within hepatocytes in the liver, and 
then erythrocytes in the blood, before finally differentiating into gametocytes that circulate in the blood. The 
parasites face a succession of challenges during this process, as they must overcome physical barriers and evade 
both non-specific innate responses and adaptive immune responses. Upon exposure to blood-stage parasites the 
non-specific innate immune response is first to be activated, triggering a release of cytokines which inhibit 
parasite development, and allow effective priming of the adaptive antibody and cell-mediated immune responses 
[65].  
After initial exposure to malaria parasites, the adaptive immune response is primed. Protection against malaria 
can be induced by the following mechanisms: antibodies opsonise and immobilise sporozoites and block invasion 
into liver cells [66]; interferon-γ (IFN-γ) and CD8+ T cells inhibit parasite development in hepatocytes [16]; 
antibodies block invasion of merozoites into erythrocytes; and IFN-γ and CD4+ T cells activate macrophages which 
phagocytose infected red blood cells and free merozoites. 
Underlying the adaptive immune response is the phenomenon of pattern recognition of parasite antigens by 
lymphocytes: either B cells responsible for humoral immunity or T cells responsible for cell-mediated immunity. In 
a simplified model of the human immune system, antigen presenting cells internalise parasite antigen and 
present it to T cells and B cells [67]. T cells proliferate into antigen-specific CD4+ or CD8+ T cells which provide cell-
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mediated immunity in the liver and blood. When antigen-specific memory B cells (MBC) recognise a presented 
antigen they will undergo proliferation generating an expanded memory B cell compartment [68] (Figure 1.6). 
Some MBCs will terminally differentiate into either short-lived or long-lived plasma B cells which reside in survival 
niches in the spleen or bone marrow [69]. Plasma B cells, also referred to as antibody secreting cells, are 
responsible for generating the immunoglobulin (Ig) antibodies which are the basis of the humoral immune 
response. There are five classes of immunoglobulin antibody: IgG, IgA, IgD, IgE and IgM. The first time an 
individual is exposed to a particular antigen, the majority of antibody produced is IgM. Upon re-exposure to the 
same antigen, a rapid secondary response can be mounted in which large amounts of antibody of other classes 
are produced, most notably IgG. 
 
 
Figure 1.6: Schematic model of the immunological processes underlying the generation of IgG antibody. Upon recognition of parasite 
antigen, memory B cells proliferate and terminally differentiate into short-lived or long-lived plasma cells. Plasma cells continuously secrete 
the antibodies required for maintaining humoral immunity.   
 
 
1.3.3. Antibodies to P. falciparum antigens 
Sequencing of the P. falciparum genome has identified approximately 5,400 proteins [70], although which of 
these proteins elicit the production of protective antibodies remains unclear [71]. There are a small number of 
well studied antigens of the pre-erythrocytic, erythrocytic and sexual stages of the parasite.  
At the pre-erythrocytic stage, the circumsporozoite protein (CSP) covers the entire surface of the sporozoite and 
is found on the plasma membrane of liver-stage parasites [72]. Antibodies to CSP immobilize sporozoites and 
inhibit parasite invasion of hepatocytes [73]. Thrombospondin-related adhesive protein (TRAP) is found primarily 
near the tip of the sporozoite (the microneme) [74]. Antibodies to TRAP inhibit sporozoite gliding motility and 
hepatocyte invasion [75]. Liver-stage antigen 1 (LSA-1) and liver-stage antigen 3 (LSA-3) are expressed once the 
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sporozoite invades a liver hepatocyte. As LSA-1 and LSA-3 are expressed only in the hepatocyte which antibodies 
are unable to access, they are not expected to provide protection from infection, although they are likely targets 
of cell-mediated immunity [76]. 
Several proteins have been identified that are expressed on the surface of merozoites, or during merozoite 
invasion of erythrocytes, the most well studied being merozoite surface protein 1 (MSP-1), merozoite surface 
protein 2 (MSP-2), apical membrane antigen 1 (AMA-1), and erythrocyte binding antigen 175 (EBA-175). 
Antibodies to these blood-stage antigens have been shown to inhibit parasite replication, and correlate with 
protection from clinical malaria [77].  
Members of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family of proteins are particularly 
important as they allow binding of infected red blood cells to the vascular endothelium [78]. This sequestration 
enables parasites to remove themselves from the blood circulation and to avoid spleen-dependent immune 
mechanisms. Sequestration is associated with the pathogenesis of severe malaria and pregnancy associated 
malaria [79]. PfEMP1 proteins are encoded by approximately 60 members of the var gene family, only one of 
which is expressed at a time. Sequential switching between var genes allows the P. falciparum parasite to avoid 
recognition by the immune system while sequestered [80]. 
  
1.4. Malaria control and elimination 
The past decade has seen dramatic declines in cases of P. falciparum malaria across a range of settings 
throughout the world [19]. These declines have been associated with increased distribution of long-lasting 
insecticide-treated nets and a switch from failing drug regimens to artemisinin-based combination therapies as 
first-line treatment [81, 82]. Although changing trends in the epidemiology of malaria are often attributed to 
expanded coverage of malaria control interventions [83, 84], often discussed but rarely researched explanations 
for the decline in malaria are increased economic development and urbanisation [85].     
Following a call from the Bill and Melinda Gates Foundation in 2007 there has been a renewed sense of optimism 
in the malaria community regarding prospects for malaria eradication [86]. The Gates Foundation, endorsed by 
WHO [87], has called for the global eradication of the malaria parasite by expanding coverage of existing 
interventions and investing in the development of new interventions such as vaccines. Although the steps taken 
towards the different targets of malaria control, elimination or eradication are often identical, there are some key 
differences between these aims [87]: 
 Malaria control is reducing the disease burden to a level at which it is no longer a public health problem. 
 Malaria elimination is interrupting local mosquito-borne malaria transmission in a defined geographical 
area, i.e. zero incidence of locally contracted cases. 
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 Malaria eradication is the permanent reduction to zero of the worldwide incidence of malaria infection 
caused by a specific agent; i.e. applies to a particular malaria parasite species. 
Whether or not eradication is possible in the foreseeable future is a contentious issue but local elimination should 
be possible in many parts of the world [88]. 
 
1.4.1. Malaria control interventions 
There is a wide range of existing malaria control interventions that target the parasite and vector at several stages 
of their respective lifecycles. Anti-malarial drugs can be used to treat clinical episodes of malaria and clear 
patients of parasitemia by targeting blood-stage parasites. In the past chloroquine and sulphadoxine-
pyrimethamine (SP) were widely used as first-line treatment for malaria, however the emergence of drug 
resistance has rendered these drugs ineffective in many regions [89]. The current first-line treatment in almost all 
malaria endemic countries is artemisinin combination therapy (ACT) – an artesunate drug combined with a longer 
lasting partner drug. ACTs have the additional benefit of killing gametocytes, thus reducing onward malaria 
transmission from humans to mosquitoes [90]. Improvements in treatment have also been accompanied by 
improved diagnostic techniques, in particular rapid diagnostic tests (RDTs) which allow malaria parasites to be 
quickly tested for [91]. RDTs can prevent over-diagnosis of malaria leading to cost savings on treatment, improved 
health outcomes for patients without malaria, and can reduce the risk of emergence of drug resistance.  
In addition to treating malaria, anti-malarial drugs can be used as preventive interventions. There are several 
interventions based on the use of anti-malarial drugs as prevention: 
 Intermittent preventive therapy in infants (IPTi) protects infants in the vulnerable first months of life by 
administering several courses of drugs, usually SP [92]. 
 Intermittent preventive therapy in pregnant women (IPTp) protects pregnant women from their second 
trimester onwards by administering SP – due to safety considerations the only drug for such use [93].  
 Seasonal malaria chemoprophylaxis (SMC) – previously referred to as IPT in children – protects school 
age children in regions with high seasonality of transmission by administering drugs throughout the rainy 
season [94]. 
 Mass drug administration (MDA) involves treatment of an entire population with drugs to reduce 
parasite rates and malaria transmission [95]. 
 Mass screen and treat (MSAT) involves screening a population for parasites using diagnostic tools such as 
RDTs and only treating those identified as parasite positive [95]. 
Arguably, the most effective interventions for preventing malaria are those that target the vector, either by killing 
the mosquito outright or by preventing contact between mosquitoes and human. The most important vector 
control interventions are: 
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 Insecticide treated bed nets (ITNs) protect the user by creating a physical barrier around their sleeping 
space with a net [13]. Treating the net with a pyrethroid insecticide provides additional protection by 
killing any mosquitoes that contact the net. 
 Long lasting insecticidal nets (LLIN) are a technological improvement on ITNs. Whereas ITNs need to be 
regularly re-treated with insecticide, in LLINs the insecticide is impregnated in the fibre of the net. If 
maintained properly, an LLIN can remain efficacious for 3-5 years [96]. 
 Indoor residual spraying (IRS) involves spraying the inside walls of houses in a community with residual 
insecticide [97]. Community level protection is conferred by reducing the size of the mosquito population 
and repelling mosquitoes from sprayed houses. There are several classes of insecticide suitable for IRS 
including pyrethroids, carbamates and DDT. 
 Larviciding involves the application of insecticides to larval breeding sites to kill the aquatic stages of the 
mosquito [98]. 
There are several other novel vector control tools under development including genetically modified mosquitoes 
[99], sterile insect techniques [100], attractive toxic sugar bait [101], auto-dissemination of insecticides by adult 
mosquitoes [102], improved housing structure [44], and insecticide treating of cattle to target outdoor biting 
mosquitoes [103].  
 
1.5. Malaria vaccines 
Perhaps the most important class of novel interventions under development are vaccines. Malaria vaccines can 
be split into three categories depending on the stage of the Plasmodium parasite targeted (Figure 1.7). 
 Pre-erythrocytic vaccines (PEV) prevent infection with malaria by targeting the pre-erythrocytic stages of 
the parasite, namely sporozoites inoculated into the skin by blood-feeding mosquitoes and the intra-
cellular forms of the parasite in liver hepatocytes. 
 Blood-stage vaccines (BSV) do not prevent malaria infection but reduce the probability of clinical or 
severe episodes of malaria by reducing blood-stage parasite densities. 
 Transmission-blocking vaccines (TBV) aim to prevent transmission of the Plasmodium parasite from 
human to mosquito, either by targeting the sexual stages of the parasite in humans or by interrupting the 
process of parasite development in mosquitoes who have taken a blood meal from a vaccinated human. 
TBVs do not confer direct protection to the vaccinated individual, but instead protect the wider 
community by reducing transmission intensity. 
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Figure 1.7: Lifecycle of the P. falciparum parasite with targets for pre-erythrocytic, blood-stage and transmission-blocking vaccines 
highlighted. Figure reproduced from PATH Malaria Vaccine Initiative (http://www.malariavaccine.org/malvac-lifecycle.php).  
 
In each of the three categories, there are several candidate vaccines currently undergoing clinical trials. All 
vaccines currently undergoing clinical trials, and those which have been discontinued are described in detail in the 
WHO’s rainbow tables [104]. The most promising candidates in each of the categories are summarised in Table 
1.1. 
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Table 1.1: A selection of malaria vaccines currently being tested in clinical trials based on data from the WHO’s Rainbow Table [104]. 
Vaccine Developer Antigen Trial 
phase 
Countries 
tested 
Registration Reference 
Pre-erythrocytic vaccines 
RTS,S/AS01E GlaxoSmithKline CSP Phase III several sub-
Saharan countries 
NCT00866619 Agnandji [15] 
Ad35 vectored 
CSP+ 
RTS,S/AS01 
GlaxoSmithKline CSP Phase I/IIa Belgium, USA NCT01366534 Shott [105] 
ChAd63/MVA 
ME-TAP 
University of Oxford TRAP + 
multiple 
epitopes 
Phase I/IIa UK, Gambia NCT00890760 Reyes-
Sandoval[106] 
PfSPZ Sanaria, Inc. Whole 
sporozoite 
Phase I/IIa USA NCT01001650 Epstein [16] 
       
Blood-stage vaccines 
FMP2.1/AS02 GlaxoSmithKline  AMA1 Phase II Mali NCT00460525 Thera [107] 
AMA1-C1/ 
Alhydrogel 
NIAID AMA1 Phase II Mali NCT00341250 Sagara [108] 
AdCh63/MVA 
MSP1 
University of Oxford MSP1 Phase Ia UK NCT01003314 Sheehy [109] 
       
Transmission-blocking vaccines 
Pfs25 NIAID Pfs25 Phase I USA NCT00295581  Wu [110] 
  
1.5.1. Clinical trials for testing malaria vaccines 
Candidate malaria vaccines must be tested for safety, immunogenicity and efficacy in clinical trials. In addition, 
clinical trials are used to provide data to regulatory authorities, assess how vaccines can be integrated into 
existing health systems, and to contribute to research and development into vaccine technology. Clinical trials can 
also be used to test vaccines on groups of special interest such as young children and pregnant women. A full set 
of clinical trials for a candidate malaria vaccine can take up to 15 years, involve up to 50,000 volunteers, and cost 
$500 million or more [111, 112].  
The following is a summary of the typical clinical trial phases for a candidate malaria vaccine according to 
guidelines from PATH Malaria Vaccine Initiative [113]. 
 Research and preclinical development involves identifying relevant antigens, testing in animal models, 
combining with adjuvants, developing manufacturing processes, and conducting preclinical evaluation. 
 Phase I clinical trials assess the safety profile of a candidate vaccine and its ability to induce a relevant 
immune response. Trials usually involve less than 100 volunteers and last for up to a year. For malaria, 
trials conducted in non-endemic countries on malaria-naïve volunteers are classified as Phase Ia trials, 
and trials in endemic countries on malaria-exposed volunteers are classified as Phase Ib trials. If the 
vaccine is found to be safe it can proceed to Phase II trials. 
 Phase II clinical trials monitor safety and potential side effects, immunogenicity, and produce estimates 
of efficacy against infection, clinical malaria or severe malaria. Phase II trials can involve up to a few 
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thousand volunteers and can last for several years. Phase IIa trials are usually undertaken in non-endemic 
countries on malaria-naïve volunteers who are vaccinated and then artificially challenged with infection 
via exposure to infectious mosquitoes. Volunteers are monitored for signs of parasites and treated with 
anti-malarial drugs if necessary. Phase IIb trials are undertaken in malaria-endemic countries under 
conditions of natural exposure to malaria. If the vaccine demonstrates suitable safety and efficacy, it can 
proceed to Phase III trials.    
 Phase III clinical trials monitor safety and potential side effects, and evaluate efficacy on a large scale 
across a range of transmission settings. Phase III trials can include thousands of volunteers and last for up 
to five years. If Phase III trials demonstrate safety and sufficient efficacy, the manufacturer can apply for a 
license to bring the vaccine to market, and submit a plan for long-term, post-licensure safety monitoring. 
 Phase IV clinical trials involve monitoring the safety and effectiveness of a vaccine post-licensure. They 
do not involve comparisons against a control group. Additional monitoring ensures that any rare or 
delayed serious adverse events are identified. Phase IV trials can also evaluate the duration of protection, 
and effectiveness when the vaccine is delivered through different health systems. 
 
1.5.2. Measuring vaccine efficacy  
Malaria is a disease with a complex life history. As such, vaccination can affect infection rates, episodes of clinical 
and severe malaria, and malaria associated deaths. This diversity of outcomes makes designing field trials for 
estimating vaccine efficacy against multiple endpoints a challenging problem. Summarised below are the 
endpoints against which pre-erythrocytic or blood-stage vaccines can be evaluated. 
 Efficacy against infection estimates the reduction in the force of infection due to vaccination. Only pre-
erythrocytic vaccines are expected to reduce the incidence of infection in the absence of community-wide 
effects. Measuring infection-blocking requires clearing volunteers of parasites with an anti-malarial and 
following them with active case detection (ACD) for infection by testing for parasites every week or 
fortnight. 
 Efficacy against clinical malaria estimates the reduction in the incidence of clinical malaria due to either 
pre-erythrocytic or blood-stage vaccines. Measuring efficacy against clinical malaria requires monitoring 
volunteers for episodes of clinical malaria with ACD of malaria episodes or passive case detection (PCD) 
where symptomatic episodes of malaria are reported by the trial participants. Efficacy against clinical 
malaria will depend on the definition of an episode of clinical malaria: usually taken to be fever plus 
parasite density above a given cut-off, e.g. > 2500 parasites/µL. The choice of parasite density cut-off will 
affect the efficacy estimate: too high a cut-off and sensitivity will be low, too low a cut-off and specificity 
will be lost as fever due to other causes may be classified as due to malaria [114]. 
 Efficacy against severe malaria measures the vaccine-induced reduction in the incidence of severe 
malaria. Efficacy estimates will depend on the clinical definition of an episode of severe malaria, usually 
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defined according to WHO guidelines [37]. Clinical trials for estimating efficacy against severe malaria 
need to be large to ensure sufficient statistical power to detect an effect as the incidence of severe 
malaria can often be low. 
 Efficacy against malaria-associated death estimates the reduction in deaths attributable to malaria due 
to vaccination. As deaths due to malaria can often be quite rare, (particularly in clinical trials where access 
to good quality healthcare is high) most clinical trials are underpowered to evaluate vaccine efficacy 
against death. In addition to efficacy against malaria-attributable deaths, the efficacy against all cause 
mortality can be estimated [115]. 
Due to the epidemiology of malaria transmission, almost all volunteers in trials in endemic settings are likely to 
develop infection and many will experience multiple episodes of clinical malaria. For malaria, vaccine efficacy can 
thus be measured either against the first episode of malaria, or against multiple episodes. Furthermore, 
calculation of vaccine efficacy can be either risk-based or rate-based [116]. Risk-based efficacy is based on the 
difference in malaria associated events between the vaccine and control groups a fixed time after vaccination. It 
can be defined as 
 
events in vaccine group
risk-based efficacy  1
events in control group
 
 If the force of infection is high such that the majority of volunteers experience an event, then risk-based 
measures of efficacy can be uninformative. Furthermore, risk-based measurements do not properly account for 
delayed times to event due to vaccination. An alternative is to use rate-based measures of efficacy which account 
for person years at risk (PYAR): the time between vaccination and first event or censoring at the end of the trial. 
Rate-based efficacy can be defined as  
 
events in vaccine group PYAR
rate-based efficacy  1
events in control group PYAR
 
Estimates of rate-based vaccine efficacy based on time to first event can be calculated from clinical trial data 
using Cox Proportional Hazards (Cox PH) analysis which allow estimates to be adjusted for covariates such as LLIN 
use, gender, trial site and age [117]. Vaccine efficacy against multiple events can be calculated using regression 
models adjusted for covariates. Poisson regression models have been used for analysis of data from Phase II 
clinical trials of RTS,S [118], but there has been a switch to negative binomial regression models for the analysis of 
Phase III trial data to capture the over-dispersion in the incidence of malaria [117].  
Malaria vaccines are not characterised by their efficacy alone, the variation in efficacy between individuals and 
the duration of efficacy must also be considered. The variation in efficacy of a partially efficacious vaccine can be 
described by two simple models: leaky and all-or-nothing [119]. A leaky vaccine with 50% efficacy will provide 
50% protection to all vaccinees, whereas an all-or-nothing vaccine with 50% efficacy will provide 100% protection 
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to 50% of vaccinees and no protection to the other 50%. In reality the protection profile of a vaccine is likely to be 
heterogeneous, providing a different level of protection to all vaccinees [120]. 
The efficacy induced by existing vaccines to several pathogens has been observed to wane over time [121], with 
malaria vaccines likely to be no different. Two models for the waning of vaccine efficacy have been proposed: the 
selection and deterioration models [122]. In the selection model, waning arises from heterogeneity in the 
duration of protection, i.e. a vaccinated person is protected for a period of time dependent on the vaccine half-
life and then loses all protection. In the deterioration model, waning arises from the gradual decline in an 
individual’s efficacy. The rate of waning of vaccine efficacy under both models can be estimated from extended 
follow up of clinical trials by fitting an interaction between time and vaccination status in Cox regression models.  
 
1.5.3. The RTS,S malaria vaccine 
During the development of the hepatitis B vaccine, it was reported that viral surface proteins (HBsAg, also known 
as S antigen) could be made to spontaneously assemble into viral particles devoid of DNA [123]. Scientists 
working at GlaxoSmithKline (GSK) in collaboration with the Walter Reed Army Institute of Research (WRAIR) were 
able to fuse the Asparagine-Alanine-Asparagine-Proline (NANP) repeat of the P. falciparum CSP antigen to the N-
terminus of HbsAg, and produce virus like particles in yeast cells (Saccharomyces cerevisiae) [124]. High anti-CSP 
antibody titres were induced in mice immunized with these particles. In order to induce a cell-mediated immune 
response, a second generation particle expressing the NANP repeats of the CSP protein plus T cell epitopes from 
the C-terminal of the CSP protein was created. To stabilise these viral particles, they were co-expressed in yeast 
cells with wild-type HBsAg antigen. The result was RTS,S comprised of 25% RTS (B cell repeats (R) + T cell epitopes 
(T) + HBsAg (S) antigen) and 75% wild-type HBsAg (S) antigen [125]. 
Modern vaccine formulations are considered very pure, presenting only a small number of carefully selected 
antigens to the immune system, in contrast to older vaccines such as BCG for immunisation against tuberculosis 
which expose the vaccinee to thousands of antigens and cause the immune system to react aggressively. When a 
vaccine is administered with an adjuvant, the adjuvant safely triggers danger signals that mobilise a strong 
immune response to the vaccine antigens [126]. GSK tested a number of different adjuvant systems (AS) with 
RTS,S, the most successful formulations being AS02 and AS01.  AS02 is an adjuvant system that contains an oil-in-
water emulsion and the immunostimulants monophosphoryl lipid A (MPL) and QS21 [127]. AS01 is a related 
liposome-based adjuvant system that also contains MPL and QS21. 
RTS,S has been tested extensively in both laboratory and field trials [128]. In laboratory studies conducted at 
WRAIR, malaria-naïve volunteers were vaccinated with RTS,S and then challenged with the bites of five P. 
falciparum infectious mosquitoes [129]. The resulting efficacy against infection was 32% (95% CI, 18% - 48%) and 
50% (95% CI, 33% - 67%) for RTS,S/AS02 and RTS,S/AS01, respectively. RTS,S has undergone extensive testing in 
Phase II field trials at multiple sites and in varying age groups (Table 1.2). Across these trials, the efficacy against 
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clinical malaria has been estimated to be approximately 30% and 50% for RTS,S/AS02 and RTS,S/AS01, 
respectively. However, there is significant heterogeneity in vaccine efficacy due to differences in age, 
transmission intensity and choice of adjuvant (P. Bejon, M. White et al – in preparation). In addition efficacy is 
likely to wane over time, although individual Phase II trials are underpowered to estimate rates of waning. 
Phase III clinical trials of RTS,S/AS01 began in 2009 in children from 11 trial sites in 7 sub-Saharan countries. In 
total, 15,460 children were enrolled in two age categories, 6 to 12 weeks of age and 5 to 17 months of age [15]. 
Children were randomly assigned to three study groups in a 1:1:1 ratio, with one group receiving a control 
vaccine, a second receiving 3 doses of RTS,S/AS01 at 1-month intervals, and a third receiving RTS,S/AS01 plus a 
booster dose 18 months after the third dose. First results from a cohort of 6,000 children in the 5 to 17 month 
category indicate an efficacy of 55.8% (97.5% CI, 50.6% - 60.4%) against clinical malaria (Figure 1.8), and 47.3% 
(95% CI, 22.4% - 64.2%) against severe malaria. In the combined age categories, followed for an average duration 
of 16 months after the third dose of vaccine, the efficacy against severe malaria was 34.8% (95% CI, 16.2% - 
49.2%). Data from Phase III trials so far has not allowed a statistically significant estimate of efficacy against 
malaria-attributable deaths.     
 
 
Figure 1.8: Cumulative incidence of first or only episode of clinical malaria in a cohort of children vaccinated with RTS,S/AS01 and a control 
cohort. Children are from the according-to-protocol cohort and are followed for 12 months. Figure reproduced from Agnandji et al [15]. 
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1.5.4. Vaccination campaigns 
Should RTS,S/AS01 demonstrate sufficient safety and efficacy upon completion of Phase III clinical trials in 2014, it 
will be submitted to regulatory authorities for approval to market. Pending regulatory approval, RTS,S/AS01 may 
be available as a tool for controlling malaria from 2015. At present there are three notable mechanisms through 
which RTS,S/AS01 could potentially be administered: 
 Expanded Program on Immunization (EPI). The EPI is a WHO program with the aim of administering a 
standardized schedule of vaccines to children throughout the world. When administered through the EPI, 
RTS,S/AS01 has been demonstrated to be safe, efficacious, and not cause interference with other 
vaccines in the EPI schedule [130]. 
 EPI plus booster dose. RTS,S/AS01 could be administered through EPI campaigns with an additional 
booster dose 18 months later. A potential drawback of campaigns with booster doses is that in most sub-
Saharan African countries, there is no existing framework such as the EPI for providing booster doses. 
 Mass vaccination campaigns involve vaccinating as many people as possible in a community with the aim 
of reducing incidence of malaria and potentially causing a reduction in transmission. At present, RTS,S has 
not undergone the necessary clinical trials required for regulatory approval in adults. In order for mass 
vaccination campaigns to become a reality, further Phase III clinical trials in adults would be required, 
involving thousands of volunteers and lasting 3 – 5 years. In addition, special trials for at risk groups such 
as pregnant women and HIV positive individuals would be required. 
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Table 1.2: Results of RTS,S vaccine efficacy from Phase II field trials. Updated from Casares et al [128]. Efficacies are for according-to-protocol analysis and are adjusted by confounding factors where necessary, 
e.g. bed net, sickle cell trait, area, distance from health centre. Efficacies are based on the total person-years-at-risk. 
Trial site Age Adjuvant Immunization time 
(dose of RTS,S/volume 
of adjuvant) 
Surveillance 
period post 
immunization 
Adjusted vaccine efficacy from according-to-protocol analysis Reference 
     Infection 
(subject/total 
subjects) 
First clinical episode 
(subjects/total 
subjects) 
All clinical episodes 
(episodes/total 
subjects) 
Severe malaria 
(subjects/total 
subjects) 
 
Gambia 18–45 years AS02 0/1/5 months 
(50 µg/0.5 mL) 
0–15 weeks 34%  
(81/131 vs. 80/119) 
 31%  
(44/131 vs. 50/119) 
 Bojang [131] 
    0–9 weeks 71%     
    9–15 weeks 0%     
   Booster dose at 19 
months 
0–9 weeks 47%  
(19/73 vs. 29/86) 
    
          
Kenya 18–35 years AS02A 0/1/2 months 
(50 µg/0.5 mL) 
0–14 weeks 35% 
 (28/79 vs. 37/75) 
   Polhemus 
[132] 
  AS01B  0–14 weeks 11% 
 (28/74 vs. 37/75) 
    
Mozambique 
(Manhica) 
Cohort 1 
1–4 years AS02A 0/1/2 months 
(25 µg/0.5 mL) 
0–6 months  29.9%  
(123/745 vs. 159/745) 
27.4% 
 (153/745 vs. 190/745) 
57/7%  
(11/745 vs. 26/745) 
Alonso [133] 
   6–18.5 months  28.9%  
(110/723 vs. 140/719 
28.8% 
 (157/723 vs. 193/719) 
38.8%  
(8/723 vs. 13/719) 
Alonso [134] 
    0–18.5 months  35.3%  
(186/745 vs. 251/745) 
29.8%  
(310/745 vs. 384/745) 
48.6%  
(19/745 vs. 37/745) 
 
    0–43 months  30.5%  
(307/745 vs. 370/745) 
25.6% 
(658/745 vs. 774/745) 
38.3%  
(29/745 vs. 47/745) 
Sacarlal [135] 
Mozambique 
(Ilha Josina) 
Cohort2 
1–4 years   0–4 months 51.1% 
 (111/189 vs. 
147/178) 
61%  
(21/189 vs. 40/178) 
  Alonso [134] 
   0–6 months 45%  
(157/189 vs. 166/178) 
35.4%  
(46/189 vs. 56/178) 
30%  
(52/189 vs. 68/178) 
  
    8.5–18.5 months  9%  
(60/181 vs. 59/171) 
  Guinovart 
[136] 
Mozambique 
(Ilha Josina & 
Taninga) 
8–10 weeks AS02D 10/14/18 weeks of age 
(25 µg/0.5 mL)  
0–3 months 65.9% 
 (22/93 vs. 46/92) 
65.8%  
(9/93 vs. 22/92) 
 NS 
 (6/209 vs. 6/208) 
Aponte [137] 
Tanzania 8–10 weeks AS02D 8/12/16 weeks of age 
(25 µg/0.5 mL) 
0–6 months 65.2%  
(8/146 vs. 20/151) 
43.2%  
(7/146 vs. 11/151) 
  Abdulla [138] 
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Table 1.2 (contd.): Results of RTS,S vaccine efficacy from Phase II field trials. 
Trial site Age Adjuvant Immunization time 
(dose of RTS,S/volume 
of adjuvant) 
Surveillance 
period post 
immunization 
Adjusted vaccine efficacy from according-to-protocol analysis Reference 
     Infection 
(subject/total 
subjects) 
First clinical episode 
(subjects/total 
subjects) 
All clinical episodes 
(episodes/total 
subjects) 
Severe malaria 
(subjects/total 
subjects) 
 
Kenya & 
Tanzania  
5–17 months AS01E 0/1/2 months 
(50 µg/0.5 mL) 
0–8 months  53%  
(32/402 vs. 66/407) 
56%  
(38/402 vs. 86/407) 
 Bejon [118] 
    0–12 months  39%  
(82/415 vs. 125/420) 
42%  
(123/415 vs. 209/420) 
 Olotu [139] 
    0–15 months  46%  
(58/209 vs. 85/206) 
51%  
(108/209 vs. 175/206) 
  
          
Ghana, 
Tanzania & 
Gabon 
6–10 weeks AS01E 0/1/2 months 
(25 µg/0.5 mL) 
0–6 months  
(after dose 3) 
 67%  
(9/159 vs. 23/155) 
  Asante [130] 
   0–12 months 
(after dose 3) 
 62% 
 (21/159 vs. 46/156) 
   
   0/1/7 months 
(25 µg/0.5 mL) 
0–6 months  
(after dose 2) 
 15% 
 (15/154 vs. 17/159) 
   
    0–12 months 
(after dose 3) 
 64%  
(23/154 vs. 48/153) 
   
   0/1/2 & 0/1/7 months  0–17 months 
(after dose 2 & 3) 
 53% 
 (30/159 vs. 52/156) 
59%  
(43/159 vs. 102/156) 
  
 
 
 
 
 
 
 
 
35 
 
1.6. Mathematical models of malaria transmission 
Mathematical models can provide insight into the dynamics of malaria transmission, inform the use of malaria-
control interventions, and aid in the evaluation of malaria control programs [140]. Models are particularly useful for 
extrapolating findings from one transmission setting to other settings. For example, the results of a trial of LLINs in 
one setting can be used to estimate the impact of LLINs in other settings [141]. Models are becoming increasingly 
useful tools for informing policy on malaria control.  For example, mathematical models formed a key part of the 
body of evidence to support the wide-scale use of intermittent preventive therapy in children in regions of seasonal 
malaria transmission [142]. 
The first model of malaria transmission was developed by Ronald Ross during a trip to control malaria in Mauritius in 
1907 [143]. Ross’ model was further developed by George MacDonald during the Global Malaria Elimination 
Program and used to guide malaria control interventions [144]. The resulting Ross-MacDonald model provided key 
analytical insights into why spraying with DDT was such a potent malaria control strategy by highlighting the non-
linear relationship between increasing mosquito death rates and decreasing sporozoite positivity rates.  
In the 1970’s the WHO sponsored a project in the Garki district of Nigeria to investigate if malaria could be 
eliminated from a region of intense transmission using effective treatment with chloroquine and spraying with DDT 
[145]. Mathematical models had a key role in the design and analysis of the Garki project. Dietz, Molineaux and 
Thomas constructed a model of malaria transmission incorporating human immunity and the effect of malaria 
control interventions, and validated it against data from the project [146]. As well as providing important insights 
into the successes and failures of the project, the model identified key indices of malaria transmission, including the 
vectorial capacity and the human blood index.   
The foundations laid by the classical Ross-MacDonald and Garki models have been built upon by contemporary 
modelling groups, aided by increased computing power and more sophisticated statistical methods for validating 
models against data. In addition to methodological improvements, modern malaria transmission models incorporate 
improved scientific understanding of both human immunity and mosquito behaviour. Mathematical models have 
been developed to investigate many aspects of the epidemiology of malaria transmission and the impact of malaria 
control interventions (reviewed in detail by Mandal et al [147]), some notable efforts being those by modelling 
groups at Imperial College London [63], the Swiss Tropical and Public Health Institute [64, 148], Dave Smith and 
colleagues [149, 150], and Intellectual Ventures [151].  
 
1.6.1. The Ross-MacDonald model 
The Ross-MacDonald captures the key parts of the malaria transmission cycle, and can be used to predict basic 
malariological quantities such as the entomological inoculation rate (EIR), the parasite rate (PfPR) and the basic 
reproductive number (R0). It is defined by the following set of ordinary differential equations. 
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A flow diagram of the model and explanation of the parameters is shown in Figure 1.9. An expression for the basic 
reproductive number can be derived analytically for the Ross-MacDonald model by calculating the dominant 
eigenvalue of the next generation matrix, or more heuristically as described in Table 1.3. R0 is a key quantity for 
malaria transmission – if control measures can reduce transmission such that R0 < 1 then malaria will no longer be 
able to persist. R0 has been estimated in several African populations, resulting in estimates varying by an order of 
magnitude from around one to more than 3,000 [40]. A key insight derived from the Ross-MacDonald model, is the 
exponential dependence of R0 on the mosquito death rate µM, as a mosquito taking an infectious blood meal must 
survive the τ days of duration of sporogony in order to become infectious to humans. During each of these τ days, 
the mosquito is liable to die at rate µM. This sensitive dependence of malaria transmission on mosquito death rate 
highlights the importance of vector control tools such as LLINs and IRS which kill adult mosquitoes.   
The Ross-Macdonald model has been extended to consider age structure [152, 153], acquired immunity [154, 155], 
spatial heterogeneity [156, 157], individual-based models [158], strain theory [159] and other phenomena. 
 
 
Figure 1.9: Flow diagram and parameters of the Ross-MacDonald model. 
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Table 1.3: Derivation of R0 for the Ross-MacDonald model. 
 Probability infections 
become infectious 
Contacts per day Duration of infectivity 
0R contribution 
human to mosquito 1 mac  1
r
 mac
r
 
mosquito to human e  ab  1  abe  
total    2
0
ma bce
R
r
 
 
 
1.6.2. The Imperial College malaria transmission model 
An individual-based simulation model for Plasmodium falciparum transmission for estimating the impact of packages 
of malaria control interventions [63] has been developed by the malaria modelling group at Imperial College London 
and collaborators at the London School of Hygiene and Tropical Medicine. The model has been extensively fitted to 
parasitological and clinical data from a range of transmission settings. A flow diagram of the model is shown in 
Figure 1.10 and full details are given in Griffin et al [63]. Briefly, individuals begin life susceptible (S) to infection but 
with partial maternal immunity which decays in the first months of life. Individuals become infected at a rate 
determined by the force of infection (Λ) which depends on the number of mosquitoes per person, the proportion of 
infectious mosquitoes, and the person’s level of anti-infection immunity. Once infected, a person passes through the 
pre-patent (liver) stage of infection, and then progresses to develop clinical disease (D) or asymptomatic (A) 
infection, depending on their level of clinical immunity φ. A proportion fT of those with clinical disease will be treated 
(T). Untreated individuals with clinical disease recover to the asymptomatic stage at a rate rD, and treated individuals 
recover at a rate rT after which they are afforded a period of prophylactic protection (P) with average duration 1/rP. 
Asymptomatic individuals (patent infection – detectable by microscopy) will move to a sub-patent stage of infection 
(U) at a rate rA, from which they eventually return to susceptible at a rate rU. Malaria can be transmitted from human 
to human by three different vector species: An. gambiae s. s., An. arabiensis and An. funestus.      
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Figure 1.10: Flow diagram and parameters for the Imperial College malaria transmission model. Full details are available in Griffin et al [63]. 
 
1.6.3. The Swiss TPH Model 
A group at the Swiss Tropical and Public Health Institute under the guidance of Prof. Tom Smith have developed a 
detailed micro-simulation model of the clinical epidemiology of malaria transmission. The model is described in 
detail in a supplement to The American Journal of Tropical Medicine and Hygiene [64] and summarised in Figure 
1.11. It consists of multiple component modules for different aspects of the life history of malaria, each of which has 
been validated against epidemiological data. There are separate models for the relationship between EIR and the 
force of infection [160], acquisition of blood-stage immunity [161], infectiousness of humans to mosquitoes [162, 
163], within-host dynamics of asexual P. falciparum parasites [164], incidence of clinical and severe malaria [165, 
166], neonatal mortality [167], malaria-associated anemia [168], pre-erythrocytic vaccines [120, 169], and the costs 
of treatment [170]. The complexity of the model necessitates computationally expensive simulation distributed 
across volunteer computers.     
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Figure 1.11: Key processes and relationships simulated by the Swiss TPH models of Plasmodium falciparum transmission and morbidity. Figure 
reproduced from Smith et al [64]. 
 
Although the Swiss TPH model includes components for multiple aspects of the life history of malaria, its main focus 
is on the evaluation of pre-erythrocytic vaccines on the clinical epidemiology of P. falciparum. One of the key results 
was the prediction that vaccines with efficacy similar to that of RTS,S/AS02 administered through the Expanded 
Program on Immunization would have a substantial impact on malaria morbidity and mortality, but have negligible 
effects on levels of malaria transmission typical of sub-Saharan Africa. Follow up publications from the Swiss TPH 
have further validated these findings [171], and extended model predictions to blood-stage and transmission-
blocking vaccines [172].   
 
1.6.4. Models of the impact of malaria vaccination on transmission 
In the past, mathematical models have been used to explore the theoretical relationship between malaria 
transmission and pre-erythrocytic, blood-stage or transmission-blocking vaccines [173-176]. Following the progress 
of RTS,S through clinical trials, models are now being used as predictive tools as opposed to tools for purely 
theoretical investigations. A number of models have incorporated pre-erythrocytic vaccination with parameters 
chosen to reflect the properties of RTS,S [63, 177]. Following on from the Swiss TPH’s findings, there has been a 
consensus across different models that although RTS,S/AS01 or RTS,S/AS02 administered through the EPI will have 
considerable public health benefits for vaccinated children, there is unlikely to be a substantial impact on malaria 
transmission. Similarly, it is predicted that mass vaccination with RTS,S/AS01 is unlikely to cause substantial 
reductions in malaria transmission, except in regions of low transmission [171]. In addition to estimating the impact 
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of vaccination campaigns, models can be used to investigate the interaction between vaccines and other malaria 
control interventions [63], and the likely cost-effectiveness of vaccination campaigns [178, 179].  
 
1.6.5. Within-host models of malaria infection 
There is an extensive literature on within-host models of malaria in both mice and humans, predominantly of the 
erythrocytic stage of malaria infection [180], with some models also investigating the sexual stages [181]. The first 
published model of the within-host dynamics of P. falciparum parasites was described by Anderson et al [176] who 
used a system of differential equations to model blood-stage infection as a population of merozoites infecting and 
replicating within a population of red blood cells. Anderson et al demonstrate that a blood-stage immune response 
that increases in proportion to parasite density can predict non-linear parasite dynamics similar to those observed in 
natural infections [182]. This approach of modelling blood-stage malaria using continuous differential equations has 
been extended to investigate gametocyte densities [183], antigenic variation [184] and the effects of anti-malarial 
drugs [185].  
A key characteristic of blood-stage P. falciparum dynamics is the discrete 2 day replication cycle. Continuous 
differential equation models can recreate this periodicity, but at considerable computational expense [186]. An 
elegant solution to capture this periodicity has been to use difference equations with a 2 day time step, first utilised 
by Kwiatkowski and Nowak [187]. The most sophisticated and biologically realistic difference equation model is that 
developed by Dietz and Molineaux [188] which includes intra-clonal antigenic variation based on differential 
expression of PfEMP1 antigens by parasitized red blood cells, between individual variation in parasite replication 
rates, innate auto-regulation of asexual parasite density, acquired variant-transcending immunity, and acquired 
variant-specific immunity. The model was validated against data from patients artificially infected with P. falciparum 
malaria for extended periods of time as part of malaria therapy to cure neurosyphilis [182]. A version of Dietz and 
Molineaux’s discrete time model has been used to consider the effect of a hypothetical malaria vaccine that induces 
blood-stage antibodies which inhibit asexual parasite replication [164].  
Although several within-host models have been developed for the erythrocytic stage of the malaria parasite’s 
lifecycle, no published models have considered the pre-erythrocytic stage – the key stage that must be understood 
in the development of vaccines to prevent infection with P. falciparum.   
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1.7. Thesis aims 
The aim of this thesis is to use mathematical models to provide insight into a number of pressing problems in the 
field of malaria vaccine development, ranging from the interpretation of results from clinical trials currently 
underway in Africa, to the relationship between antibody titres and protection from infection, and the effectiveness 
and cost-effectiveness of vaccination campaigns. Specific objectives in each chapter are: 
 Chapter 2: I consider the effect of heterogeneity in malaria exposure and vaccine response on the results of 
vaccine efficacy trials. 
 Chapter 3: I review the role of naturally acquired pre-erythrocytic immune responses in protection from 
infection based on sources from the published literature. 
 Chapter 4: I explore the relationship between naturally acquired antibody titres and protection from 
infection using dose-response curves, and estimate the potential efficacy of multi-component pre-
erythrocytic vaccines based on data on naturally acquired immune responses. 
 Chapter 5: I estimate the relationship between anti-CSP antibody titres, numbers of CSP-specific CD4+ T 
cells and protection from infection in malaria-naïve volunteers vaccinated with either RTS,S/AS02 or 
RTS,S/AS01. 
 Chapter 6: I develop simple models of antibody kinetics and the maintenance of immunological memory, 
and consider the implications for duration of vaccine efficacy. 
 Chapter 7: I estimate the effectiveness and cost-effectiveness of vaccination campaigns across a range of 
transmission settings, and in combination with insecticide treated nets. 
Throughout this thesis I aim to demonstrate that mathematical models incorporating an understanding of the 
dynamics of malaria transmission provide an ideal framework for synthesising knowledge and data from across 
different disciplines engaged in research into malaria vaccines. Thus, for example, insight gained from immunological 
studies can be incorporated in models for investigating epidemiological problems, which can in turn be used to 
address public health questions. 
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Chapter 2. Heterogeneity in malaria exposure and vaccine 
response: implications for the interpretation of vaccine 
efficacy trials 
 
Published as: White MT, Griffin JT, Drakeley CJ, Ghani AC: Heterogeneity in malaria exposure and vaccine response: 
implications for the interpretation of vaccine efficacy trials. Malaria Journal 2010, 9:82. 
  
Randomised clinical trials carried out under conditions of natural exposure to malaria remain the most important 
tool for assessing the safety, immunogenicity and efficacy of candidate malaria vaccines. With the majority of the 
evidence required for vaccine licensure coming from such clinical field trials, it is vital that we do not misinterpret 
their results. In this chapter, I discuss how heterogeneities in malaria exposure, vaccine response and waning of 
efficacy need to be considered when analysing data from clinical trials.     
 
2.1. Introduction  
There are many sources of bias that may arise when measuring an infection-blocking malaria vaccine’s efficacy in 
clinical trials. A significant source of bias that is often overlooked is due to the effects of heterogeneity. 
Heterogeneity can arise in one of three ways. Firstly, heterogeneity in exposure occurs due to some individuals being 
bitten more frequently than others. Between-individual variation has been observed in experimental trials in which 
differential attractiveness to humans sleeping in tents was quantified using mosquito traps [45].  This heterogeneity 
in biting rate has also been attributed to age due to differences in surface area between adults and children [189], 
differences in human sweat components [190], proximity to larval breeding sites [191], bed net usage [192] and 
differences in house design [44].  
Secondly, there can be heterogeneity in vaccine response, which occurs due to variation in the degree of protection 
(or take) of the vaccine between individuals. For example if a vaccine is reported to have 90% efficacy against 
infection, at one extreme this could mean that each infection will be blocked 90% of the time, whilst at the other 
extreme it could mean that 90% of vaccinated people will be completely protected from infection. Smith et al [116] 
and Halloran et al [119] have investigated this concept and coined the terms all-or-nothing and leaky vaccines. An 
all-or-nothing vaccine is one which offers complete protection to a subset of the vaccinated population and has no 
effect on the rest of the population whilst a leaky vaccine is one which offers the same level of partial protection to 
everyone. In a malaria vaccine trial it is possible that the candidate vaccine will induce a different level of protection 
in each of the trial participants. The level of protection given to a vaccinated person will be described by their 
vaccine response which will depend on the relative immunogenicity of the vaccine and the magnitude of the induced 
antibody titres. Individual vaccine response may further depend on genetic and nutritional factors [193] as well as 
age, past exposure and season [194]. 
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Finally, for a candidate malaria vaccine offering partial protection from infection, waning of efficacy is also likely to 
be observed. Understanding how a vaccine’s efficacy wanes over time is at least as important as measuring its initial 
efficacy. Waning of efficacy can be estimated from clinical trials by measuring a vaccine’s half-life: the time taken for 
the initial efficacy to be halved. However, a vaccine’s half-life is a crude measure of waning, as the effects of a 
vaccine may not decay at a constant rate, and thus some people may remain protected for longer than others. This 
type of heterogeneity is often neglected in the interpretation of trial results. 
Mathematical models have been used to investigate the impact of heterogeneity in exposure [149, 156, 172], 
heterogeneity in vaccine response [120, 172] and waning of efficacy [172] on malaria transmission. In this chapter 
theoretical arguments are used to understand how these three types of heterogeneity can affect measurement of 
vaccine efficacy in clinical trials. Examples are motivated by the RTS,S vaccine and hence focus on a pre-erythrocytic 
vaccine which is assumed to act by partially blocking infection. In the first section the basic methods currently used 
to estimate vaccine efficacy in Phase II and Phase III trials are described. The effects of the three types of 
heterogeneity on the estimates of vaccine efficacy from clinical trials are then investigated.  
 
2.2. Measurements of vaccine efficacy 
For a vaccine with efficacyVE , if the probability of an unvaccinated person becoming infected after an infectious 
bite isb (also referred to as transmission efficiency [195])  then the probability that a vaccinated person becomes 
infected is (1 )VE b . This efficacyVE , hereafter referred to as the individual efficacy, can be defined as the 
proportion of infectious bites on a vaccinated population that are blocked by the vaccine. This proportion can be 
directly estimated in laboratory based Phase IIa trials where healthy adult volunteers are exposed to bites from 
infectious mosquitoes and then monitored for blood-stage malaria infection [196, 197].  
In field-based Phase IIb clinical trials in malaria endemic regions, it is impossible to directly estimate this proportion. 
Instead vaccine efficacy must be estimated by measuring malaria-related events in both the vaccine and control 
arms of the trial. Vaccine efficacy can then be calculated as 
events with vaccine
efficacy=1-
events without vaccine
 
Malaria infection has a complex life history giving rise to a choice of events to measure [198]. These include 
prevalence of infection as detected by the presence of parasitaemia, time to first infection, episodes of febrile 
malaria, episodes of severe malaria or multiple episodes in fixed time periods. Each of these end-points will be 
relevant in different settings. For example, infection-blocking efficacy would be most important to a traveller to a 
malaria endemic region, whereas efficacy against severe disease would be most important for a child living in an 
area of high transmission. Vaccine efficacy against time to first infection and prevalence of infection are focused 
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upon as these are the outcomes directly affected by pre-erythrocytic vaccines, although they can also be expected to 
have a downstream effect on morbidity and mortality. 
Following the notation of Smith et al [116], the vaccine efficacy against cumulative incidence of infection, also known 
as risk-based infection-blocking efficacy, is denoted
rVE . This gives a measure of the risk of having become infected 
by the end of a trial of durationT for the vaccine group compared to the control group. Note that the cumulative 
incidence of infection is different to the prevalence of infection as it measures the proportion who have ever 
become infected and not the proportion infected at a given time. Vaccine efficacy against time to first infection, also 
known as rate-based infection-blocking efficacy, will be denoted
fVE . This gives a measure of the rate at which the 
vaccine group becomes infected compared to the control group.  
In a trial of a vaccine with individual efficacyVE , of lengthT , in a setting with constant force of infection , 
estimates for the proportion infected and the person years at risk (PYAR) can be calculated using the formulae in 
Table 2.1.  
 
Table 2.1: Expected values for the observed infected proportion I(T), and expected person years at risk (PYAR) in a clinical trial with follow-up 
period T, of a vaccine with individual efficacy VE, in a region with force of infection Λ. 
Group Proportion infected ( )I T  Person years at risk (PYAR) 
Control 1 Te  1
Te
 
Vaccine (1 )1 VE Te  
(1 )1
(1 )
VE Te
VE
 
 
 
The risk-based efficacy can be calculated as 
(1 )
proportion infected with vaccine
1
proportion infected without vaccine
1 1
1
1 1
r
VE T VE T
T T
VE
e e
e e
 
Thus the risk-based efficacy, 
rVE , as measured in a field trial can be estimated from the individual efficacy. This 
measure approaches 0 as T  increases as it is assumed that everyone will become infected if the follow-up is 
sufficiently long. In addition, for small T we have rVE VE . 
In a field trial the rate at which a cohort becomes infected can be estimated by dividing the infected proportion at 
the end of the follow-up period by the total person years at risk. The rate-based efficacy can then be calculated as 
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(1 )
(1 )
infection rate with vaccine
1
infection rate without vaccine
1
1
(1 ) (1 )
1 1
1
1
f
VE T
VE T
T
T
VE
e
e
VE VE
VE
e
e
 
Therefore the rate-based efficacy is equal to the individual efficacy. In particular it is independent of the force of 
infection  and the length of the trialT .  
VE is an unbiased measure of vaccine efficacy, in contrast to 
rVE and fVE which are measured in field trials and are 
potentially subject to bias.VE is the efficacy that would be estimated from a large scale Phase IIa trial where all 
volunteers are equal and receive the same number of infectious bites. The risk-based definition of efficacy is 
commonly used for diseases in which natural infection with the causative agent provides near complete protection 
against a second infection with the same agent, for example measles. However the high frequency at which people 
living in endemic regions are challenged with malaria infection makes risk-based infection-blocking efficacy 
uninformative as most trial participants are likely to have become infected during a trial. In order to overcome this 
difficulty a consensus has formed amongst vaccine trialists to primarily use rate-based measures based on time to 
first infection [198, 199]. 
 
2.3. Heterogeneity in transmission 
In a site where a malaria intervention is being trialled, the transmission intensity is usually measured using the 
entomological inoculation rate (EIR). In the analysis of trial results it is often assumed that all participants experience 
the same homogeneous force of infection. Making this assumption and ignoring the effects of heterogeneity in 
transmission can bias trial results.  
If the average force of infection is measured to be b , where b is the transmission efficiency (the probability 
that a bite from an infectious mosquito results in infection), and is the measured EIR, then the heterogeneity in 
malaria transmission can be modelled using some distribution f . A proportion ( )f x  of the population under 
observation will experience a force of infection x . In order for the average force of infection across the entire 
population to be , the distribution f must have mean 1. Examples of distributions that will be considered are given 
in Table 2.2. 
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Table 2.2: Examples of distributions describing heterogeneity in exposure in order of increasing heterogeneity. 
Distribution Description 
constant All individuals receive the same number of infectious mosquito bites. 
gamma The distribution of infectious mosquito bites follows a gamma distribution with parameter 4.2 as 
suggested by Smith et al [149]. 
80/20 The distribution of infectious bites follows an 80/20 rule as suggested by Woolhouse et al [200] 
where 20% of people receive 80% of the bites. 
extreme A hypothetical example of extreme heterogeneity as might be observed in a localised epidemic, in 
this case modelled as 5% of people receiving 95% of infectious bites. 
 
 
In an area with constant force of infection  (i.e. homogeneous transmission), the average proportion infected by 
time T  will be ( ) 1 TI T e . In an area with heterogeneity in transmission described by a distribution f , the 
average proportion infected will be 
0
( ) 1 ( )x TfI T e f x dx  
Figure 2.1A shows the average infected proportion in a trial as a function of the follow-up time T  for the 
heterogeneity distributions listed in Table 2.2. As heterogeneity in exposure to infection increases, the proportion of 
individuals infected in any given setting decreases. Furthermore, for a given force of infection, homogeneous 
exposure, whereby everyone receives the same number of infectious bites, always leads to the highest proportion 
infected (see 2.9. Appendix 1). To understand this result, consider the problem from the hypothetical point of view 
of a mosquito population trying to infect as many humans as possible with malaria. In order not to waste any bites 
on people already infected, the mosquitoes should evenly distribute their bites on the entire population. If there is 
heterogeneity in the bite distribution, then many bites will be wasted on humans who are already infected. 
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Figure 2.12: Cumulative proportion of infected trial participants for an infection-blocking vaccine with an average individual efficacy of 45.0% 
based on RTS,S, and in a similar setting to the Mozambique trial site described by Alonso et al [133]. (A) Cumulative proportion of 
unvaccinated trial participants infected under a range of transmission heterogeneities. (B) Cumulative proportion of vaccinated trial 
participants infected for a range of vaccine types. The proportion infected for an all-or-nothing vaccine can never cross the dashed line marked 
1-V=0.55 as the 45% of vaccinees with total protection will never become infected. Note that the 4 vaccines each have the same average 
efficacy but different heterogeneities in vaccine efficacy.  
 
2.4. Heterogeneity in vaccine response 
Leaky and all-or-nothing vaccines represent the extreme cases of a vaccine that has a completely homogeneous 
effect on the vaccinated population and a vaccine that has a very heterogeneous effect. In reality one would expect 
to observe a range of intermediate behaviours between these two extremes. A vaccine that has variable individual 
efficacy on the vaccinated population can be described by an efficacy distribution g . Let ( )g x  be the proportion of 
the population on which the vaccine has individual efficacy x . These efficacy distributions have been described 
previously by Halloran and Longini using frailty mixing models [201, 202]. Some examples are given in Table 2.3. 
 
Table 2.3: Examples of distributions describing vaccine response in order of increasing heterogeneity. 
Vaccine Description 
leaky Vaccination gives everyone the same level of partial protection. 
leaky-or-nothing Vaccination offers partial protection to some people but no protection to others, as described 
by Halloran et al [202].  
beta Vaccination offers a variable level of protection to all vaccinees. The effect of vaccination 
follows a beta distribution as described by Maire et al [120]. 
all-or-nothing Vaccination offers full protection to some people but no protection to others. 
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For a vaccine with efficacy distribution g , the average individual efficacy can be calculated by averaging the 
individual efficacy for the entire population 
1
0
( )xg x dx VE  
For a population in an area with force of infection , given a homogeneous (leaky) vaccine with individual efficacy
VE , the average proportion infected after follow-up time T will be (1 )( ) 1 VE TI T e . If the same population is 
instead given a vaccine with the same average individual efficacyVE , but with vaccine response described by a 
distribution g  the average proportion infected will be 
1
(1 )
0
( ) 1 ( )x TgI T e g x dx  
Figure 2.1B shows the average infected proportion as a function of the follow up time T  for the efficacy 
distributions listed in Table 2.3 for a specified average individual efficacy. The all-or-nothing vaccine always protects 
more people from infection than the leaky vaccine regardless of follow-up time. Thus, the more heterogeneous a 
vaccine is (i.e. the more it resembles an all-or-nothing vaccine), the more people will be protected from infection. In 
fact it can be proved (see 2.9. Appendix 1) that if a vaccine has average individual efficacy VE , then it will always 
protect at least as many people as would be expected from a leaky vaccine with the same average individual 
efficacy, and at most as many people as an all-or-nothing vaccine. To understand this, compare a leaky vaccine with 
an all-or-nothing vaccine. Given long follow-up, everyone in a group given a leaky vaccine will eventually become 
infected as eventually one of the infectious bites will evade the vaccine response. In contrast, a group given an all-or-
nothing vaccine will contain a subgroup that will always remain free from infection. The unprotected subgroup will 
become infected at a natural rate, but the number of infections in this subgroup will be less than the number of 
infections in the entire leaky group. Therefore there will be fewer infections in the entire all-or-nothing group than in 
the leaky group. 
 
2.5. How heterogeneity affects estimates of vaccine efficacy 
Consider an infection-blocking vaccine with constant individual efficacy being tested in a range of transmission 
settings described by the distributions in Table 2.2. Figures 2.2A and 2.2C show the risk-based and rate-based 
efficacies that would be observed as a function of increasing follow-up time. Comparing the curves for the risk-based 
(Figure 2.2A) and rate-based (Figure 2.2C) efficacies it is apparent that the rate-based efficacy is a more useful 
measure as it converges to the individual efficacy as the follow-up time increases. The estimates of rate-based 
efficacy in the presence of transmission heterogeneity (Figure 2.2C), show that the more heterogeneous the 
transmission setting, the lower the measured value for the rate-based infection-blocking efficacy. This means that if 
a vaccine is tested in an area with a high level of transmission heterogeneity, its efficacy will be underestimated. 
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Figure 2.2: (A) Risk-based infection-blocking efficacy for a vaccine under the range of transmission heterogeneities in Table 2.2. (B) Risk-based 
infection-blocking efficacy for the four vaccines described in Table 2.3 with the same individual efficacy. (C) Rate-based infection-blocking 
efficacy under different transmission heterogeneities. (D) Rate-based infection-blocking efficacy for the four vaccines. 
 
To understand this, consider a population where 20% of the population receive 80% of the infectious mosquito bites 
as suggested by Woolhouse et al [200]. In the unvaccinated control group, the high-risk 20% will almost certainly 
become infected whereas only a small proportion of the low-risk 80% will become infected. Now consider the 
vaccinated group. Despite being vaccinated a large proportion of the high-risk 20% will develop malaria infection, as 
they will be bitten so frequently that the vaccine will be unable to block all infections. In the low-risk group, only a 
small proportion will become infected due to the low number of infectious bites and the effect of the vaccine. Thus, 
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heterogeneity in the force of infection makes the infection profiles (who ends up infected) of the vaccine and control 
groups more similar, and hence a lower efficacy is measured. 
Next consider an infection-blocking vaccine whose individual efficacy has been estimated from Phase IIa trials, but 
whose distribution of responses between individuals is unknown. Figures 2.2B and 2.2D show the risk-based and 
rate-based efficacies that would be observed for each of the response distributions described in Table 2.3. Note how 
the risk-based efficacies in Figure 2.2B decrease with follow-up time. This is because eventually everybody will 
become infected regardless of vaccination status. The exception to this is the case of an all-or-nothing vaccine where 
the subgroup which is fully protected will always remain uninfected. In contrast the rate-based efficacies in Figure 
2.2D increase with follow-up time. This is because individuals who receive a high level of protection from the vaccine 
will remain susceptible for a longer time and significantly increase the total person years at risk used in the rate-
based efficacy calculation. Finally, we observe that vaccines that induce more heterogeneous responses between 
individuals are estimated to be more efficacious than their homogeneous counterparts (Figure 2.2D), despite both 
vaccines having the same average individual efficacy. In particular, the upper limit for the observed rate-based 
efficacy is given by an all-or-nothing vaccine and the lower limit is given by a leaky vaccine. Therefore in a trial of a 
candidate malaria vaccine, if there is heterogeneity in vaccine response and this is ignored in the analysis, the 
vaccine efficacy will be overestimated.  
 
2.6. Waning vaccine efficacy 
RTS,S has been observed to induce long-lasting protection against malaria for up to 45 months [136, 203]. For 
example in a Phase II trial of children in Mozambique, Alonso et al [133] recorded a rate-based vaccine efficacy 
against first clinical episode of malaria of 29.9% (95% CI, 11.0-44.8) in a six-month follow-up period. In an extended 
follow-up of the Mozambique trial Sacarlal et al [203] recorded a vaccine efficacy of 16.8% (95% CI, -2.5-32.4) over 
months 21-33, and an efficacy of 11.8% (95% CI, -20.1-35.2) over months 33-45.  These results could either be 
consistent with RTS,S inducing protection from infection over an extended period but with waning efficacy, or an 
artefact due to the apparent waning of efficacy due to the effects of heterogeneity.   
Kanaan and Farrington [122] propose two models of waning vaccine efficacy; the selection and deterioration models. 
In the selection model, waning arises from heterogeneity in the duration of protection, i.e. a vaccinated person is 
protected for a period of time dependent on the vaccine half-life and then loses all protection. For example a person 
receiving a vaccine with initial individual efficacy 45% and a half-life of 1 year will have a 50% chance of still being 
protected after one year. In the deterioration model, waning arises from the gradual decline in the individual 
efficacy. For example a vaccine with initial individual efficacy of 45% and a half-life of 1 year will have an efficacy of 
22.5% one year after it is administered. These two models are with-waning analogues of the all-or-nothing and leaky 
models. In both cases there can be additional heterogeneity between individuals in the rate of waning, with some 
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individuals remaining protected for longer than others. This would occur if a vaccine’s efficacy is dependent on 
natural boosting through continuous exposure to infection.  
Figure 2.3 shows the effects of waning efficacy for both leaky and all-or-nothing vaccines. The solid lines represent 
the cumulative infected proportion (Figure 2.3A) and the rate-based infection-blocking efficacy (Figure 2.3B) whilst 
the dashed lines represent these same quantities except with the addition of waning vaccine efficacy with a half-life 
of one year using the deterioration model for the leaky vaccine and the selection model for the all-or-nothing 
vaccine. As expected, waning efficacy reduces the observed rate-based vaccine efficacy for both leaky and all-or-
nothing vaccines. If the effects of waning efficacy are ignored, estimates of rate-based efficacy can be prone to bias. 
For example, a waning vaccine with high initial efficacy could be confused with a non-waning vaccine with lower 
efficacy. Or a waning all-or-nothing vaccine could be mistaken for a non-waning leaky vaccine. Thus the only way to 
detect the presence of waning vaccine efficacy in clinical field trials is to ensure that there is extended follow-up of 
the trial participants. 
 
 
Figure 2.3: (A) Cumulative proportion of vaccinated trial participants infected for leaky and all-or-nothing vaccines. The dashed lines represent 
the infected proportion when vaccine efficacy wanes with a half-life of 1 year. (B) Rate-based efficacy for leaky and all-or-nothing vaccines. The 
dashed lines represent the expected rate-based efficacy with a waning vaccine. 
 
 
 
 
52 
 
2.7. Discussion  
A measurement of vaccine efficacy may be biased if the way in which it is measured causes systematic differences 
between the estimated efficacy and the true efficacy. The results presented here demonstrate that several sources 
of heterogeneity can lead to biased estimates of vaccine efficacy if their effects are ignored. In general, 
heterogeneity in exposure to infectious mosquitoes will result in an underestimate of vaccine efficacy. In contrast, 
heterogeneity in individuals’ response to the vaccine (often termed the take of the vaccine) will result in an 
overestimate of vaccine efficacy. In addition, waning efficacy of the vaccine will further complicate the observed 
patterns. Thus simple calculations that ignore these sources of heterogeneity can easily give biased results and it will 
be difficult to assess the extent to which these are biased upwards or downwards.  
Whilst these results are intuitively clear, it is often assumed that randomization will diminish or remove their effect. 
Clearly randomization should at the least ensure that characteristics such as individual-level attractiveness to 
mosquitoes are balanced in the trial arms. Moreover, cluster-based designs in which villages or other population 
units are randomized should ensure a balance in village-level exposure between the arms. However, even if 
heterogeneity is balanced across trial arms through robust randomization, this will not counter-balance the biases 
identified here. For exposure-driven heterogeneity, in the control arm those that are highly exposed will almost 
certainly become infected whilst the low-risk population will avoid infection. Similarly, in the vaccinated arm a large, 
albeit lower, proportion of the highly exposed population will become infected but as in the control arm, the 
remainder will likely avoid infection. Because a large proportion of both the control and vaccinated group are 
unexposed, this will always result in an underestimate of vaccine efficacy.  
In contrast, heterogeneity in vaccine response will only affect the vaccine arm of the trial. In this arm of the trial 
heterogeneity will cause some trial participants to receive a higher level of protection than others, whereas the 
control arm will be unaffected. The presence of a highly protected subgroup in the vaccine arm of the trial will cause 
the measurement of the rate-based infection-blocking efficacy to be greater than the individual vaccine efficacy. 
Thus the individual vaccine efficacy will be overestimated. 
Given these heterogeneities, how can their impact on estimates of vaccine efficacy be minimized? The first step is to 
ensure that trial participants are as homogeneous as possible. For example children in a malaria vaccine trial should 
be of similar age, live in similar settings and have similar access to healthcare and anti-malaria interventions such as 
bed nets. This should occur not just through randomization but by ensuring that trials are undertaken in areas of 
relatively homogeneous transmission. However even with the most carefully selected study cohort there is likely to 
be residual heterogeneity in exposure and response. Thus analysis methods need to account for these possible 
biases. In studies of malaria immunity Bejon [204] and Kinyanjui [205] have suggested that the effects of 
heterogeneity be reduced by excluding individuals likely to be unexposed. However, when infection rather than 
blood-stage disease is the primary outcome this may be problematic given that infection is generally the most 
reliable marker of exposure. In addition Valim et al [206] recently proposed a statistical estimator of individual 
vaccine efficacy that corrects for the effects of heterogeneity in exposure by taking account of multiple exposures. 
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Whilst I am not aware of comparable estimators that account for heterogeneity in response, this may in fact not be a 
major problem for the RTS,S vaccine because in one of the Phase II trials of RTS,S [5], nearly all of the vaccinated 
group became infected with P. falciparum at some stage during the monitoring period. This suggests that the current 
RTS,S vaccine is leaky - although there may still be considerable heterogeneity in this leakiness. Thus further 
characterization of the heterogeneity in response is needed to ensure that estimates of vaccine efficacy are not 
substantially biased.  
Extended follow-up of clinical trials of RTS,S have observed the apparent waning of vaccine efficacy against clinical 
malaria, as demonstrated by the coming together of Kaplan Meier plots comparing the infected proportions in 
vaccine and control groups [136]. This waning could be consistent with either a deterioration model where efficacy is 
gradually lost, or a selection model where efficacy is maintained for a random period of time dependent on the 
vaccine half-life, or may just be an artefact of heterogeneity in exposure and vaccine response. In addition there may 
be heterogeneity in waning where the vaccine has a variable half-life. Early efficacy estimates based on 6 or 12 
month follow-up may be biased and this bias is difficult to quantify. For example, 12 month results could be 
consistent with a vaccine with high initial efficacy and a short half-life, or medium initial efficacy and a longer half-
life. Extended follow-up, potentially spanning several years, is therefore required to obtain unbiased estimates. 
 
2.8. Conclusion 
RTS,S is currently undergoing extensive testing in Phase III clinical trials. These trials will enrol up to 16,000 children 
and infants across 11 sites in seven different African countries. The results presented here demonstrate that 
heterogeneity in exposure, response and vaccine waning can bias vaccine efficacy measures in ways that are not 
easily measurable. These factors need to be borne in mind when combining results from the wide range of 
transmission settings in these Phase III studies. 
 
 
 
 
 
 
 
 
 
 
54 
 
2.9. Appendix 1: Mathematical Supplement 
2.9.1. Calculating the expected infection proportion 
For an initially susceptible population in an area of constant, homogeneous malaria transmission with force of 
infection , the expected cumulative infected proportion after timeT , ( )I T , can be described by the following 
simple equation 
 
(1 )
(0) 0
dI
I
dt
I
 
That is people in the susceptible class 1S I  move to the infected class I at a constant rate . This equation can 
be solved to give 
 ( ) 1 TI T e  
 
2.9.2. Calculating the expected person years at risk 
In a trial, person years at risk are computed for each individual as the time from entry into the study to malaria 
infection, or to the end of the study period for those who do not become infected. For a single unvaccinated trial 
participant under conditions of homogeneous transmission intensity the expected person years at risk (PYAR) is 
calculated as 
 
0
1 TT T ePYAR e dt  
When there is heterogeneity in transmission described by some distribution f  the mean PYAR can be calculated as 
follows 
 
0 0
0
0
0
( )
( )
1
( )
T
x t
f
T
x t
x T
PYAR e f x dx dt
e
f x dx
x
e
f x dx
x
 
When there is heterogeneity in vaccine response described by some distribution g  the mean PYAR can be 
calculated as follows 
55 
 
 
1
(1 )
0 0
(1 )
1
0
0
(1 )
1
0
( )
( )
(1 )
1
( )
(1 )
T
x t
g
T
x t
x T
PYAR e g x dx dt
e
g x dx
x
e
g x dx
x
 
  
2.9.3. Table of transmission heterogeneity distributions with calculated heterogeneities 
A measure for the heterogeneity of a transmission distribution f , where f  has mean 1, can be obtained by 
calculating the variance of the distribution. 
 
2 2
0
2
0
( 1) ( )
( ) 1
f x f x dx
x f x dx
 
   
Appendix Table 2.1: Transmission heterogeneity distributions with calculated heterogeneities. 
Transmission Description Distribution Heterogeneity – 2f  
constant All individuals receive the same 
number of infectious mosquito 
bites. 
( 1)x  0 
80/20 The distribution of infectious bites 
follows an 80/20 rule as suggested 
by Woolhouse et al [200] where 
20% of people receive 80% of the 
bites. 
0.8 ( 0.25)
0.2 ( 4)
x
x
 
3.25 
gamma The distribution of infectious 
mosquito bites follows a gamma 
distribution with variance 4.2 as 
suggested by Smith et al [149]. 
11
4.24.2 4.21 1
4.2
1
4.2( )
x
x e
 
4.2 
extreme A hypothetical example of 
extreme heterogeneity as might 
be observed in a localised 
epidemic, in this case modeled as 
5% of people receiving 95% of 
infectious bites. 
1
19
0.95 ( )
0.05 ( 19)
x
x
 
18.053 
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2.9.4. Table of vaccine response distributions with calculated heterogeneities 
A measure for the heterogeneity of a distribution of vaccine response g can be obtained by calculating the variance 
of the distribution 
 
1
2 2
0
1
2 2
0
( ) ( )
( )
g x V g x dx
x g x dx V
 
 
Appendix Table 2.2: Vaccine response distributions with calculated heterogeneities. 
Vaccine Description Distribution Heterogeneity – 2g  
leaky Vaccination gives everyone the same 
level of partial protection. 
( )x V  0 
leaky-or-nothing Vaccination offers partial protection to 
some people but no protection to 
others, as described by Halloran et al 
[119] 
3 4 1
4 3 4
( ) ( )x V x  2
3
V
 
beta Vaccination offers a variable level of 
protection to all vaccinees. The effect 
of vaccination follows a beta 
distribution as described by Maire et 
al [120] ( 1 ) 
1
1 1
1
(1 )
( , )
V
V
V
V
x x
B
 
2(1 )
1
V V
V
 
all-or-nothing Vaccination offers full protection to 
some people but no protection to 
others. 
(1 ) ( ) ( 1)V x V x  (1 )V V  
 
2.9.5. Proof that heterogeneity in transmission reduces the infected proportion in a clinical 
trial 
The heterogeneity in force of infection of malaria upon a population can be described by a distribution f . Let F be 
the family of such distributions, then f F satisfies 
 0
0
:
( ) 1
( ) 1
f
f x dx
xf x dx
 
The expected cumulative proportion infected under a homogeneous force of infection will be ( ) 1 TI T e . Under 
a heterogeneous force of infection the expected infection proportion will be  
 
0
( ) 1 ( )x TfI T e f x dx  
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To show that on average fewer people become infected in a heterogeneous setting, we need to prove 
( ) ( )fI T I T . 
For 0a T prove 
 
0
( ) 1a axe e f x dx  
First calculate the upper bound 
 
0
sup ( )axf
f F
U e f x dx  
Since 1 [0, )axe x we have 
 
0 0
( ) ( ) 1axe f x dx f x dx  
so 1fU . Now consider the family of mean-1 distributions 
 
1 1
( ) ( ) ( )f x x x  
with 
 
0
1 1
( )ax ae f x dx e  
which tends to 1 as . Thus 
 
0 0
sup ( ) sup ( ) 1ax axf
f F
U e f x dx e f x dx  
So 1fU . Note that this bound is not attained in F since lim ( ) ( )f x x which has mean 0, and therefore isn’t 
in F .  
Now calculate the lower bound fL . 
 
0
inf ( )axf
f F
L e f x dx  
Let ( )T x be the tangent to axe at 1x . 
 ( ) (1 )aT x e a ax  
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Since ( ) axT x e xwe have 
 
0 0 0 0
( ) ( ) ( ) (1 ) ( ) ( )ax a a ae f x dx T x f x dx a e f x dx ae xf x dx e  
So afL e . Now considering the mean-1 distribution ( ) ( 1)f x x  we have 
 
0
( 1)ax ae x dx e  
so afL e . 
 
2.9.6. Prove that a vaccine with individual vaccine efficacy V will protect at least as many 
people as a leaky vaccine and at most as many people as an all-or-nothing vaccine. 
The mean infected proportions for leaky and all-or-nothing vaccines with individual efficacy V will be given by 
 
(1 )
leak
aon
( ) 1
( ) (1 )(1 )
V T
T
I T e
I T V e
 
The distribution of vaccine response for a vaccine with individual efficacy V can be described by a distribution g . Let 
G be the family of such distributions, then g G  satisfies 
 
1
0
1
0
:[0,1]
( ) 1
( )
g
g x dx
xg x V
 
The mean infected proportion for a vaccine with response described by distribution g  will be 
 
1
(1 )
0
( ) 1 ( )x TgI T e g x dx  
Prove that the mean proportion infected is always greater than it is for an all-or-nothing vaccine, and less than it is 
for a leaky vaccine, i.e. 
 aon leak( ) ( ) ( )gI T I T I T  
This is equivalent to proving  
 
1
0
( ) 1 ( 1)aV ax ae e g x dx V e  
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for 0a T . First calculate the upper bound 
 
1
0
sup ( )axg
g G
U e g x dx  
Let ( )U x be the straight line between (0,1) and (1, )ae  
 ( ) 1 ( 1)aU x e x  
Since ( ) [0,1]axU x e x  we have 
 
1 1 1 1
0 0 0 0
( ) ( ) ( ) ( ) ( 1) ( ) 1 ( 1)ax a ae g x dx U x f x dx g x dx e xg x dx V e  
So 1 ( 1)agU V e . Now consider the function aon ( ) (1 ) ( ) ( 1)g x V x V x  which gives 
 
1
aon
0
( ) 1 ( 1)ax ae g x dx V e  
And hence 1 ( 1)agU V e . 
Now calculate the lower bound  
 
1
0
inf ( )axg
g G
L e g x dx  
Let ( )L x be the tangent to axe at the point x V . 
 ( ) (1 )aVL x e aV ax  
Since ( ) [0,1]axL x e x  we have 
 
1 1 1 1
0 0 0 0
( ) ( ) ( ) (1 ) ( ) ( ) (1 )ax aV aV aV aV aVe g x dx L x g x dx aV e g x dx ae xg x dx aV e ae V e  
So 
aV
gL e . Now consider the function leak ( ) ( )g x x V which gives 
 
1
leak
0
( )ax aVe g x dx e  
and hence 
aV
gL e .  
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Chapter 3. Methods for estimating the relationship between 
pre-erythrocytic immune responses and protection from P. 
falciparum infection in treatment re-infection studies 
 
Vaccines to several diseases provide protection by inducing a similar or superior immune response to that generated 
following naturally occurring infection. However, despite considerable progress in the development of vaccines for 
preventing P. falciparum infection, the relationship between naturally acquired pre-erythrocytic immune responses 
and protection from infection remains poorly understood. In this chapter, I review published studies investigating 
the relationship between markers of pre-erythrocytic immunity and protection from infection and clinical malaria.   
 
3.1. Introduction 
Vaccines targeting the pre-erythrocytic stages of the P. falciparum parasite are likely to be an invaluable tool for 
preventing malaria associated deaths and reducing transmission in the future. There are several infection-blocking 
malaria vaccines currently under development [15, 16, 207], all of which confer protection by boosting some 
element of the pre-erythrocytic (PE) immune response, often to levels much higher than observed under conditions 
of natural exposure. Recent advances in vaccine development have led to renewed interest in the PE immune 
response [33], both naturally acquired and vaccine-induced. 
When a P. falciparum infectious Anopheles mosquito takes a blood meal from a human, sporozoites are inoculated 
into the tissue surrounding the injection site [208]. Some sporozoites migrate to blood vessels where they are 
carried to the liver, and others are immobilised or drained to regional lymph nodes [209]. Upon reaching the liver 
sporozoites invade a hepatocyte where they differentiate into liver-stage parasites before finally releasing 
merozoites into the blood stream a few days later [29]. The PE immune response can prevent the successful 
development of sporozoites via antibody- or cell-mediated immune responses targeting sporozoite antigens: the 
prime targets being circumsporozoite protein (CSP), thrombospondin-related adhesion protein (TRAP) and liver-
stage antigen 1 (LSA-1). The mechanisms underlying antibody-mediated protection include inhibition of hepatocyte 
invasion or opsonisation of sporozoites for uptake by macrophages and dendritic cells. It has also been observed that 
mosquitoes inoculate fewer sporozoites into immunized as compared to non-immunized mice, presumably due to 
the formation of antigen-antibody complexes in the proboscis [210]. Cell-mediated immunity is provided by CD4+ or 
CD8+ T cells, both of which have been observed to eliminate infected hepatocytes in vitro [211, 212]. Furthermore, 
CD4+ T cells specific for liver-stage antigens produce a mixture of the cytokines IL-2, IFN-γ and TNF-α which have 
been shown to inhibit the intracellular stages of the parasite [213].  
The failure of sporozoite inoculations to consistently progress to blood-stage malaria has been observed in both 
artificial challenge studies [214] and under conditions of natural exposure [145, 152]. In children exposed to malaria 
in Ifakara, Tanzania it was estimated that 93% and 99.6% of sporozoite inoculations failed to progress to blood-stage 
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infection in the low and high transmission seasons, respectively [215, 216]. The proportion of infectious mosquito 
bites progressing to blood-stage infection has been termed the transmission efficiency. Transmission efficiency can 
be defined on an individual level as the probability that an infectious mosquito bite leads to blood-stage infection, or 
on a population level as the proportion of mosquito bites on a population that cause new blood-stage infections. 
Smith et al [195] have reviewed studies reporting both  the entomological inoculation rate (EIR) and the force of 
infection in young children and noted that transmission efficiency decreases with increasing EIR. Several 
explanations for this effect have been put forward; heterogeneity in the force of infection [195]; an infection-
blocking PE immune response [217, 218]; density-dependent inhibition of sporozoite inoculation [160, 219]; and 
inhibition of intra-hepatic development by blood-stage parasites [220]. In addition, a strong blood-stage immune 
response that induces rapid clearance of parasites before detection can be conflated with a reduction in 
transmission efficiency [221]. 
Transmission efficiency is also dependent on age. In studies of the time taken for P. falciparum parasites to re-
appear in the blood following treatment, the time until detection of re-infection for adults has been observed to be 
significantly longer than for children, suggesting a reduction in transmission efficiency with age [216, 222, 223]. This 
effect has been observed despite the fact that Anopheles mosquitoes bite adults more often than smaller children 
because of their larger surface area [189, 224]. 
Understanding the relationship between transmission efficiency and EIR and age is crucial for understanding the 
epidemiology of malaria transmission and the impact of PE vaccines. Smith et al [195] have explained the variation in 
transmission efficiency in children under six in terms of heterogeneity in the force of infection. If biting is 
homogeneous then infections are evenly distributed across the population resulting in a high transmission efficiency. 
If instead biting is heterogeneous, for example if 20% of people receive 80% of bites, then transmission efficiency 
will be low as most bites will be concentrated on the highly exposed 20% who are likely to already be infected.  
Heterogeneity in the force of infection, density-dependent inhibition of sporozoite inoculation and inhibition of 
intra-hepatic development by blood-stage parasites cannot however explain the observed difference in transmission 
efficiency between children and adults. The most common explanation for this reduction in transmission efficiency 
with age is the acquisition of PE immunity [217]. However, attempts to quantify the magnitude of the PE immune 
response have been complicated by apparently contradictory results from studies investigating the relationship 
between markers of immunity and protection from infection. For example, the relationship between naturally 
acquired anti-CSP antibodies and protection from infection has been found to be positive [225], negative [226] and 
non-significant [227]. In order to explain these contradictory observations, we review existing published studies of 
the relationship between PE immune responses and protection from infection or clinical malaria, and describe how 
the results of these studies must be interpreted in terms of their study design and statistical power.   
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3.2. Methods 
3.2.1. Review of studies of pre-erythrocytic immune responses 
A search of the published literature using a systematic methodology for studies investigating the relationship 
between markers of naturally acquired PE immunity and protection from P. falciparum infection was conducted 
using the electronic online database PubMed. The search terms used were “(malaria OR falciparum) AND (pre-
erythrocytic OR infection-blocking)”. The results of this search were supplemented by iterative reviews of the 
reference lists of relevant published papers. 21 studies investigating the relationship between measures of antibody- 
and cell-mediated PE immune responses and protection from P. falciparum infection were identified (Table 3.3). A 
further 9 studies with clinical malaria as an endpoint were identified; these studies are summarised in Table 3.4. 
There was substantial variation in the design of the studies identified. With a few exceptions the studies had either 
cross-sectional or longitudinal designs. In cross-sectional studies volunteers from a cohort are tested at the 
beginning and end of (and sometimes during) a study for parasites and immune responses. In longitudinal studies, 
active detection of infection (ADI) is performed by testing volunteers for parasites at a given frequency, for example 
every week. These study designs are summarised in Figure 3.1. Studies can be further classified according to how the 
immune response data are analysed. Some studies treat immune responses as a binary variable (e.g. high vs. low 
responders, or sero-positive vs. sero-negative), whereas some treat immune response as a continuous variable (e.g. 
antibody titre or number of antigen specific T cells per million). Based on study design and classification of immune 
response, the studies can be classified into four categories: 
1. Cross-sectional study with binary immune response. Volunteers are split into two categories according to the 
measured immune response (e.g. antibody titre), and the presence of infection is tested at cross-sections. A 
common study design involves clearing existing infections and then taking a cross-section to test for new 
infections a number of weeks later. Logistic regression can be used to test for an association between immune 
response and protection from infection. Alternative suitable tests are a chi-square test or Fisher’s Exact test. 
 
2. Cross-sectional study with continuous immune response. Similar to the previous study design except that PE 
immune responses are analysed as a continuous variable. Logistic regression can be used to investigate the 
association between PE immunity and protection from infection. An alternative suitable test would be a Student 
t-test. 
 
3. Longitudinal study with binary immune response. Volunteers are treated to clear existing infections and 
followed longitudinally with ADI every week or every fortnight. Immune responses, usually measured at the 
beginning of follow-up, are used to classify participants into high and low categories. Cox Proportional Hazards 
(PH) can be used to test for an association between immune response and protection from infection.  
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4. Longitudinal study with continuous immune response. Similar to the previous study design except that PE 
immune responses are analysed as a continuous variable. Cox PH is a suitable tool for statistical analysis. 
 
 
Figure 3.13: Schematic representation of a treatment re-infection study for measuring pre-erythrocytic immune responses. The solid black 
lines denote when samples are taken for a study with two cross-sections, and the dashed lines indicate when additional samples need to be 
taken for a longitudinal study. The difference between the cumulative proportion exposed to infection (green) and the cumulative proportion 
parasite positive (blue) is explained by pre-erythrocytic immunity and sporozoite inoculations that do not progress to blood-stage infection 
due to chance. The difference between the cumulative proportion parasite positive (blue) and the cumulative proportion with clinical malaria 
(red) is explained by blood-stage immunity. 
 
Logistic regression and Cox PH analyses provide a convenient statistical framework for investigating the relationship 
between PE immunity and protection from infection, as it is straightforward to include interactions between multiple 
immune responses and to adjust for confounders such as LLIN use, age and location [226, 228]. Most treatment re-
infection and PE vaccine studies using Cox PH to analyse data take the time of infection as the date of sampling when 
parasites were detected. However the true time of infection will have occurred at some time between the first 
positive sample and the previous negative sample. An interval censored analysis can be used to allow for the 
unknown infection time between consecutive samples. However, here, in keeping with the methodology of existing 
studies, we use the time to detection of parasites for analysis [117, 226].   
In addition to differences in study design and statistical methodology, there was a great deal of variation in the 
characteristics of the identified studies, with the most notable differences being in the endpoint under investigation, 
the study size and duration of follow-up, the age range of the cohort and the transmission intensity. With such 
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variation in study characteristics it was not feasible to perform a meta-analysis of the effects of PE antibody- and 
cell-mediated immune responses on protection from infection.  
In order to give an indication of a study’s power to detect an effect, each study identified in the review was scored 
against four key characteristics relating to study design and statistical methodology: 
 Study design. Studies with a longitudinal design with active detection for infection are scored 1 and cross-
sectional studies scored 0. 
 Immune response. Studies analysing immune response as a continuous variable are scored 1, and as a binary 
variable are scored 0. 
 Statistical test. Studies using Cox proportional hazards for analysis of longitudinal data or logistic regression 
for analysis of cross-sectional data are scored 1. 
 Study size. Studies where statistical tests are performed on populations of size greater than or equal to 100 
are scored 1.  
Based on these criteria, each study was assigned a Power Score between 0 and 4 as an indication of their power to 
detect an association between PE immune responses and protection (Table 3.3, Table 3.4). Similar metrics have been 
used with successful results in clinical medicine [229]. Although such a simple metric is somewhat arbitrary, it 
provides a useful tool for assessing evidence across multiple studies.  
 
3.2.2. Relationship between immune response and protection 
The relationship between a marker of PE immunity and protection from infection can be described by a dose-
response curve [230, 231]. Standard statistical tests for an association between markers of PE immunity and 
protection from infection generally don’t account for dose-response relationships, only assuming that greater 
immune responses are associated with increased protection.  
Consider the hypothetical dose-response relationships between PE antibody titres and protection from infection 
depicted in Figure 3.2.When protection from infection is described by dose-response curve (A), the population under 
investigation will consist of a protected and an unprotected group. A statistically significant association between high 
antibody titres and protection is likely to be found whether antibody titres are analysed as a binary or a continuous 
variable. Dose-response curve (B) describes a continuous relationship between antibody titre and protection from 
infection. If antibody titre is analysed as a binary variable by splitting the cohort into low and high titre groups, an 
association between high titres and protection may be missed, as statistical tests will be based on comparisons 
between two partially protected groups. Analysing titres as a continuous variable will improve chances of detecting 
an association between antibody titres and protection. Dose-response curve (C) depicts a situation where there is a 
threshold for protection that is substantially higher than the median antibody titre observed in the population. 
Although there will be a small number of individuals protected by antibodies, the association is likely to be missed as 
the majority of the population are not protected despite some having high antibody titres.  
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Figure 3.2: Distribution of antibody titres (grey) and hypothetical dose-response curves for the relationship between antibody titre and 
protection from infection. (A) Threshold for protection lies in the region of observed antibody titres. (B) No threshold for protection but there 
is a continuous increase in the probability of protection with increasing antibody titre. (C) A threshold for protection exists at a substantially 
higher titre than the median observed antibody titre. 
 
3.2.3. Simulation of cross-sectional and longitudinal studies 
To aid in the interpretation of study results we performed simulations to demonstrate the effect of study size, 
duration of follow-up, and transmission intensity on the statistical power to detect an effect of PE immunity.  
In the absence of PE immunity, we assume transmission efficiency 0b , that is, a proportion 0b of inoculations 
progress to blood-stage infection. Transmission efficiency can be reduced by PE antibodies (or cell-mediated 
immunity). We assume that antibody titre confers protection from infection described by a dose response curve of 
the form 50
log(2)
( )P e , where 50 is the antibody titre conferring 50% protection from infection (corresponding 
to curve B in Figure 3.2) [232]. The transmission efficiency of a person with antibody titre is then reduced to
0( ) ( )b b P . In a region with entomological inoculation rate , the force of infection will then be given by
0( ) ( )b P . After clearance of any existing infection with anti-malarial drugs, the probability that a person 
with antibody titre will have been re-infected by time t is given by
( )( ) 1 tI t e . We further assume that there 
is heterogeneity in the force of infection such that the infectious bites are Log-Normally distributed across the 
population at risk, independently of their antibody titre [233]. For simplicity we assume people don’t clear parasites 
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before the detection of infection. We ignore sub-microscopic infections and issues of sensitivity and specificity, 
although the simulations can be extended to model these. 
The outcome of 1 of 10,000 simulations, as well as the variation in antibody titres and force of infection in the study 
population is shown in Figure 3.3. The parameters used for the simulations are given in Table 3.1. 
 
Table 3.1: Parameters for simulation of treatment re-infection studies.  
Parameter description  30% protection 50% protection 
duration of follow-up (weeks) T 12 12 
baseline transmission efficiency 
0b  0.55 0.55 
mean Ab titre (arbitrary units)  1 1 
variance in Ab titre 2  0.75 0.75 
Ab titre for 50% protection 
50  
1.66 0.76 
low transmission EIR (ibppy)  5  5  
high transmission EIR (ibppy)  150  150  
coefficient of variation in EIR 
EIR  
0.5 0.5 
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Figure 3.3: Simulated longitudinal study for evaluation of the relationship between protection from infection and pre-erythrocytic antibodies. 
It is assumed that 100 volunteers are followed up for 12 weeks with active detection of infection. (A) Log-normal distribution of antibody titres 
in the study cohort, split into high (blue) and low (red) responders. (B)  Distribution of transmission efficiency in the study population, split into 
high (blue) and low (red) responders. (C) Heterogeneity in the force of infection: distribution in the number of infectious bites per night. (D) 
Sample Kaplan-Meier curves for high and low responders. The red and blue shaded regions represent 95% confidence intervals for the KM 
curves of low and high responders, respectively. The existence of a substantial overlap between the shaded regions illustrates the low 
statistical power to differentiate between high and low responders. 
 
3.2.4. Estimation of statistical power to detect the effect of pre-erythrocytic immunity 
We consider the effect of antibodies to two hypothetical PE antigens, causing a 30% and a 50% reduction in the force 
of infection, respectively (Table 3.4). We consider two forms of trial design: a longitudinal study with weekly ADI for 
12 weeks, and a cross-sectional study with a cross-section at the time of parasite clearance and another cross-
section 12 weeks later. Note that the cross-sectional trial design is equivalent to the longitudinal design without the 
measurements from ADI. The simulated data is analysed using either Cox proportional hazards or logistic regression. 
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3.3. Results 
3.3.1. Review of studies of pre-erythrocytic immune responses 
The review identified 21 studies of the association between markers of PE immunity and protection from infection 
(Table 3.3), and 11 studies of the association between markers of PE immunity and clinical malaria (Table 3.4). 
Although there was substantial variation in the study design and statistical methods used in the identified studies, 
there was a clear association between a study’s Power Score and the likelihood that it reported a significant 
association between a marker of PE immunity and protection from infection or clinical malaria. This is demonstrated 
in Table 3.2 which shows the outcomes of statistical tests at the 5% significance level broken down by Power Score 
and endpoint. The results in Table 3.2 suggest that the probability of detecting a significant effect can be increased 
by increasing a study’s Power Score, i.e. increasing study size, performing longitudinal follow-up, and analysing 
immune markers as continuous variable using Cox or Logistic regression.     
 
Table 3.2: Proportion of tests from identified studies reporting a statistically significant association between markers of PE immunity and 
protection from infection or clinical malaria at the 5% significance level. Tests have been stratified according to their Power Score and 
endpoint. 
 Power Score 
 1 2 3 4 
endpoint     
infection 17% (2/12) 25% (6/24) 60% (3/5) –  (0/0) 
clinical malaria 33% (2/6) 38% (5/13) 20% (1/5) 100% (3/3) 
total 22% (4/18) 30% (11/37) 40% (4/10) 100% (3/3) 
 
13 studies investigating the association between pre-erythrocytic antibodies and protection from infection were 
identified (Table 3.3); 2/12 found a significant association between anti-CSP antibodies and protection from 
infection, and 1/3 found a significant association between anti-TRAP antibodies and protection. No studies found a 
statistically significant association between anti-LSA1 antibodies and protection from infection. One study found a 
marginally significant association [234], however this association is likely due to correlation with other immune 
responses as LSA-1 epitopes are only expressed once a sporozoite has invaded a hepatocyte, at which stage 
immunoglobulin G (IgG) antibodies cease to be effective [235]. 8 studies investigating the effect of cell-mediated 
immune (CMI) responses directed against the PE stages were identified:  2/2 found a significant association between 
CSP-specific CMI responses and protection from infection, 2/2 found a significant association between TRAP-specific 
CMI responses and protection, and 4/6 found a significant association between LSA1-specific CMI responses and 
protection.  
A larger proportion of studies found a significant association between cell-mediated immune responses and 
protection than between antibodies and protection suggesting that cellular responses may have a more important 
role in preventing infections than humoral responses [218]. However, an alternative explanation could be that 
studies of CMI responses were better designed than studies of antibody responses, as reflected in higher average 
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Power Scores for studies of CMI responses (mean Power Score 2.3 vs. 1.6). Better designed and more powerful 
studies will be more likely to detect a statistically significant association, if indeed there is a true relationship 
between PE immune response and protection from infection.    
 
3.3.2. Simulated effect of study size on statistical power 
The results of simulations to estimate the probability that a study will detect the effect of PE immunity at the 5% 
significance level are shown in Figure 3.4. As expected, statistical power increases with study size, and there is a 
higher probability of detecting the effect of an antibody that confers 50% protection from infection than one that 
confers 30% protection. Furthermore, greater statistical power is expected in high transmission settings when study 
data is analysed using Cox PH. Logistic regression is expected to have lower statistical power in high transmission 
settings as it is likely that all volunteers will develop infection during follow up.  
When analysing the relationship between immune response and protection, more statistical power can be obtained 
by treating the immune response as a continuous variable (e.g. antibody titres, antigen specific T cells per million) 
than as a binary variable (e.g. high vs. low responders, sero-positive vs. sero-negative). This is because assigning 
continuous data to high and low categories reduces the amount of information captured in the data.  
Importantly, even with a longitudinal design utilising a continuous measure of immunity, studies with 50 individuals 
have around 10% power to detect a 30% protection against infection in low transmission settings and 30% power in 
high transmission settings. Even for a larger, substantial effect size similar to that conferred by the RTS,S vaccine 
(50% protection against infection [133]), a study of 50 individuals would be under-powered in a low transmission 
setting. The simulation results suggest that cross-sectional surveys are likely to be underpowered to detect any likely 
association between individual immune responses and protection from infection except if the effect size is large 
(50% or more), the study population is >100 individuals, and the immune response is considered as a continuous 
variable. 
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Figure 3.4: Probability of observing a statistical relationship at the 5% significance level between a PE immune response and protection from 
infection. (A) A study in a low transmission setting (EIR=5) where 30% of infections are prevented by PE immunity. (B) A study in a high 
transmission setting (EIR=150) where 30% of infections are prevented by PE immunity. (C) A study in a low transmission setting (EIR=5) where 
50% of infections are prevented by PE immunity. (D) A study in a high transmission setting (EIR=150) where 50% of infections are prevented by 
PE immunity. 
 
3.3.3. Simulated effect of sampling frequency on statistical power 
Analysing trial data using Cox PH as opposed to logistic regression increases the statistical power to detect a PE 
immune response as Cox PH analysis utilises the additional information contained in the time of infection, whereas 
logistic regression only utilises the information on who becomes infected. In the extreme case of a study with a 
sufficiently long duration of follow up such that all participants become infected, a logistic regression analysis will be 
completely uninformative. The additional statistical power of the Cox PH analysis needs to be balanced against the 
cost incurred by ADI. A logistic regression analysis will require at least two cross-sectional blood smears at the start 
and end of the study, whereas a Cox PH analysis will require additional cross-sectional blood smears at weekly, 
fortnightly or monthly intervals throughout the study. Increasing the frequency of sampling for ADI will increase 
statistical power but at a cost of the resources needed for additional sampling.  
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In Figure 3.5 the statistical power of a longitudinal study as a function of sampling frequency is shown. In a low 
transmission setting, the benefit of increased sampling is negligible as little additional information is obtained by 
testing volunteers who are unlikely to become infected. In a high transmission setting, statistical power decreases 
with reduced sampling frequency. As power decreases slowly with sampling frequency, it may be most efficient to 
sample fortnightly or monthly if that would allow an increase in the total number of volunteers recruited to the 
study. In more intense transmission settings where all volunteers are likely to become infected sampling frequency 
will need to be increased to capture the information contained in the time to re-infection. Selecting the optimal 
sampling frequency will depend on study size and duration, the expected magnitude of the immune response under 
investigation, transmission intensity and seasonality, the cost of processing samples and the need to avoid taking too 
many samples from any one person.  
 
 
Figure 3.5: The effect of sampling frequency on the statistical power to detect the effect at the 5% significance level of a PE immune response 
that prevents 50% of infections in a study of 100 volunteers followed for 12 weeks. (A) Low transmission setting (EIR=5). (B) High transmission 
setting (EIR=150). 
 
3.4. Discussion 
The pre-erythrocytic immune response constitutes the first line of defence as the P. falciparum parasite enters the 
human host, and as such will impact upon malaria transmission, the incidence of clinical and severe malaria, and the 
efficacy of infection-blocking vaccines. Despites its key role in the clinical epidemiology of malaria, the magnitude of 
the PE immune response remains poorly quantified. In particular, identifying immune responses that significantly 
correlate with protection from infection has been difficult due to the low statistical power of treatment re-infection 
studies.  Analysis of the results of a review of the published literature demonstrates that the majority of studies 
failed to detect a significant association between PE immune responses and protection from infection or clinical 
malaria (Table 3.3). However, our simple Power Score suggests that the likelihood of a study detecting statistically 
significant associations can be improved by increasing study size, implementing longitudinal follow-up of 
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participants, analysing immunological data as a continuous variable, and using Cox or logistic regression for 
estimation.  
The results of our review demonstrate that there is a clear association between markers of cell-mediated immunity 
and protection from infection. However, comparable studies of PE antibodies do not demonstrate a consistent 
association between antibodies and protection from infection, despite the well-established role of antibodies as an 
immunological correlate of protection in vaccine studies [231]. This suggests that the cell-mediated component of 
the PE immune response confers greater protection than the antibody component. However an alternative 
explanation could be due to differences in study design, with existing studies of cell-mediated immunity having more 
power to detect an effect than studies of humoral immunity. This is demonstrated by our simple Power Score which 
shows that studies of the cell-mediated response had higher average power to detect an association than studies of 
antibody-mediated responses.  
Designing a study to investigate the relationship between PE immune responses and protection from infection can 
be viewed as an optimisation problem with the aim of maximising the statistical power to detect an effect, and 
ensuring the effect size is estimated correctly, given real world limitations on time and resources. There will be a 
trade-off between the number of volunteers recruited, the frequency of sampling, the duration of follow up, and the 
number of immune responses measured. The optimal study design will depend on numerous local characteristics 
such as transmission intensity and the age of volunteers, but in general, statistical power can be maximised by 
increasing the number of study volunteers, and performing the study in a high transmission setting. The easiest thing 
to do to maximise statistical power to detect PE immunity is to use an appropriate statistical test. Treating the 
immune response as a continuous as opposed to a binary variable ensures that all collected data is utilised. Further 
adjusting for covariates such as LLIN use and location can improve the accuracy of statistical analyses. An example of 
a Cox PH analysis of the relationship between continuous antibody titres and clinical malaria adjusted for 
confounding variables can be found in the study by Greenhouse et al [226].  
It may be beneficial to transform immune response data before analysis, for example antibody titres are often log-
normally distributed in a cohort so it may be useful to investigate the relationship between the logarithm of 
antibody titre and protection from infection. Going beyond conventional statistical analyses such as logistic 
regression and Cox PH, biologically motivated models using dose-response curves for the relationship between 
immune response and protection from infection can be used to test for nonlinear phenomena such as threshold 
effects [139, 232]. 
Two of the most intractable problems encountered while investigating the relationship between immune responses 
and protection from malaria are correlation between immune responses, and the potential for immune responses to 
act as markers for exposure. A PE immune response to malaria is likely to be comprised of antibody- and cell-
mediated responses directed against multiple parasite antigens [236]. These immune responses are likely to be 
substantially correlated as the acquisition of immunity depends on malaria exposure. Thus, if only a single immune 
response is measured, that immune response may be acting as a marker for the entire immune response. Measuring 
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multiple immune responses allows a more detailed investigation of the relationship between PE immunity and 
protection from malaria. However, even if multiple immune responses are measured, it may still be the case that 
immunity is conferred via some other undetected immune response correlated with the measured response. A 
potential solution to this problem may be to use microarray analysis where plasma from individuals exposed to 
malaria is tested against a large proportion of the P. falciparum proteome [71, 236]. 
Heterogeneity in malaria exposure will lead to heterogeneity in the rate of acquisition of immunity, with those 
individuals under the most intense exposure developing the strongest immune response [204]. Individuals identified 
as having a strong immune response may therefore be at increased risk of future infection compared to the rest of 
the cohort as their increased exposure may outweigh the benefits of a stronger immune response. This phenomenon 
may lead to a study identifying protective antibodies as a risk factor for future infection. 
There will be variation in the measured naturally acquired PE immune responses across a cohort (Figure 3.3A). The 
ability of a statistical test to detect an effect of an immune response is conditional on there being enough variation 
in the immune response to detect corresponding variation in the outcome. For example, if all volunteers have strong 
immune responses with little variation, then a study will be unable to detect the effect of the immune response as 
there will be no volunteers with weak immune responses to compare against. The need to have sufficient variation 
in immune response to detect an effect isn’t encountered in trials of vaccine-induced immune responses. Vaccine 
trials are designed to have a vaccine cohort with high vaccine-induced immune responses (if the vaccine is 
sufficiently immunogenic) and a control cohort with low immune responses. 
 
3.5. Conclusion 
The results of studies to investigate the association between markers of pre-erythrocytic immunity and protection 
from infection have often been inconclusive due to sub-optimal study design. The power to detect an effect of a pre-
erythrocytic immune response can be increased by increasing study size, performing longitudinal follow-up and 
analysing immune responses as a continuous variable using Cox proportional hazards. In addition, mathematical 
models based on dose-response curves may be used to identify non-linear relationships between markers of pre-
erythrocytic immunity and protection from infection that may be missed by conventional statistical analyses. 
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Table 3.3: Review of quantitative studies of the relationship between pre-erythrocytic immune responses and protection from malaria infection. Statistical results labelled * indicate that immune markers are 
positively associated with increased risk of infection. 
Location Cohort  Transmission Immune response Significance Study details Malaria 
endpoint 
Notes Score Ref 
Nyanza, Kenya 77 adults EIR = 120 CSP IgG NS (68) Weekly ADI for 12 
weeks 
infection Participants split as high-
low. High titres to 3 
antigens: HR = 0.43 (0.23 – 
0.80). 
2 [237] 
   TRAP IgG NS (68)    
   LSA-1 IgG NS (68)    
   Multiple IgG P = 0.006 (68)    
          
Uasin Gishu, 
Kenya 
71 adults  CSP IgG NS (50) Weekly ADI for 10 
weeks 
infection Participants split as 
positive/negative. 
2 [222] 
  TRAP IgG NS (50)    
  LSA-1 IgG NS (50)    
37 children  CSP IgG NS (32)    
  TRAP IgG P = 0.108 (32)    
          
Ndiop, Senegal 110 all age groups  CSP IgG NS (110) Weekly ADI 11 
weeks, clinical 
malaria for 21 
weeks 
infection Participants split as high-
low. CSP was significantly 
associated with duration 
of asymptomatic carriage.  
3 [228] 
          
Asembo Bay, 
Kenya 
79 infants EIR = 2-10 CSP IgG NS (51) Monthly ADI 1 
year 
 
infection Associations tested for 
were between maternal 
IgG and infection. Possible 
maternal IgG confounding. 
1 [238] 
  LSA1 IgG NS (51)    
          
Mali 39 young children, 
66 older children, 
88 adults 
 TRAP IgG P=0.005 (66) ADI every 2 
weeks for 30 
weeks 
infection 
p/µL > 
5000 
PH linear regression 2 [239] 
          
Thailand 135 adults  CSP IgG NS (53) Every 10 days for 
2 months then 
PCD for clinical 
malaria 
Infection Comparison of titres in 
infected volunteers. 
2 [240] 
          
Saradidi, Kenya 83 adults EIR≈135 CSP IgG NS (83) ADI every 2 
weeks for 98 days 
infection Linear regression between 
titre and day of 
parasitemia 
2 [241] 
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Table 3.3 (contd.): Review of quantitative studies of the relationship between pre-erythrocytic immune responses and protection from malaria infection. Statistical results labelled * indicate that immune 
markers are positively associated with increased risk of infection. 
Location Cohort  Transmission Immune response Significance Study details Malaria 
endpoint 
Notes Score Ref 
Farafenni, The 
Gambia 
Children 1-11 years  CSP IgG P = 0.01 (124) Weekly morbidity 
survey, 
fortnightly clinic, 
Cross-sectional 
comparison at 
beginning and 
end of season 
infection Participants split into sero-
positive/sero-negative. 
Significance for 
parasitemia tested with χ
2
 
test. 
2 [242] 
Adults 12+  CSP IgG NS (64) infection   
       
          
Gabon All ages  CSP IgG NS (144) 2 cross sections infection  1  [243] 
          
Thailand 140 children 5-15 
years 
 CSP IgG P = 0.07 (17 +34) 17 cases 
identified, and 34 
controls matched. 
Weekly ADI for 25 
weeks 
infection Participants were split into 
low and high titres. 
1 [244] 
          
Farafenni, The 
Gambia 
376 children EIR=25 in 
adults, EIR<6 
in children 
CSP IgG P < 0.01 (292)* 2 cross sections at 
beginning and 
end of rainy 
season 
infection CSP was positively 
associated with 
parasitemia but negatively 
associated with 
protection.  
1 [245] 
          
Burkina Faso All ages – 3212 
serum samples 
Seasonal 
EIR≈3-300 
CSP IgG NS 3 cross sections, 
every 2 months 
infection Participants split into high 
low titres. 
1 [246] 
          
Dienga, Gabon 61 children  CSP IgG (NANP)5 P=0.82 (n=25) ADI weekly then 
bi-weekly until 30 
weeks 
 Participants split by sero-
positive/sero-negative 
1 [234] 
   CSP IgG (NAAG)5 P=0.84 (n=25) infection   
   LSA-1 Rep IgG P=0.08 (n=25)    
   LSA-1 J IgG P=0.051 (n=25)    
          
Uasin Gishu, 
Kenya 
Children and adults  LSA-1 IgG NS (93) Weekly ADI for 10 
weeks 
Infection Participants split as 
positive/negative 
2 [247] 
 LSA-1 cell 
proliferation (SI) 
NS (57)    
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Table 3.3 (contd.): Review of quantitative studies of the relationship between pre-erythrocytic immune responses and protection from malaria infection. Statistical results labelled * indicate that immune 
markers are positively associated with increased risk of infection. 
Location Cohort  Transmission Immune response Significance Study details Malaria 
endpoint 
Notes Score Ref 
Uasin Gishu, 
Kenya 
Children and adults  LSA-1 IL-5 NS (69) Weekly ADI 10 
weeks 
infection Participants split as 
responder/non-responder 
2 [248] 
   LSA-1 IL-10 P=0.083 (77)      
   LSA-1 IFN-γ NS (94)      
   LAS-1 TNF-α NS (54)      
          
Asembo Bay, 
Kenya 
107 children 6 
months – 2 years 
EIR = 100-200 CSP, TRAP LSA-1 
IFN-γ 
P=0.007 (107) ADI infection Participants split into 
responders/non-
responders. 
2 [249] 
          
Nyanza, Kenya 178 adult males, 
12-35 years 
EIR ≈ 300 LSA-1 IL-10 P=0.05 (137) Weekly ADI for 16 
weeks 
infection Participants split into 
responders/non-
responders.  
3  [250] 
          
Kilifi, Kenya 217 all ages, 1 
month to 81 years 
EIR = 10 (3-15) TRAP IFN-γ P =0.05 (138) Weekly ADI 6 
months 
infection in 
2 months 
Participants split into 
responders/non-
responders.  
3 [251] 
   NS P=0.73 (138) infection in 
6 months 
  
          
Farafenni, The 
Gambia 
391 children, 3-8 
years 
 CSP-specific T cells P=0.04 ADI weekly infection Th3R peptide, multiple 
logistic regression 
3  [252] 
          
Papua New 
Guinea 
55 adults 17-88 
years 
 LSA-1 IFN-γ P<0.001 (n=38) Cross-sections at 
6 month intervals 
infection Only the aa 84-107 
peptide tested significant. 
3 others did not. 
1  [253] 
 LSA-1 IgG NS (n=38)    
          
Gabon 100 children with 
mild malaria 
EIR = 10-100 LSA-1 IFN-γ P<.001 (n=100) Case matching. 
ADI every 2 
weeks after 
discharge from 
hospital. 
infection  2  [254] 
 100 children with 
severe malaria 
EIR = 10-100 LSA-1 IFN-γ NS (n=100)     
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Table 3.4: Review of quantitative studies of the relationship between pre-erythrocytic immune responses and protection from clinical malaria. Statistical results labelled * indicate that immune markers are 
positively associated with increased risk of clinical malaria. 
Location Cohort  Transmission Immune 
response 
Significance Study details Malaria 
endpoint 
Notes Score Ref 
Farafenni, The 
Gambia 
Children 1-11  CSP IgG P = 0.08 (126) Weekly morbidity 
survey, fortnightly 
clinic, Cross-sectional 
comparison at 
beginning and end of 
season 
clinical 
malaria 
Participants split into sero-
positive/sero-negative. 
Clinical malaria tested 
with t-test. 
2 [242] 
          
Farafenni, The 
Gambia 
376 children EIR=25 in adults, 
EIR<6 in children 
CSP IgG NS (317) 2 cross sections at 
beginning and end of 
rainy season 
fever + 
parasite
mia 
 1 [245] 
          
Nyanza, 
Kenya 
86 children 3 
months – 8 years 
 CSP IgG NS (83) ACD 52 weeks clinical 
malaria 
Participants split as high-
low. High titres to 3  
antigens: HR = 0.29 (0.10 – 
0.81) 
2 [255] 
 TRAP IgG NS (83)    
 LSA-1 IgG P=0.02 (83)    
  Multiple IgG P=0.009 (83)     
          
Kilombero, 
Tanzania 
83 infants EIR≈365 CSP IgG NS (83) PCD clinical 
malaria 
Cox PH using titration 
units. Possible maternal 
IgG confounding. 
3 [256] 
  LSA-1 IgG NS (83)    
          
Balonghin, 
Burkina Faso 
244 children 6 
months 10 years 
EIR<10 CSP IgG P = 0.12 (124) ACD for clinical 
malaria during peak 
transmission 
clinical 
malaria 
HR = 0.74 (0.50-1.09). 
Participants split into 
responder/non-responder. 
3 [225] 
Tensobenteng
a, Burkina 
Faso 
142 children 6 
months 10 years 
EIR>100 CSP IgG P=0.012 (29)  HR = 0.37 (0.17-0.80). 
Participants split into 
responder/non-responder. 
2  
          
Bamako, Mali 327 children aged 
1-12 years 
 TRAP 1.0 IgG P=0.32 (n=327) case matching in 
hospitals 
cerebral 
and 
clinical 
malaria 
85 children admitted to 
hospital case-matched to 
242 children with 
uncomplicated malaria. 
Comparisons made 
between seroprevalence 
of cerebral and 
uncomplicated cases. 
1 [257] 
  TRAP C IgG P=0.003 (n=327)   
  CSP IgG P=0.0735 (n=327)   
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Table 3.4 (contd.): Review of quantitative studies of the relationship between pre-erythrocytic immune responses and protection from clinical malaria. Statistical results labelled * indicate that immune markers 
are positively associated with increased risk of clinical malaria. 
Location Cohort  Transmission Immune 
response 
Significance Study details Malaria 
endpoint 
Notes Score Ref 
Bancoumana, 
Mali 
285 children 1-9 
years 
 TRAP IgG NS 5 serological cross-
sections and one 
longitudinal follow 
up. 
 Article in French. 2 [258] 
 CSP IgG NS    
          
Kampala, 
Uganda 
414 Children 1-4 
years 
 CSP IgG P=0.01* Monthly ACD. clinical 
malaria 
Cox PH adjusted for 
covariates. Continuous 
antibody response. 
4 [226] 
  LSA-1 IgG P=0.02*    
          
Kisumu, 
Kenya 
Adults and children High trans: PfPr0-
5= 95%. Low 
trans: 
 PfPR0-5=5% 
TRAP IFN-γ NS (38) ACD 36 weeks clinical 
malaria 
Participants split as 
responder/non-responder. 
LSA-1 T3 peptide 
measured by ELISA, high 
trans 
1 [259] 
 LSA-1 IFN-γ P=0.02 (38)    
          
Ngerenya, 
Kenya 
112 all ages, 1 
months to 81 years 
EIR = 10 Cultured TRAP P=0.028 (94) Weekly ACD for 300 
days 
clinical 
malaria 
Logistic multivariate 
analysis with continuous 
variable.  
3 [260] 
 Cultured CSP P=0.16 (80) 3  
 CD4
+
CD25
high
 P=0.039 (108) 4  
          
Dienga, 
Gabon 
300 children  LSA-1 Rep IgG P=0.065 (n=76) ACD bi-weekly clinical 
malaria 
Relationships were 
significant in Dienga but 
not Pouma.  
2 [261] 
   LSA-1 IFN-γ and 
IL-10 
P=0.024 (n=78)   
   LSA-1 CTL IFN-γ 
and IL-10 
P=0.036 (n=78)   
Pouma, 
Cameroon 
186 children  LSA-1 IgG NS   
  LSA-1 IFN-γ and 
IL-10 
NS    
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Chapter 4. Efficacy Model for Antibody-mediated Pre-
erythrocytic Malaria Vaccines 
 
Published as: White MT, Griffin JT, Riley EM, Drakeley CJ, Moorman AM, Sumba PO, Kazura JW, Ghani AC, John CC: 
Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proceedings of the Royal Society B-Biological 
Sciences 2011, 278(1710):1298-1305. 
 
In the previous chapter I reviewed the association between markers of pre-erythrocytic immunity and protection 
from infection. In this chapter I will demonstrate how the relationship between antibodies to the sporozoite antigens 
circumsporozoite protein, thrombospondin-related adhesive protein and liver-stage antigen 1, and protection from 
infection can be estimated by fitting models to data from a treatment re-infection study in Kenyan adults. Using this 
relationship between naturally acquired antibodies and protection from infection, I estimate the effect of anti-CSP 
and anti-TRAP antibody boosting vaccines on protection from P. falciparum infection.  
 
4.1. Introduction 
The outcome of an infectious bite is often viewed as a binary event in which the host either does or does not 
develop blood-stage malaria. However every bite can inject from 0 to 100+ sporozoites [262, 263] with the 
probability of blood-stage infection increasing for larger doses. Sporozoites that have been deposited in the skin or 
capillaries will remain at the injection site for up to an hour before trickling into the blood stream and migrating to 
the liver [209, 264]. Sporozoites are susceptible to antibody opsonisation from immunoglobulin G antibodies 
recognising sporozoite antigens at any stage in this journey [66]. 
Antibodies to the pre-erythrocytic antigens circumsporozoite protein (CSP), thrombospondin-related adhesive 
protein (TRAP) and liver-stage antigen 1 (LSA-1) have been shown to correlate with protection from P. falciparum 
infection in field studies [222, 237, 255]. CSP covers the entire surface of the sporozoite and is found on the plasma 
membrane of liver-stage parasites [72]. Antibodies to CSP immobilise sporozoites and inhibit parasite invasion of 
hepatocytes [73]. TRAP is found primarily within the sporozoite’s micronemes and on the sporozoite surface [74]. 
Antibodies to TRAP inhibit sporozoite gliding motility [265] and hepatocyte invasion [75], however there is some 
evidence to suggest that anti-TRAP antibodies do not inhibit sporozoite infectivity in vivo [266]. LSA-1 is expressed 
soon after the sporozoite invades the hepatocyte in the liver [76]. As LSA-1 is only expressed inside the hepatocyte, 
which antibodies are unable to access, anti-LSA1 antibodies are not expected to provide protection from infection 
although LSA-1 is a likely target of cell-mediated immunity [76]. As pre-erythrocytic antibodies are directed at 
different aspects of sporozoite biology they are likely to interact cooperatively in the prevention of infection. 
John et al [237] demonstrated a significant correlation between titres to the pre-erythrocytic antigens CSP, TRAP and 
LSA-1 and protection from infection. Individuals with titres to all three antibodies above a cut-off of 2 arbitrary units 
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(AU) were found to have a reduced risk of infection of 0.43 (95% CI, 0.23 – 0.80) compared to individuals with low 
antibody titres. Here we develop a mathematical model to characterise the relationship between pre-erythrocytic 
antibody levels and the probability of infection per infectious bite based on these data. This relationship is then used 
to explore the efficacy of antibody boosting vaccines based on combinations of the antigens CSP and TRAP.  
 
4.2. Methods 
4.2.1. Data  
We analysed data on IgG antibody titres to CSP, TRAP and LSA-1, as well as the blood-stage antigens apical 
membrane antigen-1 (AMA-1), erythrocyte binding antigen-175 (EBA-175) and merozoite surface protein-1 (MSP-1), 
and time to re-infection with P. falciparum, from a study of 68 adults conducted in Kanyawegi, Nyanza Province, 
Kenya from August to December 2001. Approval for this study was obtained from the Ethical Review Board for the 
Kenya Medical Research Institute and University Hospitals of Cleveland at Case Western Reserve University. Full 
details of the trial can be found in John et al [237]. In brief, the population of Kanyawegi is approximately 3,500 and 
is located in a malaria-endemic region with an approximate entomological inoculation rate (EIR) of 120 infectious 
bites per person per year [267]. Individuals agreeing to participate were given quinine for five days and doxycyline 
for seven days to clear parasitemia, and then followed for malaria infection by microscopic inspection of blood 
smears obtained weekly for 14 weeks. P. falciparum infection was confirmed by PCR. Individuals who missed more 
than two weeks of blood smear testing were included in analysis up to the time of their last blood smear. Blood for 
laboratory studies to measure antibody titres was obtained by venepuncture prior to anti-malarial treatment. 
Antibody titres were measured in arbitrary units (AU) [237]. The IgG antibody titres to CSP, TRAP and LSA-1 were 
approximately Log-Normally distributed with mean and standard deviation of 6.83 (5.54) AU, 4.80 (4.31) AU and 8.60 
(12.34) AU respectively.  
 
4.2.2. Probability of infection per infectious bite 
Data from experiments by Beier et al [262, 263] suggest that the number of sporozoites injected per bite follows an 
approximately Geometric distribution with arithmetic mean 10 and range 0-100+. For an infectious bite to progress 
to blood-stage malaria just one sporozoite must evade the pre-erythrocytic immune response. Denote the 
probability that a single sporozoite causes blood-stage malaria infection by 1p r . If sporozoites from an infectious 
bite act independently, the probability that k sporozoites cause blood-stage malaria is 1 (1 ) .kkp r  If the 
distribution of the number of sporozoites per bite follows a Geometric distribution with mean n, then the probability 
that k sporozoites will be injected is 
1
1 1
1 .
k
n n
 Thus the probability that a bite will cause blood-stage malaria 
infection, b, is: 
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1
1
1 1
1 1 (1 ) .
( 1) 1
k
k
k
nr
b r
n n n r
 
 
4.2.3. Dose-response curves 
We assumed that IgG antibodies to each of the CSP, TRAP and LSA-1 antigens will induce the opsonisation and 
phagocytosis of invading sporozoites as they make their way from the skin to the liver, and hence antibody titres 
constitute a correlate of risk [268] with higher titres reducing the probability infection. The relationship between IgG 
antibody titre and the probability of a sporozoite evading the associated immune response is modelled using a dose-
response curve. These fall into two qualitatively different categories: (i) convex where increases in dose lead to 
reduced increases in response; and (ii) threshold where the antibody response has a significant effect only once a 
threshold dose has been reached (Figure 4.1). A convex dose-response will result in leaky immunity and a threshold 
dose-response will give rise to all-or-nothing immunity.   
Let ijx be the IgG antibody titre to antigen j in individual i. Let ijr be the probability that a sporozoite survives the 
immune response to antigen j in individual i. For a Hill function dose-response in individual i with antibody titre to 
antigen j of ijx the probability that a sporozoite evades that antibody’s immune response is 
 
1
1
j
ij
ij
j
r
x
 
 where
j
is the antibody titre that reduces the probability of a single sporozoite infection by half and 
j
is a shape 
parameter. 1j gives a convex dose response-curve and 1j gives a threshold dose-response curve. For an 
exponential dose-response in individual i the probability that a sporozoite evades the immune response to antibody j 
is  
 
log(2)ij
j
x
ijr e  
 where
j
is the antibody titre that reduces the probability of sporozoite infection by half. An exponential function is 
always convex. 
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Figure 4.1: Example dose-response curves for the probability of sporozoite survival as a function of IgG antibody titre. The solid and dashed 
curves depict a convex dose-response relationship where the antibody is effective even at low levels. The dotted curve depicts a threshold 
dose-response curve where the antibody only becomes effective once a threshold has been reached. 
 
4.2.4. Pre-erythrocytic immune response 
For a sporozoite to successfully evade the pre-erythrocytic immune response it must survive the attack from each of 
the different antibodies and the cell-mediated immune response. Following the approach of Saul et al [269, 270] we 
assume each immune response is independent of the others so that 0 ,CSP ,TRAP ,LSAi i i ir r r r r , 
where r0 is the 
probability of a sporozoite evading the cell-mediated immune response in the absence of antibody. An alternative 
model incorporating interactions was also considered (see 4.6. Appendix 1). The probability that a bite from an 
infectious mosquito causes blood-stage infection is therefore  
( 1) 1
i
i
i
nr
b
n r
 
Given a constant EIR and infection probability ib , the probability that individual i will have developed blood-stage 
infection by time t will be 
( )
( ) 1 i L
b t t
I t e where 10Lt days is the time between sporozoite inoculation and the 
appearance of detectable blood-stage parasites.   
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4.2.5. Parameter estimation 
The parameters ,  and 0r were estimated by fitting this model to the data on time to re-infection using maximum 
likelihood methods. The data used are the antibody titres CSP TRAP LSA( , , )x x x x , and the time to re-infection or 
final censoring t.  
For individuals infected in the trial, the likelihood of them developing infection at time it  is 
( )i i Lb t t
ibe  
whilst for those censored at time it  the likelihood of remaining free from infection is 
( )i i Lb t te  
If individuals (1... )m  become infected and individuals ( 1... )m I are censored, the data likelihood is 
( ) ( ) ( )
0
1 1 1 1
( , , , ) i i L i i L i i L
m I m I
b t t b t t b t t
i i
i i m i i
L r x t b e e b e
 
Model fits were compared using the Akaike Information Criterion (AIC). 95% confidence intervals for the model 
parameters were estimated by calculating the inverse hessian of the log-likelihood surface at the maximum 
likelihood estimate. When fitting the model using Hill functions, an exponential function was retained for the LSA-1 
dose-response curve as this was better able to model the low level of protection offered by anti-LSA1 antibodies. 
In the model described here the pre-erythrocytic immune response is directed towards sporozoites, with the 
assumption that individual sporozoites act independently of each other. A model where the immune response was 
directed towards the infectious bite as a whole was also fitted. This gave an inferior fit to the data and predicted 
similar results to the sporozoite model, but it was not possible to distinguish between the two assumptions with the 
available data. 
 
4.2.6. Infection probability of humans 
Let ix be the vector of antibody titres from study participant i and assume that each data point ix is sampled from a 
multivariate Log-Normal distribution. Then log( )y x  follows the distribution 
3 1
2 2
11 1( ) exp ( ) ( )
2(2 ) det( )
Ty y V y
V
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where mean(log( ))ix  is the mean of the observed log antibody titres, and V  is the covariance matrix of the 
data. The mean transmission efficiency baseb  is obtained by integrating over the range of all possible titres to the 
three antibodies. 
3
base
R
( ) ( )b b y y dy  
where ( )b y is the infection probability given log antibody titre y . 
 
4.2.7. Antibody-boosting pre-erythrocytic vaccination 
If antibody titres to antigen j in a population are Log-Normally distributed before vaccination,
baseln ,j jjx V , 
then the mean antibody titre is 
2
base 2
baseAb
jjVe . Assume that vaccination will boost the antibody titres so that 
they are log-normally distributed about a higher mean,
vacln ,j jjx V , with vac base . The mean antibody 
titre after vaccination is then
2
vac 2
vacAb
jjVe . The mean vaccine-induced antibody boost is therefore 
2
vac base
2
boost vac baseAb Ab Ab .
jjVe e e  Hence the log antibody titres of the vaccinated population are 
Normally distributed with a mean of vac and variance matrix V. 
1
vac vac vac3/2 1/2
1 1
( ) exp ( ) ( )
(2 ) det( ) 2
Ty y V y
V
 
The probability that a vaccinated person will become infected after a bite from an infectious mosquito is 
 
3
vac vac
R
( ) ( )b b y y dy  
and vaccine efficacy is given by 
 vac
base
1
b
VE
b
. 
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4.3. Results 
4.3.1. Relationship between antibody titre and probability of infection 
The exponential dose-response curves provided a better and more parsimonious fit than the Hill function dose-
response curves (Table 4.1). The fitted dose-response curves for CSP and TRAP indicate that increased antibody titres 
will provide increased protection against sporozoite infection (Figure 4.2). In contrast, and in accordance with 
biological expectations, the fitted dose-response curve for LSA-1 indicates no significant role for anti-LSA-1 
antibodies in protection from infection.  
In the absence of any antibody response we estimated the probability of sporozoite survival r0=0.011 (95% CI, 0.004-
0.017). This captures failure of a sporozoite to initiate blood-stage infection due to cell-mediated immunity, chance 
(e.g. migrating to tissues other than the liver), and the possibility that inoculated sporozoites are immature or 
damaged [271]. There is expected to be a substantial T cell-mediated immune response directed at liver stage 
parasites as the data were collected from semi-immune adults in a region of stable malaria transmission. 
 
Table 4.1: Maximum likelihood estimates for dose-response curve parameters ( , )  to each of the antigens CSP, TRAP and LSA-1, and the 
probability of sporozoite survival in the absence of antibodies (r0). The Exponential dose-response model provides the most parsimonious fit 
based on the AIC. 
Dose-response 
curve  
MLE Parameter Estimates (95% confidence intervals) Model Fit 
0r  CSP  TRAP  LSA  CSP  TRAP  LSA
 
log( )L
 
AIC 
Exponential 0.011 
(0.005 – 0.017) 
 
13.07 
(0 – 27.96) 
11.64 
(0 – 27.75) 
9085.91 
(0 – 192936) 
– – – -223.7 455.5 
Hill function 0.010 
(0.000 – 0.033) 
20.30 
(0 – 274.3) 
6.51 
(0 – 49.3) 
7777 
(0 – 177461) 
96.2 
(0 – 8667) 
0.77 
(0 – 3.79) 
– -222.5 457.1 
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Figure 4.2: Estimated exponential dose-response curves for the relationship between probability of sporozoite survival and IgG antibody titre 
to each of the antigens CSP, TRAP and LSA-1. Dashed lines represent 95% confidence intervals for estimates. 
 
4.3.2. Probability of infection per infectious bite 
We estimate the mean transmission efficiency for this population to be b=0.056 which is in good agreement with the 
previously reported values of 0.012-0.086 [272] and 0.05-0.13 [273] for semi-immune adults in areas of intense 
malaria exposure. Figure 4.3 shows the estimated distribution of infection probability. Note that this variation is only 
due to variation in the IgG antibody titres as we assume the cell-mediated immune response is constant. The 
maximum infection probability is b=0.09 corresponding to the case of a person with very low IgG antibody titres and 
an average cell-mediated immune response. 
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Figure 4.3: Estimated distribution of infection probability per infectious bite in the study population. The variation in infection probability 
represented here is due only to variation in the CSP, TRAP and LSA-1 IgG antibody titres. 
 
4.3.3. Pre-erythrocytic vaccination 
The maximum anti-CSP antibody titre observed in the study by John et al [237] was 27 AU, 4 times the mean anti-CSP 
titre. A vaccine that boosts average anti-CSP antibody titres above the baseline titre by this amount would have a 
predicted efficacy (VE) of 0.47 (Figure 4.4), assuming that the parameters estimated for the protection associated 
with naturally acquired antibody levels also apply to vaccine-induced antibodies. The maximum anti-TRAP antibody 
titre observed in the study was 22 AU, 4.5 times the mean anti-TRAP titre. A vaccine that boosts average anti-TRAP 
antibody titres by this amount would have a predicted efficacy of 0.52 (Figure 4.4). A multi-component vaccine 
combining CSP and TRAP is predicted to give an increase in efficacy of approximately 25% over a single component 
vaccine, with a predicted VE of 0.75 for a vaccine that gives a boost equal to the maximum anti-CSP and anti-TRAP 
antibody titres observed in the study (Figure 4.4). 
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Figure 4.4: Predicted pre-erythrocytic vaccine efficacy using fixed boost vaccination. The maximum anti-CSP and anti-TRAP titres observed in 
the study participants are marked to indicate the vaccine efficacy that could be obtained by giving a boost equal to the maximum observed 
antibody titre. Dashed lines represent 95% confidence intervals. 
 
4.3.4. Vaccine efficacy in different transmission settings 
People living in a region of intense exposure to malaria will have a high baseline level of IgG antibodies. The benefit 
of a pre-erythrocytic vaccine that gives an antibody boost to a partially-immune individual is likely to depend on the 
vaccinee’s baseline antibody level, as the relative increase in antibody levels due to boosting by vaccination may be 
highest in those people with a low baseline antibody level. Therefore when comparing the measured efficacy of a 
vaccine given in adults between regions of high and low malaria transmission, higher efficacy may be observed in the 
region of low transmission. 
Using our model, the estimated additional efficacy over and above that already provided by naturally acquired 
immunity is observed to decrease monotonically as transmission intensity is increased (Figure 4.5).  This result 
highlights the fact that if trials are undertaken in semi-immune adults with high baseline antibody titres, then the 
measured efficacy in terms of the proportion of infections averted could be lower than the efficacy measured in a 
population with lower baseline titres. 
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Figure 4.5: Predicted vaccine efficacy as a function of baseline antibody titre. The average baseline antibody titre relative to the study site at 
Kanyawegi is used as a marker of transmission intensity. Dashed lines represent 95% confidence intervals. 
 
4.4. Discussion 
Our results demonstrate a dose-response relationship between titres of antibodies to two of the pre-erythrocytic 
antigens, circumsporozoite protein (CSP) and thrombospondin-related adhesive protein (TRAP), and time to re-
infection with P. falciparum. In contrast, we did not observe such a relationship between antibody titres for liver-
stage antigen 1 (LSA-1) and time to re-infection. This is biologically plausible given that LSA-1 antigens are only 
expressed inside hepatocytes in the liver, where they are inaccessible to antibodies; the presence of these 
functionally redundant anti-LSA1 antibodies in the blood is likely due to immune recognition of the remains of 
eliminated parasites. The apparent correlation between anti-LSA1 antibody titres and protection from infection 
observed in field studies [237, 255] is therefore likely due to the correlation between anti-LSA-1 titres and titres of 
other effective pre-erythrocytic antibodies.  
Despite the importance of the infection-blocking immune response, it is unclear whether it is primarily mediated by 
immune responses directed against sporozoites in the skin and liver, by a blood-stage response that clears emerging 
hepatic merozoites before replication, or by a blood-stage response that suppresses parasite density below 
detectable levels. The prevalence and titre of pre-erythrocytic and blood-stage antibodies are likely to be correlated 
with exposure to malaria, and hence with each other. We tested for such associations in our data by calculating the 
correlations between the pre-erythrocytic antibodies CSP, TRAP and LSA-1 and the blood-stage antibodies AMA-1, 
EBA-175 and MSP-1 (see 4.6. Appendix 1). Anti-CSP titres were not significantly correlated with antibody titres to the 
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other tested antigens suggesting that CSP has a genuine role in protection from infection. However, anti-CSP 
antibodies may be correlated with some other element of the pre-erythrocytic immune response not tested for 
[236]. Conversely, anti-TRAP titres were found to be highly correlated with anti-AMA-1 and anti-LSA-1 titres. 
Although AMA-1 is usually thought of as a blood-stage antigen, there is evidence that AMA-1 is expressed together 
with TRAP in the sporozoite micronemes during hepatocyte invasion [274]. Therefore anti-TRAP associated infection-
blocking activity could be due to either direct anti-TRAP mediated inhibition of hepatocyte invasion, combined anti-
TRAP and anti-AMA-1 inhibition of hepatocyte invasion, or simply reflect anti-AMA-1 mediated clearance of blood-
stage parasites.  
Several studies, including this one, have observed a role for naturally acquired pre-erythrocytic antibodies [222, 255] 
and naturally acquired cell-mediated immune responses [252] in preventing P. falciparum infection, although this 
association hasn’t been observed in all studies [228]. On the other hand, some studies have concluded that pre-
erythrocytic antibodies simply act as markers of exposure [242, 275], with protection from infection being mediated 
by correlated blood-stage immune responses  Moreover, studies showing significant correlation between presence 
of parasitaemia before treatment and extended time to reinfection [216] or to symptomatic disease [276] suggest 
that blood-stage antibodies induced by previous infections are able to prevent subsequent infections. However, the 
observation that vaccine-induced pre-erythrocytic immune responses can prevent sporozoite infection [5, 129] 
provides strong evidence for the hypothesis that naturally acquired immune responses against the sporozoite 
prevent infection and are not just a marker for exposure. 
Our model predicts that both CSP and TRAP-based malaria vaccines should be efficacious vaccine candidates. The 
most advanced candidate malaria vaccine, RTS,S, is a pre-erythrocytic CSP-based sub-unit vaccine inducing high anti-
CSP IgG antibody titres [66, 129, 196] and moderate CSP-specific T cell responses [129, 277, 278] in vaccinated 
humans.  Phase II trials have confirmed an association between anti-CSP IgG antibody titre and protection from 
infection in a challenge model [129, 279] and in the field [136]. Although the immunological mechanisms induced by 
RTS,S are not yet fully understood, it is believed that anti-CSP antibodies play a primary role in protection from 
infection, with a secondary role for CSP-specific CD4+ T cell responses [231]. Our results agree with the observation 
from Phase II trials that RTS,S efficacy depends on the induced anti-CSP antibody titre. However, our model was 
fitted to antibody levels acquired under conditions of natural exposure and so care must be taken when 
extrapolating to the significantly higher titres observed after RTS,S vaccination. An additional caveat is that if an 
antibody is directly protective, we do not know how much of the protection is due to a direct causal mechanism, 
which is likely to confer protection in vaccine-induced boosting, and how much is due to the antibody’s role as a 
marker of exposure and hence associated with other protective mechanisms, which would not confer protection in 
vaccine-induced boosting. 
Our results suggest that a multi-component vaccine expressing both CSP and TRAP antigens could give an increase in 
efficacy of approximately 25% over a single component vaccine. A multi-component RTS,S/TRAP/AS02 vaccine has 
been trialled [280] but proved less efficacious than RTS,S/AS02 alone, possibly due to immunological interference 
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between the antigens. Despite this, considerable progress is being made in the development of a sub-unit pre-
erythrocytic vaccine based on the TRAP sporozoite antigen. ME-TRAP, a heterologous prime-boost vaccine encoding 
the TRAP antigen and a string of T cell epitopes from various pre-erythrocytic antigens, offered 10% efficacy against 
infection in Gambian adults in a phase II trial [207]. However, protection from P. falciparum infection due to ME-
TRAP is associated with high levels of interferon-γ secreting T cells [281], rather than IgG antibody titres, which were 
not explicitly included in our model. One limitation of our current model is the assumption that non-antibody 
mechanisms of protection such as cell-mediated immunity can be described by a constant factor
0r . This assumption 
will be considered further in the next chapter.  
Our model can be used to investigate properties of vaccines other than efficacy. For example, evidence from clinical 
trials of RTS,S indicates that it is a leaky vaccine offering partial protection to everyone [133, 134]. This may be due 
to the convex dose-response curve we observed linking anti-CSP IgG antibody titre with protection from malaria 
infection. This does not, however, exclude the possibility of a threshold existing at the antibody titres induced by 
RTS,S which are an order of magnitude higher than naturally occurring titres [131]. The mechanics of sporozoite 
inoculation may further define vaccine type. When sporozoites are injected into the skin they remain at the bite site 
for up to an hour [209, 264]. Anti-sporozoite antibodies may opsonise and remove those remaining in the skin but 
fail to protect against those that enter the bloodstream quickly. Furthermore, the number of sporozoites injected 
during an infectious mosquito bite is highly variable [262, 263], so a vaccine may fail to prevent infection from bites 
injecting a large number of sporozoites. Therefore, despite the high anti-CSP antibody titres induced by RTS,S some 
sporozoites may still invade hepatocytes in the liver and initiate blood-stage infection. A combination vaccine 
incorporating LSA-1 may provide added protection by reducing the probability that infected hepatocytes survive to 
produce viable merozoites [76]. Even if a pre-erythrocytic vaccine fails to prevent infection, it can still provide partial 
protection by reducing the number of exo-erythrocytic forms in the liver [282], thus reducing the number of 
merozoites emerging from the liver and reducing the severity of blood-stage disease [283]. The increased efficacy 
against severe as compared to uncomplicated disease in Phase II trials of RTS,S may support this contention [118, 
133].  
RTS,S is currently undergoing extensive testing in Phase III clinical trials, enrolling up to 16,000 children and infants 
across 11 sites in 7 different African countries [15]. Our results predict that lower efficacy may be measured in the 
trial sites with the highest transmission intensity. This does not mean that the vaccine will be biologically less 
effective, rather, that in areas of high transmission intensity the ratio of infections prevented by naturally acquired 
pre-erythrocytic immunity (or maternally acquired antibodies) to infections prevented by vaccination will be higher 
than in areas of low transmission intensity. Continued sporozoite boosting in populations with higher exposure may 
also result in greater long-term vaccine efficacy and a need for fewer doses of vaccine, although there has been no 
evidence to date for this phenomenon.  
Should RTS,S satisfy the necessary criteria to progress from Phase III trials to licensure, it will become the first fully-
licensed malaria vaccine. After licensure the route to a second generation vaccine with improved efficacy could be a 
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multi-stage, multi-component vaccine based on RTS,S encoding a selection of pre-erythrocytic antigens such as TRAP 
and LSA-1, or blood-stage antigens such as AMA-1 and MSP-1 [284]. Our results suggest that if the problems of 
immunological interference can be overcome, the addition of a TRAP component to a CSP-based antibody boosting 
vaccine could provide significant improvements in efficacy.   
 
4.5. Conclusion 
This analysis demonstrates that in certain populations exposed to P. falciparum it is possible to estimate dose-
response relationships between antibodies to the pre-erythrocytic antigens CSP and TRAP, and protection from 
infection. The relationships identified at antibody titres observed under conditions of natural exposure have been 
extrapolated to estimate the efficacy of vaccines that boost naturally acquired antibody titres. However it remains to 
be investigated whether there is a dose-response relationship between vaccine-induced antibody titres and 
protection from infection.  
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4.6. Appendix 1 
4.6.1. Interaction between anti-CSP and anti-TRAP antibodies 
In our analysis of the effects of anti-CSP and anti-TRAP antibodies on the opsonisation and phagocytosis of P. 
falciparum sporozoites, our null hypothesis (independent model) is that anti-CSP and anti-TRAP antibodies act 
independently of each other. We test this against the alternative hypothesis (interaction model) that anti-CSP and 
anti-TRAP antibodies interact with each other, either synergistically or antagonistically. 
 
4.6.1.1. Interaction Model 
In a pharmacological review on the effects of combinations of interacting drugs, Greco et al [285]outline methods for 
modelling combinations of interacting drugs from a response surface perspective. The outlined framework allows 
both synergy and antagonism between pairs of drugs to be modelled. We adapt their equations so as to be 
applicable to exponential dose-response relationships between the probability of sporozoite survival and titres to 
anti-CSP and anti-TRAP antibodies. The relationship between anti-CSP and anti-TRAP antibody titres and the 
probability of sporozoite survival can be defined by the following equation: 
 CSP CSPTRAP TRAP
1 1 1 1
CSP TRAP CSP TRAP
log(2) log(2)log(2) log(2)
1
log( ) log( ) log( ) log( )r r r r
x xx x
 (1) 
where r is the probability of sporozoite survival, 
ix is the titre to antibody i, i is the titre to antibody i which gives a 
50% reduction in the probability of sporozoite survival, and is an interaction term. 
Rearranging (1) gives 
 
2 2CSP CSP TRAPTRAP1 1
CSP TRAP CSP TRAP
log( ) log(2) log( ) log(2) 0r r
x x xx
 (2) 
Now solving for 1log( )r gives 
 
22
2CSP CSP CSP TRAPTRAP TRAP1
CSP TRAP CSP TRAP CSP TRAP
2
CSP CSP CSP TRAPTRAP TRAP1
CSP TRAP CSP TRAP CSP TRAP
log(2) log(2)
log( ) log(2)
2 2
log(2)
log( ) 4
2
r
r
x x x xx x
x x x xx x
 (3) 
And isolating r and choosing the positive solution gives 
 
2
CSP CSP CSP TRAPTRAP TRAP
CSP TRAP CSP TRAP CSP TRAP
log(2)
4
2
x x x xx x
r e  (4) 
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We can test for consistency by setting 0  
 
CSP TRAP CSP TRAP
CSP TRAP CSP TRAP
log(2) log(2) log(2)
CSP TRAP
x x x x
r e e e r r  (5) 
corresponding to our null hypothesis that anti-CSP and anti-TRAP titres act independently of each other. 
 
4.6.1.2. Dependence of the probability of sporozoite survival on the interaction term γ 
By looking at the special case where
CSP TRAPx x xand CSP TRAP  we can investigate the dependence of 
the response on the interaction term  
 
log(2) 1 1
x
r e  (6) 
Setting 0 gives 
2log(2)
x
r e which once again corresponds to the assumption of independence of antibody 
titres. Setting 1gives 
log(2)
x
r e which corresponds to the antagonistic case where a combination of 
titres is only as effective as each of the titres on their own. Note that mutual inhibition where each antibody actively 
inhibits the other resulting in a combined effect less than either of the individual effects cannot be modelled in this 
framework. Appendix Figure 4.1 shows the dose-response curves for a combination of two antibodies with 
interaction ranging from strongly antagonistic to strongly synergistic. 
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Appendix Figure 4.1: Dose-response curves for a combination of two antibodies of equal titre. Β is the titre required for a single antibody 
response to kill 50% of sporozoites. γ > 0 results in synergistic interaction between antibodies, γ = 0 results in independent interaction 
between antibodies, and -1 < γ < 0 results in antagonistic interaction between antibodies.  
 
4.6.1.3. Likelihood ratio test 
As the null hypothesis is nested within the alternative hypothesis, they can be compared using a likelihood ratio test. 
Fitting both models gives the results shown in Appendix Table 4.1. The likelihood ratio statistic is 0.89  (p=0.35) 
and thus we cannot identify an interaction effect from these data.  
 
Appendix Table 4.1: Comparison of independent and interaction models. 
Model MLE Parameter Estimates
 
Model Fit 
 
0r  CSP  TRAP  
 log( )L  AIC 
Independent 0.011 13.07 11.64 - -223.7 453.5 
Interaction 0.011 151.84 172.23 962.7 -223.2 454.6 
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Interestingly for the interaction model we get a maximum likelihood estimate of 962.7 for the interaction term 
suggesting very strong synergy.  
To further investigate the dependence of our model fit on  we plot the profile log-likelihood in Appendix Figure 
4.2. We see that the profile log-likelihood surface is very flat apart from a small fall in the region 1 0 . Thus it 
is not possible to identify significant interactions between the antibody responses and outcome in these data. 
 
Appendix Figure 4.2: Profile log-likelihood for γ. Although the maximum value of the log-likelihood is given at γ = 962.7 the very flat shape of 
the profile log-likelihood demonstrates that there is very large uncertainty in this estimate. 
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4.6.2. Correlation between multiple antibody titres 
 
Appendix Table 4.2: Analysis of Spearman rank correlation between antibody titres to the studied antigens. NS = not significant. 
a
 Not 
significant after Bonferroni correction. 
 Relationship between antibody response and antigens 
Antigen CSP TRAP LSA-1 AMA-1 EBA-175 MSP-1 
CSP _ _ _ _ _ _ 
       
TRAP 0.0629 _ _ _ _ _ 
 NS      
LSA-1 0.0641 0.5033 _ _ _ _ 
 NS 1.21e-05     
AMA-1 -0.1075 0.3974 0.3753 _ _ _ 
 NS 7.89e-04 0.0016    
EBA-175 0.1820 0.0545 0.1998 0.1447 _ _ 
 NS NS NS NS   
MSP-1 0.1338 0.3629 0.3107 0.1499 0.2599 _ 
 NS 0.0023 0.0099a NS 0.0322a  
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Chapter 5. Mathematical modelling of the relationship 
between RTS,S vaccine-induced antibody levels, T cell 
mediated responses and protection against Plasmodium 
falciparum infection in malaria-naïve adults 
 
In the previous chapter we investigated how the relationship between naturally acquired pre-erythrocytic antibodies 
and protection from infection can be estimated by fitting dose-response curves to data from treatment re-infection 
studies. In this chapter we use a similar methodology to estimate the relationship between anti-CSP antibodies, CSP-
specific T cells and protection from infection in malaria-naïve volunteers vaccinated with RTS,S/AS02 and 
RTS,S/AS01. 
 
5.1. Introduction 
RTS,S comprises a chimaeric recombinant polypeptide encoding  more or less the entire circumsporozoite protein 
(CSP) linked to recombinant S antigen from the hepatitis B virus (HBs); this polypeptide is formulated with additional 
HBs and one of two alternative adjuvant systems, AS02 and AS01. AS02 is an adjuvant system that contains an oil-in-
water emulsion and the immunostimulants monophosphoryl lipid A (MPL) and QS21 [127]. AS01 is a related 
liposome-based adjuvant system that also contains MPL and QS21. Phase 2 field trials have indicated that RTS,S is 
more efficacious when formulated with the adjuvant AS01 than AS02 [130, 137, 138]. In field trials where 
RTS,S/AS01 and RTS,S/AS02 have been directly compared, RTS,S/AS01 has been found to be more immunogenic 
[132, 286, 287]. 
RTS,S induced immune responses will impact upon the within-host dynamics of pre-erythrocytic stage malaria 
infection. Sporozoites inoculated into the skin can be opsonised and immobilised by anti-CSP antibodies as they 
migrate through tissue before penetrating a capillary and entering the blood circulation [66]. Sporozoites that reach 
the liver will invade a hepatocyte where they will undergo hepatic development. Hepatocyte invasion could 
potentially be prevented by anti-CSP antibodies. Intracellular Plasmodium parasites can be targeted by vaccine-
induced CSP-specific CD4+ T cells leading to killing of the infected hepatocyte [211, 277].  After approximately 6.5 
days of hepatic development [29, 288] hepatic merozoites will be released into the blood circulation to begin the 
erythrocytic stage of infection. If a cellular response does not kill an infected hepatocyte, it may still inhibit 
intracellular parasite development leading to substantially fewer merozoites being released into the blood. When 
released from the liver, merozoites undergo blood-stage replication causing an exponential increase in parasite 
numbers. Studies of early blood-stage P. falciparum infection in human volunteers have demonstrated that the 
smaller the liver-to blood inocula the longer the time taken for parasite density to reach a given threshold [282, 289]. 
Vaccination with RTS,S induces anti-CSP antibodies and CSP-specific CD4+ T cells that produce a mixture of cytokines 
(such as IL-2, TNF-α, IFN-γ) and may also express the co-stimulatory molecule CD40L [277, 290]. Protection from 
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infection and clinical disease has been shown to be associated with both naturally acquired and RTS,S induced anti-
CSP antibodies [139, 237]. CSP-specific T cells have been associated with protection from infection in RTS,S 
vaccinated children [291] and in children with naturally acquired immunity [252]. Characterising precise 
immunological correlates of protection in field trials is, however, complicated by heterogeneous exposure to 
malaria, temporal changes in immune markers, and interactions with naturally acquired immunity. In contrast, 
challenge trials in malaria-naïve adults provide an ideal opportunity to investigate the dose-response relationship 
between immune markers and protection from infection as the infectious dose can be controlled and the timing 
known, there is no naturally acquired immunity, and immune markers can be measured on the day of challenge. 
Kester et al [129] undertook such a challenge study for RTS,S/AS01 and RTS,S/AS02 in malaria naïve adults. In their 
study, the efficacy of RTS,S/AS01 and RTS,S/AS02 against infection was estimated to be 50% (95% CI, 32.9% - 67.1%) 
and 32% (95% CI, 17.6% - 47.6%), respectively.  
Here we re-analyse the primary data from this challenge study using a novel approach based on mathematical 
models to determine the shape of the dose-response relationship between vaccine-induced anti-CSP antibody levels, 
CSP-specific T cells and protection from infection. Our results provide insights into the likely mechanism of action of 
the RTS,S vaccine as well as providing a more generalised framework for assessing the likely efficacy of vaccines in 
early stage development. 
 
5.2. Methods 
5.2.1. Challenge trial 
Kester et al [129] evaluated the efficacy and safety of the RTS,S malaria vaccine in 138 malaria naïve adults when 
formulated with the AS01 and AS02 adjuvant systems. 52 volunteers were vaccinated with RTS,S/AS01 and 50 
volunteers with RTS,S/AS02. 36 volunteers were recruited as infectivity controls and hence remained unvaccinated. 
Volunteers were challenged with the bites of five P. falciparum infectious Anopheles stephensi mosquitoes. After 
feeding the mosquito’s salivary glands were dissected to examine for sporozoites. If salivary glands tested negative 
for sporozoites, additional mosquitoes were allowed to take a blood meal until the volunteer had received five 
infectious bites [292]. 36 of the volunteers receiving RTS,S/AS01 vaccination were challenged. 9 of those protected 
from infection were re-challenged 5 months later. 44 of the volunteers receiving RTS,S/AS02 vaccination were 
challenged. 9 of those protected were re-challenged 5 months later. 24 of the infectivity controls were challenged at 
the first round; the remaining 12 were challenged 5 months later. Following challenge, volunteers were assessed by 
blood smears taken twice daily starting on day 6.5 until day 14 and then once daily until the end of the study period 
at day 21. Volunteers who tested positive for malaria parasites were then treated with chloroquine, irrespective of 
symptoms. 
Anti-CSP antibodies were measured by evaluating IgG responses to the P. falciparum CSP-repeat region measured 
using enzyme-linked immunospot assay (ELISA). Measurements of antibody titre were analysed in units of μg/mL. In 
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Phase II and Phase III field trials of RTS,S, antibody titres have been reported in ELISA units (EU/mL).  The number of 
CD4+ or CD8+ T cells responding to CSP antigen and expressing the immune markers CD40L, IFN-γ, IL-2 and TNF-α per 
million CD4+ or CD8+ T cells were also measured (see [129] for further details). The measure of cell-mediated 
immunity (CMI) used in this analysis is the number of CD4+ T cells expressing ≥2 immune markers per million CD4+ T 
cells. Data from both challenge and re-challenge were analysed. 
 
5.2.2. Model for P. falciparum infection 
Malaria-naïve volunteers were challenged with the bites of five P. falciparum infectious mosquites. Data from 
mosquito feeding studies indicates that the number of inoculated sporozoites is highly variable [262, 263, 293]. We 
assume that the number of sporozoites inoculated into the skin by five mosquitoes follows a Geometric distribution. 
If a fixed proportion of these successfully develop in the liver, then the number of sporozoites initiating blood-stage 
infection will also be Geometrically distributed with some mean n. The probability that after challenge, k sporozoites 
will initiate blood-stage infection is then   
 
1
(SPZ )
1 1
k
n
P k
n n
 (7) 
Each sporozoite that survives liver stage development will initiate blood-stage infection by releasing merozoites into 
the blood stream after tL days. We assume the number of merozoites is Normally distributed with mean µ and 
standard deviation σ. Once in the blood, parasites will begin replication increasing in number by a factor m = 3.8 per 
day [282]. Periodic fluctuations in parasite density due to sequestration, short term changes in innate immunity, and 
inter-individual differences in parasite replication rates are ignored. If blood-stage infection is initiated with Q 
parasites, then the parasite density at time t is 
 
0
( )
L
L
t t
L
t t
Pf t
Qm t t
 (8) 
Blood-stage infection can be diagnosed once parasite density reaches a threshold of
TP parasites/mL. If onset of 
parasitemia is observed on day T, the initial infectious dose of merozoites can be estimated as ( )lT tTQ P m . Thus 
the delay in onset of parasitemia can be used to estimate the reduction in merozoites emerging from the liver, with 
greater delays corresponding to greater reductions. Other explanations for the variation in time to onset of 
parasitemia could be variation in within-host blood-stage replication rates, or variation in the density at which 
parasites are detected. 
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5.2.3. Model of infectivity controls 
The initial dose of merozoites emerging from the liver in control j, jQ , can be estimated from the time to onset of 
parasitemia jT . If we assume the number of succesful sporozoites is Geometrically distributed, and the total number 
of merozoites is Normally distributed, then the  likelihood of the parameters ( , )n (the mean number of sporozoites 
initiating blood-stage infection and variation in the number of merozoites, respectively) is: 
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1 1
,
1 1 1 0 ,2
Q kj
kkJ
kj
n e
L n Q
n n k kk
 (9) 
where {1,..., }j J indexes the individuals in the study and k is the number of sporozoites injected. is the 
cumulative normal distribution, with 21 0 ,k k  being the area under a normal curve with mean k and 
variance 2k in the region [0, ) . 
  
5.2.4. Dose-response curves 
Prevention of infection or reduction in parasite load in vaccinated volunteers following P. falciparum challenge will 
depend on anti-CSP antibody titres and the number of CSP-specific T cells as well as other factors such as inter-
individual variation. Although it may not be possible to precisely characterise the relationship between immune 
markers and protection from infection, an approximate relationship can be estimated using a dose-response curve 
[231].  
Given a dose x (e.g. anti-CSP antibody titre, CSP specific T cells) the response f (e.g. probability of infection, 
probability of sporozoite success, reduction in parasite load) can be estimated using dose-response curves, a method 
commonly used in the pharmacological literature [285]. The following dose-response curves are utilised: 
1. Exponential   
log(2)
( )
x
f x e       (10) 
2. Hill function   
1
( )
1
f x
x
   (11) 
3. Restricted exponential  
log(2)
( ) (1 )
x
f x e   (12) 
where is a shape parameter, and  and are scale parameters. A response such as infection probability may 
depend on the dose of two different quantities, say anti-CSP antibody titre x , and number of CSP-specific T cells y . If 
these immune mechanisms provide protection independently of each other then their dose-response curves can 
simply be multiplied to give 
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log(2)log(2)
( , ) yx
yx
f x y e e  (13) 
There may be synergistic interactions between vaccine-induced antibody-mediated and cell-mediated immunity, 
making a combination of anti-CSP antibodies and CSP-specific T cells more efficacious than the combined effect of 
each immune component acting in isolation [294]. Alternatively, antibody-mediated and cell-mediated responses 
may have a less than multiplicative effect when combined. For example, if an antibody response prevents 50% of 
sporozoites and a cellular response also prevents 50% of sporozoites, then a combined response may only prevent 
60% of sporozoites, in contrast to the 75% that would be expected if the responses were multiplicative. Following 
the approaches of Greco et al [285] and White et al [232] interaction between immune responses can be modelled 
using the following dose-response function 
 
2
log(2)
4
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( , )
x y x y x y
x y x y xy
f x y e  (14) 
where
x
, y and  are scale parameters. Here 0 results in a dose-response surface with synergistic interaction, 
0 results in a dose-response surface where each immune component acts independently, and 1 0 results 
in a less than multiplicative combination of immune responses. 
 
5.2.5. Binary infection model 
After P. falciparum challenge a volunteer will either become infected 1I or remain uninfected 0I depending on 
their anti-CSP antibody titre and number of CSP-specific T cells x . The likelihood that the parameters { , , }
of a dose-response curve f generated the observed data can be written as 
 
1
1
, ( ) 1 ( )
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II
j j
j
L I x f x f x  (15) 
Equation (9) denotes the likelihood for a binary infection model, where volunteer j becomes infected ( 1)jI with 
probability ( )jf x , or is protected ( 0)jI with probability 1 ( )jf x .  
 
5.2.6. Sporozoite infection model 
In addition to the binary outcome of infection, there is also data on the delay in the time to detection of infection. 
The delay in onset of parasitemia can be modelled by assuming either a reduction in the number of sporozoites 
initiating blood-stage infection or a reduction in the number of merozoites per sporozoite. Given immune markers x
the probability that a sporozoite successfully initiates blood-stage infection can be described by a dose-response 
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function ( )f x , and the reduction in the number of merozoites per sporozoite can be described by the dose-
response function ( )g x . Combining equations (3) and (9), the likelihood of the dose-response parameters  fitting 
the data can be written as    
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The likelihood in equation (10) can be interpreted as follows. If volunteer j with immune marker jx is protected (
0jI ) then 0 sporozoites will be successful with probability
1
( ) 1jnf x
. If volunteer j becomes infected 1jI , 
then infection will have been initiated by [1, )k sporozoites with probability
( )1
( ) 1 ( ) 1
k
j
j j
nf x
nf x nf x
. The k
successful sporozoites will release a number of merozoites into the bloodstream following a Normal distribution
2( ( ), ( ))j jN k g x k g x . 
 
5.2.7. Comparative role of the adjuvants 
To investigate the hypothesis that the higher efficacy of RTS,S/AS01 can be explained by its superior immunogenicity 
over RTS,S/AS02, the data from vaccinated volunteers was split by adjuvant formulation: AS01 or AS02. The binary 
infection and sporozoite models were then fitted separately to each data set. 
 
5.3. Results 
5.3.1. Summary of anti-CSP antibody titres and numbers of CSP-specific T cells 
On the day of challenge volunteers vaccinated with RTS,S/AS01 had significantly higher anti-CSP titres than 
volunteers vaccinated with RTS,S/AS02 (P=0.003, t-test) (Figure 5.1). In groups vaccinated with either RTS,S/AS02 or 
RTS,S/AS01, protected volunteers had significantly higher anti-CSP titres than those infected, (P=0.0059 and 
P=0.0066, respectively). For the sub-group of volunteers who became infected after P. falciparum challenge, there 
was no significant difference in anti-CSP titres between those receiving RTS,S/AS02 and RTS,S/AS01 (P=0.16, t-test).    
RTS,S/AS01 induced a higher number of CSP-specific T cells per million than RTS,S/AS02 but this difference was not 
statistically significant (P = 0.46, t-test). Volunteers protected from infection had greater numbers of CSP-specific T 
cells than infected volunteers (P = 0.02, t-test). Anti-CSP antibody titres and number of CSP-specific T cells on the day 
of challenge or re-challenge were significantly correlated (ρ=0.24, P = 0.025).  
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Figure 5.1: Anti-CSP antibody titres (A) and CSP-specific T cells per million (B) on day of challenge for volunteers vaccinated with RTS,S/AS01 or 
RTS,S/AS02.  
 
5.3.2. Parameter estimates from the control cohort 
All of the 36 volunteers in the control cohort developed detectable malaria infection, although the time to the 
detection of infection was variable. By fitting our model to these data, we estimate that the mean number of 
successful sporozoites is n = 16.1, and that the number of merozoites released per sporozoite follows a Normal 
distribution truncated at zero with µ = 20,000 and σ = 39,000, corresponding to a mean of 39,600 and a standard 
deviation of 27,300 (Table 5.1).  
 
Table 5.1: Parameters describing biology of P. falciparum infection. Estimated parameters are shown with 95% confidence intervals. 
Parameter Description Value Reference 
n  Mean number of successful sporozoites per challenge 16.1 (9.7 – 24.0)  estimated 
Lt  Duration of liver-stage development 6.5 days Murphy et al [29] 
 Mean number of merozoites released per sporozoite 20,000 Meis et al [28] 
 Standard deviation in number of merozoites per 
sporozoite 
39,000 (15,850 – 
112,500) 
estimated 
m  Daily blood-stage parasite multiplication rate 3.8 day-1 Bejon et al [282] 
TPf  Threshold parasite density for detection of infection 50,000,000 
parasites/mL 
Bejon et al [295] 
 
5.3.3. Binary infection model 
The maximum value of the likelihood in equation (9) was calculated for several dose-response curves for the 
relationship between anti-CSP antibody titres, numbers of CSP-specific T cells and protection from infection, nine of 
which are shown in Table 5.2. The best fit was given by exponential dose-response curves with 50% protection being 
conferred by an anti-CSP antibody titre of 253 (154 – 482) μg/mL or 3235 (1696 – 18465) CSP-specific T cells per 
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million (Table 5.5). 13 of 85 volunteers had anti-CSP antibody titres greater than 253 μg/mL, and 5 of 85 volunteers 
had cellular responses greater than 3235 CSP-specific T cells per million.    
 
Table 5.2: Parameter estimates and model comparisons for 9 combinations of dose-response curves for the binary infection model. The 
models compared are based upon the dose-response curves (4), (5) and (6) applied to anti-CSP antibodies (Ab) or CSP-specific T cells (CMI). βab 
is the antibody titre required for 50% protection from infection. αab and λab are shape parameters. βcmi is the number of CSP-specific T cells per 
million required for 50% protection from infection. αcmi and λcmi are shape parameters. γ is a parameter for the interaction between antibody-
mediated and cell-mediated immune responses. Models are compared with maximum likelihood (ML) and the Akaike information criterion 
(AIC). 
Model Parameter estimates    
 βab (µg/mL)  αab λab βcmi 
(cells/million) 
αcmi λcmi γ ML AIC ΔAIC 
Ab (4) & CMI (4) 253.92 – – 3235 – – – -48.54 101.08 0 
Ab & CMI (8)  359.46 – – 9888 – – 12.61 -48.46 102.92 1.84 
Ab (6) & CMI (4) 253.78 – 8.9 x 10-8 3237 – – – -48.54 103.08 2.00 
Ab (5) & CMI (4) 240.68 1.34 – 3168 – – – -48.57 103.15 2.07 
Ab (4) & CMI (5) 278.96 – – 5182 0.69 – – -48.59 103.19 2.11 
Ab (4) & CMI (6) 258.58 – – 19.89 – 0.82 – -49.35 104.70 3.62 
Ab (4) 172.86 – – – – – – -52.08 106.16 5.08 
Ab (5) & CMI (5) 268.65 1.73 – 6644 0.49 – – -48.34 106.69 5.61 
CMI (4) – – – 931 – – – -61.21 124.42 23.34 
 
Table 5.3 compares the observed and model predicted vaccine efficacy for the volunteers stratified into low, 
medium and high groups by anti-CSP antibody titre and number of CSP-specific T cells. It is predicted that volunteers 
with high anti-CSP antibody titres and high numbers of CSP-specific T cells will have 76.2% protection from infection. 
 
Table 5.3: Comparison of predicted (black) and observed (blue) vaccine efficacy for the binary infection model. Volunteers have been stratified 
into low, medium and high groups according to their anti-CSP antibody titre and number of CSP-specific T cells per million.  
  anti-CSP antibody titre (µg/mL)  
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 1 – 268  12.7% 
12.5% (2/16) 
29.9% 
37.5% (3/8) 
47.7% 
25% (1/4) 
22.6% 
21.4% (6/28) 
268 – 820  18.8% 
33.3% (2/6) 
37.1% 
14.3% (1/7) 
58.3% 
62.5% (10/16) 
45.0% 
44.8% (13/29) 
820–8798 40.1% 
16.7% (1/6) 
52.8% 
64.3% (9/14) 
76.2% 
75.0% (6/8) 
56.8% 
57.1% (16/28) 
 1 – 8798 20.0% 
17.9% (5/28) 
42.7% 
44.8% (13/29) 
61.9% 
60.7% (17/28) 
41.5% 
41.2% (35/85) 
 
The binary infection model can be used to compare the effects of antibody and cellular responses. In the absence of 
CSP-specific T cells, the model estimates that the average vaccine efficacy in the volunteers under investigation is 
31% (95% CI, 19% – 43%). In contrast, in the absence of anti-CSP antibodies the average vaccine efficacy conferred 
by CSP-specific T cells is estimated to be 16% (95% CI, 3% – 25%). This suggests that antibodies have a greater role in 
protection from infection than cellular responses. Estimated vaccine efficacy as a function of anti-CSP antibody titre 
in the absence of T cells is shown in Figure 5.2. 
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Figure 5.2: Estimated vaccine efficacy as a function of anti-CSP antibody titre in the absence of CSP-specific T cells. The shaded green region 
represents the 95% confidence interval. The anti-CSP antibody titres of protected (blue) and infected (red) volunteers are shown at the top 
and bottom, respectively. 
 
5.3.4. Sporozoite infection model 
If blood-stage infection is initiated by a single sporozoite releasing 20,000 merozoites 6.5 days after challenge, and 
parasite density increases exponentially due to blood-stage replication, then we estimate that the onset of 
parasitemia won’t be detected until day 13. In the control group, the onset of parasitemia was detected on or before 
day 13 in 97% (35/36) of volunteers. In volunteers vaccinated with RTS,S who developed infection, the onset of 
parasitemia was detected on or before day 13 in only 52% (30/58), suggesting that many volunteers were infected 
with a dose of merozoites less than 20,000. This reduction in liver-to-blood inocula suggests that there is substantial 
inhibition of parasite development in the liver, possibly due to vaccine-induced cellular responses. 
The reduction in sporozoite survival and inhibition of parasite development within the liver were modelled using 
dose-response curves for the dependence on antibody titres and cellular responses. Four models are compared in 
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Table 5.4. The model providing the best fit to the data assumes that the probability of sporozoite survival decreases 
with both increasing anti-CSP antibody titres and CSP-specific T cells according to exponential dose-response curves, 
and that the reduction in merozoites per sporozoite decreases with increasing anti-CSP antibody titres according to a 
restricted exponential dose-response curve. Although antibody-mediated inhibition of liver-stage development isn’t 
a likely biological mechanism [235], we use it in our model as it proved to be the best marker of the effects of the 
vaccine-induced immune response on liver-stage inhibition. More detailed markers of cell-mediated immunity, in 
particular TNF-α, may better account for vaccine-induced liver inhibition. 
The model predicts that the time to onset of parasitemia increases with increasing anti-CSP antibody titre (Figure 
5.3). The time to onset of parasitemia is underestimated for a number of volunteers in Figure 5.3, as the plot doesn’t 
capture the dependence on numbers of CSP-specific T cells. In addition, there is likely to be between-volunteer 
variation in innate immunity and blood-stage replication rates which are unaccounted for. 
 
Table 5.4: Parameter estimates and model comparisons for the sporozoite infection model. βab and βcmi are the antibody titre or number of 
CSP-specific T cells required to kill 50% of sporozoites. ωab and ωcmi are the antibody titre or number of CSP-specific T cells required for a 50% 
reduction in the number of merozoites per sporozoite. λ is the maximum relative reduction in merozoites per sporozoite. Models are 
compared with ML and AIC.  
Model Parameter estimates    
 βab 
(µg/mL) 
βcmi 
(cells/million) 
ωab 
(µg/mL) 
ωcmi 
(cells/million) 
λ ML AIC ΔAIC 
Antibody liver 
inhibition 
68.1 1240 8.3 – 0.02 -579.77 1167.54 0 
Constant liver 
inhibition 
63.1 1299 – – 0.038 -582.09 1170.19 2.65 
Cellular liver 
inhibition 
57.2 1767 – 36.8 0.025 -592.89 1193.79 26.25 
No liver inhibition 50.9 771 – – – -649.36 1302.73 135.19 
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Figure 5.3: Estimated time to onset of parasitemia as a function of anti-CSP antibody titre (black line) with 95% confidence intervals (shaded 
grey region). The times to onset of parasitemia in the infectivity controls, who didn’t have detectable anti-CSP antibody titres are plotted on 
the left (gold points). The anti-CSP antibody titres of protected volunteers in whom there was no onset of parasitemia, are shown at the top 
(blue points). The model doesn’t capture all the variance in the data, with several data points lying outside the 95% confidence region. 
 
Using the sporozoite infection model, we estimate that both infection-blocking efficacy and anti-parasite efficacy 
(defined to be the percentage reduction in merozoites entering the blood from the liver [296]) increase with 
increasing anti-CSP titres and numbers of CSP-specific T cells (Figure 5.4). The sporozoite model predicts that 
vaccination will prevent all sporozoites in 31% (95% CI, 23% – 38%) of challenges. At the titres induced by RTS,S 
vaccination the anti-parasite efficacy is predicted to be 97.7% (95% CI, 96.3% – 98.7%) suggesting that a very small 
number of parasites are responsible for breakthrough infection. The confidence intervals for anti-parasite efficacy 
are very wide at low titres where there is no data.  
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Figure 5.4: Estimated infection-blocking efficacy (green) and anti-parasite efficacy (blue) with 95% confidence intervals as a function of anti-
CSP antibody titres obtained using the sporozoite model. A histogram of the distribution of anti-CSP antibody titres is shown in grey. 
 
Table 5.5: Best fit parameter estimates with 95% confidence intervals for the binary and sporozoite infection models. 
Parameter Description Value 
Binary infection model  
βab anti-CSP titre for 50% reduction in infection probability 253 (154 – 482) μg/mL  
βCMI number of CD4
+ T cells for 50% reduction in infection probability 3235 (1696 – 18465) cells/million  
Sporozoite infection model  
βab anti-CSP titre for 50% reduction in sporozoite survival probability 68 (50 – 96) μg/mL 
βCMI number of CD4
+ T cells for 50% reduction in sporozoite survival 
probability 
1240 (741 – 3026) cells/million 
βliver anti-CSP titre for 50% reduction in merozoites per sporozoite 8.2 (0.8 – 12.3) μg/mL 
λliver maximum reduction in merozoites per sporozoite 98% (95% – 99%) 
 
 
 
 
 
110 
 
5.3.5. Combined antibody and cellular response 
The efficacy against infection estimated using the binary infection model with interaction between anti-CSP antibody 
responses and CSP-specific T cell responses is shown in Figure 5.5. All 3 vaccinated volunteers predicted to have 
greater than 90% vaccine efficacy were protected. 11 of 13 volunteers predicted to have greater than 70% vaccine 
efficacy were protected. The existence of a highly protected subgroup of volunteers suggests that vaccine efficacy in 
excess of 70% is possible if both anti-CSP antibody titres and numbers of CSP-specific T cells can be boosted to high 
enough levels.  
 
Figure 5.5: Estimated infection-blocking vaccine efficacy as a function of anti-CSP antibody titre and numbers of CSP-specific T cells per million 
obtained from the binary infection model. The vertical dashed grey lines denote the median and 90% ranges of the observed anti-CSP antibody 
titres, and the horizontal dashed grey lines denote the median and 90% ranges of observed numbers of CSP-specific T cells. The solid black 
lines denote the isoclines for 30%, 50%, 70%, and 90% vaccine efficacy against infection. The blue and brown points denote the anti-CSP 
antibody titres and numbers of CSP-specific T cells of protected and infected volunteers, respectively. 
 
5.3.6. Effect of adjuvant formulation on vaccine efficacy 
The volunteers were split into two groups according to adjuvant (AS01 or AS02) and both the binary and sporozoite 
infection models were fitted to the datasets. For volunteers vaccinated with RTS,S/AS01 the binary infection model 
estimated that 50% protection from infection could be conferred by an antibody titre of 264 (95% CI, 137 – 637) 
µg/mL or 2408 (95% CI, 1138 – 18706) CSP-specific T cells per million. In comparison, for volunteers vaccinated with 
RTS,S/AS02 it was estimated that 50% protection would be conferred by an antibody titre of 255 (95% CI, 143 – 587) 
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µg/mL or 3826 (95% CI, 1794 – 18450) CSP-specific T cells. A comparison of vaccine efficacy as a function of anti-CSP 
antibody titres is shown in Figure 5.6 for RTS,S/AS01 and RTS,S/AS02. Similarly, when the sporozoite model was 
fitted separately to volunteers vaccinated with RTS,S/AS01 or RTS,S/AS02 there was no significant difference 
between the estimated parameters. This suggests that the adjuvant formulation does not have a direct effect on 
vaccine efficacy, but contributes to protection only by increasing the magnitude of induced immune responses. 
 
Figure 5.6: Comparison of vaccine efficacy as a function of anti-CSP antibody titre in the absence of CSP-specific T cells for RTS,S/AS01 (black) 
and RTS,S/AS02 (pink) based on the binary infection model. The grey and pink shaded regions denote 95% confidence intervals for the 
estimated efficacy of RTS,S/AS01 and RTS,S/AS02, respectively.   
 
5.4. Discussion 
Naturally acquired and vaccine-induced anti-CSP antibodies and CSP-specific T cells have been associated with 
protection from infection [237, 252, 278]. Using mathematical models to estimate the dose-response relationship 
between immune markers and protection from infection, we were able to estimate the probability of malaria-naïve 
volunteers vaccinated with RTS,S becoming infected after P. falciparum challenge, and if infected, the delay in onset 
of parasitemia due to vaccination.  
Our results suggest that RTS,S prevents large numbers of P. falciparum parasites from surviving the pre-erythrocytic 
stage, with an estimated average anti-parasite efficacy of 97.7% (95% CI, 96.3% – 98.7%) from the sporozoite 
infection model. A comparably large level of anti-parasite efficacy of pre-erythrocytic vaccines has been suggested 
by the results of longitudinal PCR studies on challenged volunteers [282, 296]. Such high levels of anti-parasite 
efficacy are needed to obtain significant infection-blocking efficacy, given that, in theory, a single sporozoite evading 
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the vaccine-induced immune response can initiate blood-stage infection. The need for such high levels of anti-
parasite efficacy to result in even a partially effective vaccine is a major challenge in developing highly efficacious 
pre-erythrocytic malaria vaccines. No definitive threshold for protection, in either anti-CSP antibody titres or CD4+ T 
cell responses, was identified by our model. Instead, vaccine efficacy was estimated to increase continuously, albeit 
non-linearly, across the range of observed antibody titres and cellular responses. 
The estimates of anti-parasite efficacy presented here are based on the reduction in the number of merozoites 
exiting the liver due to vaccination, in agreement with the measure used by Hill [296]. An alternative interpretation 
of anti-parasite efficacy would be the reduction in the number of sporozoites progressing to blood-stage infection, in 
which case we estimate 75% (95% CI, 68% – 79%). However, this measure of efficacy is sensitive to the mean 
number of inoculated sporozoites per infectious bite: a vaccine that prevents 75% of sporozoites will be much more 
effective at preventing infections if the mean number of successful sporozoites per bite is n = 2 than if it is n = 50. 
Our estimate of n ≈ 16 successful sporozoites from five mosquito bites is compatible with Beier et al’s observation of 
a mean of 10 sporozoites per bite, corresponding to a mean of 50 sporozoites per challenge, only a fraction of which 
will progress to blood-stage infection. In a trial of several pre-erythrocytic vaccines by Bejon et al [282] with an 
experimental design similar to that of Kester et al [129], it was estimated that on average n = 14 sporozoites 
successfully progressed to blood-stage infection, a finding comparable with our estimate.  
Our model results predict that RTS,S induced protection from infection is dependent on both anti-CSP antibodies and 
CSP-specific T cells. In the absence of cellular responses, vaccine-induced anti-CSP antibodies are estimated to 
provide 31% protection from infection. In contrast, in the absence of anti-CSP antibodies, CSP-specific T cells are 
estimated to provide 16% protection. This suggests that antibodies play a dominant role, accounting for 
approximately 2/3 of vaccine-induced protection from infection. However, this finding is only valid when the marker 
of cellular immunity is taken to be the number of CSP-specific T cells per million expressing ≥ 2 of the cytokines IL-2, 
TNF-α, IFN-γ or the co-stimulatory molecule CD40L [129]. More detailed analysis of cytokine responses may reveal a 
marker of cellular immunity with a stronger association with protection from infection. For example, CSP-specific 
CD4+ T cells producing TNF-α have been associated with a reduced risk of clinical malaria in a trial of RTS,S/AS01 in 
children [291]. 
There may be synergistic interactions between vaccine-induced antibody and cellular responses [294]. There are two 
potential stages at which synergy can act: firstly, there could be synergy at the induction stage, such that when high 
antibody titres are induced it is more likely that high numbers of CSP-specific T cells will also be induced, or vice-
versa [297]; secondly, there could be synergistic interactions between immune responses at the effector stage, such 
that an antibody response is more effective in the presence of a cellular response, and vice-versa. Mathematical 
models of the sort used here are unable to capture synergy at the induction stage, although evidence for this can be 
derived from the statistically significant correlation between anti-CSP antibody titres and numbers of CSP-specific T 
cells. Dose-response models with an interaction term suggest that there is synergistic interaction at the effector 
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stage, although this model did not provide a better statistical fit to the data than a model with independent antibody 
and cell-mediated responses (Table 5.2).   
There was significant variation between volunteers in the anti-CSP antibody titres and numbers of CSP-specific T cells 
induced by RTS,S on the day of challenge. Under our sporozoite infection model, this variation in titres predicts 
substantial between-person heterogeneity in vaccine efficacy, that is, partial protection is induced in everyone but 
some individuals are more protected than others. The protection profile (the level of protection conferred on all 
vaccinees) is estimated to be intermediate between that of a leaky and an all-or-nothing vaccine, although this may 
change if immune effectors decay over time. The nature of infectious challenge with malaria may also contribute to 
variation in vaccine efficacy as infections arising from bites with a small number of inoculated sporozoites may be 
easily prevented, whereas infections arising from large doses of sporozoites may be difficult to prevent, however this 
hypothesis is likely to be difficult to test under field conditions. 
RTS,S has been observed to be more immunogenic when formulated with AS01 compared to when formulated with 
AS02 [287]. The relationship between adjuvant formulation, induced anti-CSP antibody titres and CSP-specific T cells 
isn’t fully understood. In this study, we have demonstrated that when adjusted for anti-CSP antibody titres and 
numbers of CSP-specific T cells, both RTS,S/AS01 and RTS,S/AS02 provide equivalent levels of protection from 
infection. 
 
5.5. Conclusion 
Our results suggest that the RTS,S vaccine acts through the induction of high levels of both anti-CSP antibodies and 
CSP-specific CD4+ T cells, with the antibody response having a greater role in protection from infection. The existence 
of a subgroup of volunteers with high antibody and cell-mediated immune responses (and an estimated vaccine 
efficacy against infection greater than 70%) suggests that substantial increases in efficacy can be obtained if vaccine 
immunogenicity can be further improved. 
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Chapter 6. Estimates of the immune parameters determining 
the duration of antibody response to Plasmodium falciparum 
infection in African children 
 
In the earlier chapters of this thesis I have investigated the relationship between markers of immunity and 
protection from P. falciparum infection or clinical malaria. In particular I focussed on static measures of pre-
erythrocytic immunity such as antibody titres and CD4+ T cell responses, ignoring the dynamic nature of immune 
responses. In this Chapter, in order to better understand the acquisition and maintenance of vaccine-induced and 
naturally acquired antibody responses, I develop simple models of the kinetics of naturally acquired antibodies 
which are fitted to data from young African children to obtain estimates of the parameters determining the duration 
of antibody response.   
 
6.1. Introduction 
In malaria-endemic areas, older children and adults acquire substantial immunological protection to severe malaria 
and death, but rarely - if ever - acquire  sterile immunity [55]. Infants are particularly vulnerable to episodes of 
severe malaria in the period of time after innate resistance and maternally-acquired immunity has waned and before 
the acquisition of effective, adaptive immunity [56]. Although substantial protection from severe malaria and death 
is acquired  after a small number of infections [57] episodes of acute febrile disease may continue for many years. In 
contrast to other pathogens such as measles, rubella and varicella, the immune parameters determining the 
acquisition and duration of the antibody response to Plasmodium falciparum remain poorly quantified [121].  
Frequently cited  explanations for the slow development of protective immunity include extensive antigenic diversity 
among parasite isolates [298] as well as low immunogenicity of malaria antigens and defective immunological 
memory. Although it is widely perceived that acquired immune responses to malaria are short-lived [55, 299], and 
that previously immune individuals suffer a loss of immunity when they move away from malaria endemic areas, the 
true picture is much more complex [300, 301]. Thus, while frequent reinfection is required to maintain high 
concentrations of anti-malarial antibodies, and while antibody responses can appear very transient – especially in 
young children [299, 302-304] –there is evidence that other components of the immune response to malaria may be 
long-lived [300]. For example, when epidemic malaria emerged in Madagascar after 25 years of malaria control, 
people born before the start of the control programme were much more resistant to clinical disease than younger 
people who lacked acquired immunity [305]. Similarly, parasite density, risk of severe clinical disease and death were 
all reported to be significantly lower among individuals exposed to malaria many years before than in malaria naïve 
individuals [306, 307]. Circulating memory B cells (MBC) specific for P. falciparum antigens can be detected at least 8 
years after the most recent malaria infection [308, 309] and the best evidence suggests that they can persist for the 
lifetime of the individual [309]. Estimates of the half-life of antibody sero-positivity indicate that individuals remain 
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sero-positive for life for antibodies to conserved or relatively conserved antigens, even in areas of low ongoing 
malaria transmission [310].  
Understanding the processes underlying the acquisition and loss of various immune effector mechanisms is crucial 
for understanding the epidemiology of the disease and the likely impact of vaccines. Here we investigate the 
acquisition and loss of humoral immune responses with biological models of immunological processes fitted to 
Immunoglobulin G (IgG) antibody titres to P. falciparum antigens using data from longitudinal cohort studies of 
Ghanaian and Gambian children [303, 304, 311]. We assume that exposure to P. falciparum antigen induces 
proliferation of antigen-specific naïve or memory B cells (MBC) and their differentiation into IgG antibody secreting 
cells (ASC), and that the duration of circulating IgG is dependent upon the half-life of individual IgG molecules, the 
half-life of IgG secreting cells and rates of reinfection which induce proliferation of new populations of MBCs and 
ASCs. 
 
6.2. Methods 
6.2.1. Longitudinal cohort data 
Data from two longitudinal cohort studies of the antibody response to P. falciparum infection in African children 
were analysed. In the first study children from southern Ghana were followed from birth for over 2 years to 
investigate the association between maternal antibody and protection from malaria infection [311]. The 
entomological inoculation rate was approximately 5 to 10 infectious bites per year, 92% of which were due to P. 
falciparum [312]. Maternal blood samples were collected by venepuncture, and children’s samples were collected at 
birth, 2, 4, and 6 weeks after birth, and then every 4 weeks by heel prick. Blood samples were tested for parasites by 
microscopy and PCR. Samples were analysed by enzyme-linked immunosorbent assays (ELISA) for the presence of 
antibodies to a number of P. falciparum antigens: apical membrane antigen 1 (AMA-1); the 19-kDa C-terminal 
fragment of merozoite surface protein 1 (MSP-119); two allelic sequences of merozoite surface protein 2 (MSP-2), 
FC27 and IC1, representing the two major families of MSP-2; and circumsporozoite protein (CSP). Data from 151 
children followed from birth for up to 812 days were analysed. 
In the second study children up to 6 years of age from the town of Farafenni in The Gambia were followed for 3 
months during the dry season to investigate the decay in antibody titres following P. falciparum transmission during 
the wet season [303, 304]. Samples were taken every 2 weeks and tested for parasites by microscopy. Samples were 
analysed by ELISA for the presence of antibodies to a number of P. falciparum antigens: AMA-1, MSP-1, two allelic 
types of MSP-2, and erythrocyte binding antigen 175 (EBA-175). Data from 124 children were analysed.      
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6.2.2. Mathematical models 
We describe a simplified model of the immunological processes underlying antibody generation (Figure 6.1). Upon 
recognition of P. falciparum parasites, antigen specific B cells proliferate and terminally differentiate into antibody 
secreting plasma B cells. Two populations of plasma B cells are created: short-lived ASCs with a half-life of the order 
of days or weeks, and long-lived ASCs with a half-life of the order of months or years. ASCs generate IgG antibodies 
which are used to combat ongoing malaria infection and protect against future infections. Individual IgG molecules 
have a half life of days or weeks. 
Three models of the immunological processes underlying antibody kinetics are constructed to investigate the 
patterns observed in the Ghanaian and Gambian data (Figure 6.2). Antibody kinetics are assumed to be dependent 
on (i) the half-life of individual IgG molecules, (ii) the half-life of IgG secreting cells and (iii) rates of reinfection which 
induce differentiation of new populations of MBCs and ASCs. When antibody titres are boosted above some 
threshold between consecutive samples, antigen exposure is assumed to have occurred (which may or may not 
coincide with a new infection).  
 
 
Figure 6.1: Schematic model of the immunological processes underlying the generation of IgG antibody.  
 
Model 1 
A simplified model of the immunological processes underlying antibody production is constructed so that IgG 
antibody, A , is generated in boosts following exposure to P. falciparum antigens and decays with half-life ad days. 
When IgG antibody is generated at rate the antibody kinetics can be described by 
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 (17) 
where
log(2)
a
r
d
is the rate of decay of antibody. If antibody is generated in boosts of size i following antigen 
exposure at time i then equation (1) can be solved to give 
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Model 2 
Model 1 is adapted so that there is rapid proliferation of MBCs and differentiation into ASCs following exposure to P. 
falciparum antigens. These plasma cells,B , persist with half-life bd days secreting IgG antibody, A , throughout their 
life. When plasma B cells are generated at a rate , the antibody kinetics can be described by 
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 (20) 
where 
log(2)
b
c
d
is the rate of decay of plasma cells, and g is the rate at which antibody is secreted by plasma cells. 
If plasma cells are generated in boosts of size i at times i then equation (4) can be solved to give 
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Here the constant g has been absorbed into the boost size i . 
Model 3 
Model 2 is extended so that following antigen exposure, both short-lived plasma cells with half-life sd days (of the 
order of days/weeks) and long-lived plasma cells with half-life ld (of the order of months/years) are generated. Short-
lived plasma cells are responsible for the rapid rise in antibody titres following initial antigen exposure and are 
assumed to combat the ongoing malaria infection. Long-lived plasma cells are responsible for maintaining antibody 
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titres after the infection has been cleared. If plasma cells are generated at rate , a proportion of which are short-
lived and 1 long-lived, then the antibody kinetics can be described by 
 (1 )
s
s s
l
l l
s l
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c B
dt
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c B
dt
dA
gB gB rA
dt
 (22) 
where
log(2)
s
s
c
d
is the rate of decay of short-lived plasma cells and
log(2)
l
l
c
d
is the rate of decay of long-lived 
plasma cells. If plasma cells are generated in boosts of size i at times i then equation (6) can be solved to give 
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Figure 6.2: In Model 1 children are born with maternal antibody which decays exponentially (red). Upon exposure to P. falciparum antigen, 
antibodies are boosted and then decay exponentially (blue). In Model 2 ASCs are generated upon exposure to antigen and secrete antibody 
causing a gradual increase in titre followed by exponential decay. In Model 3 both short-lived and long-lived ASCs are generated upon antigen 
exposure. Short-lived plasma cells secrete antibody during their brief life time (blue) and long-lived plasma cells secrete antibody throughout 
their long life time (green). 
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6.2.3. Model fitting methods 
Mixed effects model likelihood 
Models 1 – 3 were fitted to the Ghanaian and Gambian longitudinal data sets using mixed effects methods such that 
local parameters are estimated for each child individually, with these local (or mixed effects) parameters being 
drawn from a global distribution [313]. For example, for each child k the half-life of maternal antibody may be 
estimated as k
md . TheseK estimates of the local parameters 
k
md will be drawn from a probability distribution. A Log-
Normal distribution is suitable as it has positive support on[0, ) . Thus we have 2log( ) ,km m md N . The mean
md and the variance
2
m
of the estimates of k
md are given by
2
2
m
m
md e and
2 222 1m m mm e e . 
 
Model 1 
For child k we have data on observed antibody titres 1,...,
k
Ja a at times 1,...,
k
JT t t , from which we can 
estimate the times of antibody boosts 1 2, ,...,
k
I according to whether there is a boost to antibody titres 
between consecutive samples. The time of exposure
i
is assumed to be the midpoint of the time period within 
which boosting of antibody titres was detected. We denote ,k k kD A T to be the vector of data for child k, and 
likewise D to be the vector of data for all K children. For child k, we estimate the half-life of maternal antibody kmd , 
the half-life of exposure-acquired antibody kad , the initial titre of maternal antibody
k
mA , and the magnitude of boosts 
to antibody titres 1 2{ , ,..., }
k
I . We denote , , ,
k k k k k
m a md d A to be the vector of parameters to be 
estimated. 
Adapting equation (18) to include maternal antibody decaying at rate
log(2)
m
m
d
gives 
 ( )A( ) A ( , ) i
r tmt
m i i
i I
t e H t e  (24) 
The predicted antibody titres will be 1 2( ), ( ),..., ( )JA t A t A t . We assume Normally distributed measurement error 
with standard deviation obs . The difference between the observed antibody titre ja and the predicted antibody titre
( )jA t will be Normally distributed with variance
2
obs , truncated at zero as negative antibody titres are not allowed. 
The data likelihood of Model 1 for child k is given by 
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is the cumulative normal distribution (i.e. a normalizing factor), with 2obs1 0 ( ),jA t  being the area under a 
normal curve with mean ( )jA t and variance 
2
obs
in the region [0, ) . 
The parameters 
k
md and
k
ad are mixed effects parameters drawn from Log-Normal distributions with means md and
ad respectively. Including the contribution to the likelihood for the distance between the local and global estimates 
gives 
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where m and
2
log( )
2
m
m md  are the standard deviation and mean of the logarithm of the local estimates of
k
md , and a and a are similarly defined. The total likelihood is obtained by multiplying the likelihood for each child 
 
total mix
k k k
k K
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where 1
obs, , , , , ,...,
K
m a m ad d is the vector of all parameters to be estimated, and 
1,..., KD D D is 
the vector of all data. 
The derivation of the likelihood of Model 1’s fit to the Gambian data is similar to that outlined above, except without 
the inclusion of maternal antibody. Where observations of infants in the Ghanaian cohort begin with maternal 
antibody mA , a Gambian child will begin with some titre 0A at the end of the rainy season which is to be estimated.   
 
Model 2 
Under Model 2 a child from the Ghanaian cohort is born with maternally-acquired antibody titre mA and receives 
boosts to plasma B cells 1 2, ,...,
k
I at times 1 2, ,...,
k
I due to exposure to P. falciparum antigens. 
We denote , , , ,k k k k k km a b md d d A to be the vector of parameters to be estimated. Adapting equation (21) to 
include maternal antibody gives 
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The data likelihood for child k  under Model 2 is given by 
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Including the contribution to the likelihood for the difference between the local and global parameters gives 
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The total likelihood is obtained by multiplying the mixed effects likelihood for allK children. 
 
total mix
k k k
k K
L D L D  (31) 
 
Model 3 
Under Model 3 a child from the Ghanaian cohort is born with maternally-acquired antibody titre mA and receives 
boosts to plasma B cells of 1 2, ,...,
k
I at times 1 2, ,...,
k
I due to exposure to P. falciparum 
antigens. A proportion of ASCs are assumed to be short-lived and a proportion1 long-lived. We denote 
, , , , , ,k k k k k k k km a s l md d d d A to be the vector of parameters to be estimated. Adapting equation (23) to include 
maternal antibody gives 
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 (32) 
The data likelihood for child k under Model 3 is given by 
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 (33) 
The proportion of short-lived plasma cells is constrained to be in the region [0,1] and thus we assume a Logit-
Normal distribution for the mixed effects parameters 
k
with mean and variance 
2
on the logit scale. There is 
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no analytical solution for the mean of a logit-normal distribution in terms of the mean and variance of the underlying 
Normal distribution, so we estimate the mean on the logit scale and then numerically calculate . 
Including the contribution to the likelihood for the difference between the local and global parameters gives 
 
2
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 (34) 
The total likelihood is obtained by multiplying the mixed effects likelihood for allK children. 
 total mix
k k k
k K
L D L D   (35) 
 
Markov chain Monte Carlo methods 
The three models were fitted to the data on each of the four antigens from both cohorts using Markov Chain Monte 
Carlo (MCMC) methods. Parameters were updated at each MCMC iteration using a random walk Metropolis-
Hastings algorithm with three update stages illustrated here for the case of Model 1 fitted to the Ghanaian data. A ʹ 
indicates an attempted update parameter. At iteration n, carry out the following parameter updates: 
1. Local parameter update.  For each child k , update the following local parameters in one step 
 Half-life of maternal antibody:                              loc, k
m
k k k
m m d
d N d V  
 Half-life of exposure-acquired antibody:            loc, k
a
k k k
a a d
d N d V  
 Calculate updated mixed effects likelihood mix
k k kL D   
 Accept the parameter update with probability 
 
mix
mix
min 1,
k k k
k k k
L D
L D
 
 If n < 5,000,000 update loc
k using the Robbins-Munro algorithm for tuning acceptance rates 
2. Nuisance parameter update. For each child k update the following parameters in one step 
 Initial titre of maternal antibody:                         nuis, k
m
k k k
m m A
A N A V  
 Magnitude of antibody boosts {1,..., }i I :     nuis, k
i
k k k
i iN V  
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 Calculate updated mixed effects likelihood mix
k k kL D  
 Accept the parameter update with probability 
 
mix
mix
min 1,
k k k
k k k
L D
L D
 
 If n < 5,000,000 update
nuis
k using the Robbins-Munro algorithm for tuning acceptance rates 
3. Global parameter update. Update the following global parameters in one step 
 Half-life of maternal antibody:                                                             glob, mm m dd N d V  
 Half-life of exposure-acquired antibody:                                            glob, aa a dd N d V  
 Standard deviation in half-life of maternal antibody:                      glob, mm mN V  
 Standard deviation in half-life of exposure-acquired antibody:  glob, aa aN V  
 Observational variance:                                                                         
obsobs obs glob
,N V  
 Calculate updated total likelihood 
totalL D and the updated prior likelihoodP  
 Accept the parameter update with probability 
 
total
total
min 1,
L D P
L D P
 
 If n < 5,000,000 update glob using the Robbins-Munro algorithm for tuning acceptance rates 
 
The variances of the proposal distributions V were first estimated by performing 10 million MCMC iterations to 
estimate the variance of the posterior distributions. No prior distributions were placed on local or nuisance 
parameters, only on global parameters (Table 6.1). 200 million MCMC iterations were computed with calibration of 
acceptance rates using a Robbins-Munro algorithm [314]. All Markov chains were visually examined for appropriate 
mixing and convergence. Such large numbers of iterations were needed because of the large number of parameters 
to be estimated. 
 
Model comparison 
The median and 95% credible intervals for the posterior distributions for each of the estimated global parameters 
are shown in Table 6.2 for the Ghanaian data and in Table 6.3 for the Gambian data. For each model, the log-
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likelihood and Akaike Information Criterion (AIC) at the median global parameter estimates are shown in Tables 6.2 
and 6.3. The results of comparisons between mixed effects models should be interpreted with caution as the 
likelihood is composed of two components: the likelihood of the model fit to each individual child, and the likelihood 
that the mixed effects parameters are drawn from the global parameter distributions. Model 1 can be shown to be 
nested in Model 2 which can in turn be shown to be nested in Model 3, and hence we expect the likelihood of Model 
3 to be greatest, followed by Model 2, when the models are fitted to the data from one child at a time. However, this 
ordering of likelihoods cannot be guaranteed in the mixed effects framework. In addition, counting the degrees of 
freedom in hierarchical, mixed effects models is not straightforward [315, 316]. The formulation of the AIC 
presented here counts each of the mixed effects and global parameters as a degree of freedom.    
 
Prior parameter distributions 
As the models were fitted in a Bayesian framework it was possible to incorporate prior information from the 
literature on the parameters under investigation (Table 6.1). No estimates of the half-life of maternal antibody were 
found in the literature. Riley et al [311] have estimated the rate at which infants become sero-negative due to 
waning of maternal antibody, but this information cannot be used to inform priors as it was derived from the same 
Ghanaian cohort under investigation in this study. Sehgal et al [317] found that in Papua New Guinean infants, most 
lost all detectable malaria-specific IgG between the ages of 5 and 7 months. This information was used to restrict the 
maximum half-life of maternal antibody.  
Prior estimates of the half-lives of exposure-acquired IgG antibodies were obtained from the literature: Kinyanjui et 
al [299] estimated that combined responses of IgG1 to the merozoite antigens MSP-1, MSP-2, AMA-1 and EBA-175 
had a half-life of 9.8 days (95% CI, 7.6 – 12.0). The half-life of IgG3 antibody was estimated to be 6.1 days (95% CI, 3.7 
– 8.4). These estimates were derived from hospitalised children after an episode of clinical malaria. We used 9.8 days 
as a prior for the half-life of exposure-acquired antibody in Models 2 and 3.  
No estimates of the relative proportions of antibody generated by short-lived and long-lived ASCs were found. Weiss 
et al [68] estimated the expansion and contraction of the MBC compartment to various merozoite antigens after P. 
falciparum infection. The proportion of short-lived MBCs can be estimated by measuring the peak number of antigen 
specific MBCs after an episode of clinical malaria and the number of MBCs 12 months later. Using data from Weiss et 
al we estimated that 86% of AMA-1 specific MBCs are short-lived and 20% of MSP-1 specific MBCs are short-lived. 
Given that we are estimating the relative proportions of ASCs and not MBCs we used these estimates as weakly 
informative priors. No estimates of the half-lives of short-lived ASCs in humans were found. Ndungu et al [318] 
report that short-lived ASCs generated following Plasmodium chabaudi infection in mice die within 3 – 5 days. We 
thus assumed a prior estimate of 4 days for the half-life of ASCs in humans.     
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Table 6.1; Prior distributions for parameters. The value shown is the mean of the probability distribution with the range containing 95% of the 
distribution, except in the case of the uniform distribution where the range denotes the minimum and maximum allowable values.   
parameter symbol distribution value (range) model Reference 
half-life of maternal antibody dm Uniform (0 – 365) days M1, M2, M3 Sehgal [317] 
half-life of IgG antibody da Log-normal 9.8 (8.3 – 11.5) days  M2, M3 Kinyanjui 
[299] 
half-life of short-lived plasma cells ds Log-normal 4.0 ( 3.1 –  5.1) days M3 Ndungu 
[318] 
half-life of long-lived plasma cells dl Log-normal 365 (208 – 596) days M3 estimate 
proportion of short-lived cells ρ Logit-normal 0.86 (0.46 – 0.98) M3 Weiss [68] 
 
6.3. Results 
 
Figure 6.3: Aggregated antibody kinetics for Ghanaian and Gambian children. The black curve represents the median age-dependent antibody 
titre. The darkly shaded regions contain 50% of the data, and the lightly shaded regions contain 95% of the data. Ghanaian children are 
followed from birth for up to 812 days. Gambian children are followed from the start of the dry season for 84 days. 
 
The aggregated age-dependent antibody kinetics for each of the antigens studied in both cohorts are shown in 
Figure 6.3. In the Ghanaian data the median antibody titre decreases substantially in the first 100 days, consistent 
with exponential decay of maternal antibodies, and then increases gradually as antibodies are acquired in response 
to malaria infection. In the Gambian data there is an observable decline in median antibody titres as antibody 
generated in the wet season decays during the dry season. Figure 6.3 captures the general time-dependent trends in 
antibody kinetics but not the individual level variation in immune parameters. In individual children, protective 
antibodies are not acquired at a continuous rate but rather in a stochastic manner in response to antigen exposure. 
Thus each child will have a unique antibody profile depending on the number of infections and individual-level 
variation in immune parameters. Figure 6.4 shows a sample of the antibody kinetics of four children from each 
cohort.  
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Figure 6.4: Measurements of antibody titres for a sample of 4 of 151 Ghanaian (a-d) and 4 of 124 Gambian children (e-h). Where P. falciparum 
parasites were tested for, it is indicated at the top of each plot as present (red) or absent (black).  
 
The Ghanaian children were born with maternally acquired IgG antibodies but no ASCs of their own, hence antibody 
titres decay at a constant rate in the first months of life (Figure 6.4 a-d). Throughout the period of follow-up children 
experienced sporadic boosts to antibody titres upon exposure to P. falciparum antigens, after which antibody titres 
decay again. In some children there is evidence for a bi-phasic decay, with antibody titres dropping rapidly 
immediately after boosting and then decaying at a much slower rate over a period of months to years. This bi-phasic 
decay may be due to generation of populations of short-lived and long-lived ASCs following antigen exposure. Short-
lived ASCs produce large quantities of antibody needed to protect against current malaria infection, while long-lived 
ASCs maintain a sustained antibody response for protection against future infections.         
The Gambian children ranged in age from 1 to 6 years, too old for maternal antibodies to be present in appreciable 
quantities [56]. Follow-up commenced after the end of the rainy season, during which the children are likely to have 
been exposed to P. falciparum parasites [303]. During follow-up a steady decay in antibody titres punctuated by 
occasional boosts was observed (Figure 6.4 e-h). Following a boost, titre appears to decay at a faster rate than 
before boosting (as seen in Gambian child 1, Figure 6.4e), possibly due to the decay of short-lived ASCs induced by 
recent antigen exposure. 
In both cohorts longitudinal parasite presence data as detected by PCR or microscopy was available for most 
children. As antibody titres are boosted in response to antigen exposure, one would expect a new malaria infection 
to be accompanied by an increase in antibody titres. However, upon examination of the data, new infections as 
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determined by the presence of parasites were a poor predictor of the timing of boosts to antibody titres. New 
infections were often not followed by boosts to titres, and antibody titres were regularly boosted in the absence of 
detectable infection (Figure 6.4). Although the kinetics of antibodies to different antigens were often synchronous, 
with boosting and decay of titres happening simultaneously, there were many instances where the kinetics to 
different antigens appeared to act independently. For example in Figure 6.4d antibody titres to MSP-1 and MSP-2 
are boosted without boosting of AMA-1. This poor agreement between times of antibody boost and infection could 
be due to poor sensitivity or specificity of the parasite detection methods, delayed antigen presentation by follicular 
dendritic cells [319], or bystander activation [67]. Due to this asynchronous boosting the kinetics of antibodies to 
each antigen were investigated independently of parasite prevalence data and the kinetics of antibodies to other 
antigens.  
The three models were fitted to the Ghanaian and Gambian datasets (see Model fitting methods), with the 
parameters providing the best fit to both datasets shown in Tables 6.2 and 6.3. A sample of model fits to the 
antibody kinetics of two Ghanaian and two Gambian children is shown in Figure 6.5. For the Ghanaian cohort, Model 
1 predicts that maternally acquired antibody persists with a half-life of 26 – 42 days, and that exposure-acquired 
antibody circulates with a half-life of 15 – 42 days. Model 2 predicts that maternally acquired antibody persists with 
a half-life of 27 – 55 days, and that ASCs generated upon exposure persist with a half-life of 13 – 16 days, producing 
IgG antibody that circulates in the blood-stream for 10 – 11 days. Model 3 predicts that maternal antibodies persist 
with a half-life of 20 – 41 days, 89% – 98% of ASCs are short-lived persisting with half-life 3.6 – 3.9 days, the rest 
being long-lived persisting with half-life 303 – 469 days. IgG antibody secreted by ASCs is estimated to persist in the 
blood stream with a half-life of 8 – 9 days.     
For the Gambian cohort, Model 1 predicts that antibody circulates in the blood stream with a half-life of 33 – 98 
days. Model 2 predicts that circulating antibodies in the blood-stream are due to ASCs with a half-life of 55 – 80 days, 
producing antibody that decays with a half-life 12 – 16 days. Model 3 predicts that circulating antibody is generated 
by short-lived ASCs with half-life 2.0 – 2.3 days, and long-lived ASCs with half-life 374 – 503 days producing IgG 
antibody with half-life 7 days. Following antigen exposure 74% – 87% of ASCs are estimated to be short-lived. 
All three models were able to reliably reproduce the patterns observed in the data, with the more biologically 
realistic models resulting in improved fits (as judged by the model likelihood), although at the expense of a greater 
number of parameters. The fits of Model 3 to the Ghanaian data suggest that infants are only able to mount a 
transient antibody response to their first few infections, with only 2 – 11% of plasma cells estimated to be long-lived. 
In contrast, Model 3 predicted that the older Gambian children were able to mount normal antibody responses with 
13 – 26% of the induced plasma cells being long-lived and contributing to the maintenance of humoral immunity.  
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Figure 6.5: Model fits for a sample of two Ghanaian and two Gambian children. Estimated antibody kinetics for two Ghanaian children under 
Model 1 (a-b), under Model 2 (c-d), and under Model 3 (e-f). Estimated antibody kinetics for two Gambian children under Model 1 (g-h), under 
Model 2 (i-j), and under Model 3 (k-l). 
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Table 6.2: Median parameter estimates from the posterior distribution and 95% credible intervals for Models 1, 2 and 3 fitted to the 
longitudinal data from the Ghanaian cohort. 
  AMA-1 MSP-1 MSP-2 CSP 
Model 1      
maternal antibody ½-life (days) dm 42 (35 – 53) 26 (19 – 37) 37 (26 – 56) 27 (22 – 36) 
maternal antibody ½-life st. dev. 
(days) 
Σm 
33 (24 – 51)  26 (17 – 46) 44 (25 – 80) 15 (10 – 30) 
IgG antibody ½-life (days) da 18 (13 – 28) 25 (17 – 40) 42 (30 – 66) 15 (12 – 24) 
IgG antibody ½-life st. dev. (days) Σa 
22 (14 – 41) 35 (21 – 66) 56 (35 – 103) 11 (7 – 25) 
observational variance σobs
 
0.165  
(0.160 – 0.171) 
0.174  
(0.168 – 0.180)  
0.188  
(0.182 – 0.194) 
0.095  
(0.091 – 0.100) 
log-likelihood  1192 1397 1694 1185 
AIC  -1560 -1986 -2560 -1992 
      
Model 2      
maternal antibody ½-life (days) dm 48 (38 – 63) 55 (37 – 89) 27 (20 – 39) 55 (28 – 129) 
maternal antibody ½-life st. dev. 
(days) 
Σm 
42 (27 – 66) 75 (42 – 147) 25 (14 – 46) 81 (32 – 300) 
IgG antibody ½-life (days) da 10 (9 – 11) 10 (9 – 12) 11 (9 – 12) 10 (8 – 11) 
IgG antibody ½-life st. dev. (days) Σa 
11 (9 – 14) 11 (9 – 14) 11 (9 – 13) 10 (7 – 13) 
plasma B cell ½-life (days) db 16 (13 – 21) 16 (13 – 21) 16 (13 – 21) 13 (10 – 18) 
plasma B cell ½-life st. dev. (days) Σb 
22 (16 – 32) 19 (13 – 28) 17 (13 – 24) 14 (9 – 23) 
observational variance σobs 
0.164  
(0.159 – 0.170) 
0.128  
(0.124 – 0.133) 
0.129  
(0.125 – 0.134) 
0.055  
(0.051 – 0.059)  
log-likelihood  1045 1494 1818 1301 
AIC  -1052 -1982 -2590 -2112 
      
Model 3      
maternal antibody ½-life (days) dm 41 (35 – 49) 31 (24 – 42) 20 (17 – 24) 40 (26 – 72) 
maternal antibody ½-life st. dev. 
(days) 
Σm 
29 (22 – 41) 29 (18 – 48) 13 (9 – 20) 46 (25 – 110) 
IgG antibody ½-life (days) da 8 (7 – 10) 8 (7 – 10) 8 (7 –10) 9 (7 – 10) 
IgG antibody ½-life st. dev. (days) Σa 
11 (9 – 15) 12 (9 – 15) 12 (9 – 16) 13 (9 – 17) 
short-lived B cell  ½-life (days) ds 3.9 (3.3 – 4.5) 3.9 (3.3 – 4.5) 3.7 (3.2 – 4.3) 3.6 (3.1 – 4.2) 
short-lived B cell ½-life st. dev. 
(days) 
Σs 
6.0 (4.9 – 7.4) 5.7 (4.6 – 7.0) 5.4 (4.4 – 6.7) 4.7 (3.7 – 5.9) 
long-lived B cell ½-life (days) dl 371 (257– 548) 303 (197 – 477) 313 (207 – 482) 469 (309 – 711) 
long-lived B cell ½-life st. dev. 
(days) 
Σl
 
650 (381 – 1167) 644 (358 – 1236) 606 (341 – 1126) 801 (456 – 1531) 
proportion short-lived Ρ 0.97 (0.92 – 0.99) 0.89 (0.80 – 0.95) 0.91 (0.84 – 0.95) 0.98 (0.92 – 0.99) 
proportion short-lived st. dev. Σρ 0.09 (0.04 – 0.17) 0.21 (0.13 – 0.31) 0.19 (0.12 – 0.28) 0.06 (0.01 – 0.18) 
observational variance σobs 
0.152  
(0.147 – 0.158) 
0.099 
(0.095 – 0.103) 
0.148 
(0.141 – 0.151) 
0.051 
(0.047 – 0.055) 
log-likelihood  1375 1856 2193 1414 
AIC  -1284 -2310 -2904 -2114 
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Table 6.3: Median parameter estimates from the posterior distribution and 95% credible intervals for Models 1, 2 and 3 fitted to the 
longitudinal data from the Gambian cohort. 
  AMA-1 MSP-1 MSP-2 EBA-175 
Model 1      
IgG antibody ½-life (days) da 64 (53 – 81) 69 (46 – 113) 33 (21 – 60) 98 (64 – 161) 
IgG antibody ½-life st. dev. (days)  Σa 
43 (30 – 68) 109 (64 – 221) 55 (30 – 124) 156 (88 – 319767) 
observational variance σobs
 
2.8 (2.7 – 3.0) 3.9 (3.8 – 4.1) 7.5 (7.2 – 7.8) 1.5 (1.4 – 1.6) 
log-likelihood  -1428 -1913 -1797 -936 
AIC  3358 4328 4096 2374 
      
Model 2      
IgG antibody ½-life (days) da 16 (14 – 18) 15 (13 – 18) 12 (11 – 14) 14 (12 – 16) 
IgG antibody ½-life st. dev. (days) Σa 
20 (17 – 24) 20 (16 – 24) 15 (11 – 19) 19 (15 – 23) 
plasma B cell ½-life (days) db 77 (56 – 106) 78 (56 – 109) 55 (37 – 81) 80 (57 – 113) 
plasma B cell ½-life st. dev. (days) Σb 
98 (63 – 153) 100 (63 – 159) 82 (47 – 139) 123 (77 – 192) 
observational variance σobs 
2.8 (2.7 – 3.0) 4.1 (3.9 – 4.3) 7.4 (7.2 – 7.7) 1.6 (1.5 – 1.7) 
log-likelihood  -1199 -1849 -1698 -942 
AIC  3400 4700 4398 2886 
      
Model 3      
IgG antibody ½-life (days) da 7 (6 – 9) 7 (6 – 9) 7 (6 – 9) 7 (6 – 9) 
IgG antibody ½-life st. dev. (days) Σa 
12 (9 – 16) 12 (9 – 16) 12 (9 – 16) 11 (8 – 15) 
short-lived B cell  ½-life (days) ds 2.1 (1.8 – 2.5) 2.0 (1.7 – 2.5) 2.3 (1.9 – 2.9) 2.3 (1.9 – 2.7) 
short-lived B cell ½-life st. dev. 
(days) 
Σs 
0.9 (0.5 – 1.6) 0.9 (0.4 – 1.7) 1.2 (0.6 – 2.0) 1.2 (0.7 – 1.8) 
long-lived B cell ½-life (days) dl 503 (328 – 787) 376 (233 – 600) 374 (235 – 606) 414 (251 – 658) 
long-lived B cell ½-life st. dev. 
(days) 
Σl
 
1564 (875 – 2902) 1257 (655 – 2429) 1195 (639 – 2349) 1680 (851 – 3250) 
proportion short-lived  Ρ 0.87 (0.77 – 0.93) 0.84 (0.73 – 0.91) 0.83 (0.73 – 0.90) 0.74 (0.60 –0.85) 
proportion short-lived st. dev. Σρ 0.20 (0.11 – 0.30) 0.22 (0.13 – 0.32) 0.22 (0.13 – 0.31) 0.30 (0.19 – 0.39) 
observational variance σobs 
2.6 (2.3 – 2.8) 4.4 (4.1 – 4.8) 2.4 (2.2 – 2.7) 1.3 (1.2 – 1.4) 
log-likelihood  -1008 -1647 -1559 -838 
AIC  3624 4932 4754 3248 
 
6.4. Discussion 
In humans exposed to malaria parasites, both short-lived [299, 303, 320] and long-lived [60, 309] anti-Plasmodium 
antibody responses have been observed in longitudinal studies. Underlying these antibody responses are antigen-
specific memory B cells and plasma cells. Upon exposure to P. falciparum antigens activated B cells undergo rapid 
expansion and differentiation into ACSs [321]. Short-lived antibody responses suitable for protecting against current 
malaria infections are generated by short-lived plasma cells in the spleen, lymph nodes and other peripheral tissues. 
In the absence of essential survival signals only found in bone marrow, these cells die by apoptosis. We assumed that 
long-lived antibody responses are generated by long-lived plasma cells, which can continuously secrete IgG 
antibodies from survival niches in the bone marrow or spleen in the absence of detectable memory B cells [69]. An 
alternative explanation for the persistent secretion of antibodies is given by the continuous activation of antigen-
specific MBCs and their differentiation into short-lived ASCs [67, 322].  
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The half-life of exposure-acquired IgG antibodies to Plasmodium antigens was estimated to be in the range of 7 – 9 
days in both cohorts, in agreement with Kinyanjui et al’s estimate of 9.8 days [299]. In contrast the half-life of 
maternally acquired IgG antibodies from the Ghanaian cohort is estimated to be 26 – 42 days. Neither of these 
estimates match the 21 day half-life of naturally metabolised IgG1 in adults [323]. However the quantity estimated 
from the data is the half-life of detectable IgG circulating in the blood and not the half-life of naturally metabolised 
IgG. Differences between the half-lives of circulating IgG and naturally metabolised IgG could be due to depletion of 
circulating IgG by parasite opsonisation or penetration of IgG into tissue. Also, early studies have shown that half-life 
is inversely related to serum concentration and can vary from 11 – 70 days depending on IgG subclass [324]. An 
analysis of IgG kinetics split by subclass will be necessary to fully understand the observed differences in antibody 
half-life.     
In our model of antibody kinetics, the long term maintenance of antibodies is assumed to be due to long-lived 
plasma cells, which are estimated to decay exponentially with a half-life of 303 – 503 days. The duration of long-lived 
ASCs will have implications for the detection of malaria transmission via serological methods [325]. In catalytic 
models for measuring malaria transmission, it is assumed that sero-positive individuals revert to sero-negative at a 
constant rate [310]. However the reality is more complex, as the time until sero-reversion will depend on the half-life 
of long-lived ASCs and the antibody titre threshold for sero-conversion. 
The infection-blocking vaccine RTS,S induces high anti-CSP antibody titres and CSP-specific CD4+ T cells, both of 
which have been shown to be associated with protection from infection [279, 291]. Vaccine-induced anti-CSP 
antibody titres exhibit a pattern of bi-phasic decay, with titres decaying rapidly immediately after vaccination and 
then decaying at a slower rate over a number of years [118, 129] – kinetics which can be reproduced by Model 3.  
Under conditions of natural exposure, we estimated that only 2% of anti-CSP antibody secreting cells are long-lived, 
but that these persist with a half-life of 469 days. Although no estimates of the half-life of anti-CSP antibody 
responses following RTS,S vaccination have been published to date, the observed patterns of antibody decay appear 
consistent with a 469 day half-life [139]. In addition, it is likely that the proportion of long-lived ASCs generated by 
vaccination will be different to the proportion generated during natural infection, possibly due to the effect of the 
adjuvant. Further analysis of immunological data from Phase II trials of RTS,S should allow a more detailed 
comparison of the kinetics of naturally acquired and vaccine-induced antibodies. 
The models described in this study are necessary simplifications of the complex processes underlying the generation 
of antibody responses. ASCs are assumed to be generated in sudden bursts following antigen exposure (boosting), 
corresponding to the assumption of rapid proliferation and differentiation of MBCs. However blood-stage malaria 
infections can persist for weeks or months continuously exposing newly minted naïve B cells and MBCs to antigen. 
An alternative model formulation could include the underlying parasite dynamics and continuous stimulation of 
MBCs and differentiation into ASCs. Also, the simple models investigated here do not distinguish between infection 
and re-infection. It has been observed that functional MBCs generated in a primary infection give rise to a faster ASC 
and antibody response upon re-infection [318]. Alternative model formulations could consider the possibility of 
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faster and stronger secondary antibody responses and a greater likelihood of MBCs differentiating into long-lived 
ASC compared to naïve B cells. However, the data used here are unlikely to be sufficient to distinguish between 
these models of increased complexity. 
The temporal resolution of the data presents a limitation to the model. Antibody titres are available every 4 weeks in 
the Ghanaian cohort and every 2 weeks in the Gambian cohort. With antibody titres sampled at a weekly frequency 
it is difficult to make inferences on the processes of MBC proliferation and decay of short-lived ASCs. The limitations 
encountered due to the temporal resolution of the data could be overcome by fitting the models to data from 
experimental malaria infection in mice where antibody responses can be measured more frequently. In addition, the 
kinetics of MBCs and plasma-cell responses can be directly measured as has been demonstrated by Langhorne and 
colleagues [318, 326] following blood-stage P. chabaudi infection in mice. 
Although the cellular and molecular determinants of the duration of antibody response have been investigated in 
mouse models [318, 326] they remain poorly studied in humans. Memory B cells specific to Plasmodium antigens are 
detectable in human peripheral blood mononuclear cells (PBMC) and studies have reported their expansion and 
contraction [68], and their longevity [309, 327]. However there are no comparable studies of ASCs in humans 
exposed to malaria. Such studies would be very difficult to undertake, as ASCs are located primarily in bone marrow 
and lymphoid organs, and are detectable in PBMCs only in the short window between differentiation and migration 
to the bone marrow [326]. Data from mouse models demonstrate a strong correlation between numbers of ASCs in 
the bone marrow and liver, and concentrations of antibody in blood sera, suggesting that antibody titres are a good 
surrogate for the number of plasma cells [318]. In the absence of data on ASCs in humans, simple models of 
immunological processes can be used to infer the kinetics of plasma-cell responses from the observable antibody 
kinetics.  
The simple models developed here assume that the immunological processes underlying antibody production 
remain constant with time and age. In reality we would expect development of the immune response with age. For 
example in young infants (less than 100 days old) from the Ghanaian cohort, antibody titres are rarely boosted, even 
though the infants are regularly exposed to Plasmodium parasites. This suggests that young infants may be unable to 
mount their own B cell response, perhaps because high avidity maternally transferred antibodies sequester the 
antigen and reduce its availability to prime the child’s naïve B cells. Comparing the younger Ghanaian cohort with 
the older Gambian cohort, we see that older children generate a higher proportion of long-lived plasma cells with 
longer half-lives suggesting development of the immune response with age. 
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6.5. Conclusion 
In summary, our findings demonstrate that the acquisition of immunity to P. falciparum is a gradual process with 
repeated infections inducing proliferation of short-lived plasma cells for generating antibody to combat ongoing 
infection and long-lived plasma cells for the maintenance of a sustained antibody response. Our results suggest that 
the antibody response in infants (< 2 years of age) is abnormal, waning over a period of days to weeks due to the 
absence of appreciable quantities of long-lived plasma cells. In contrast, we estimate that older children are able to 
generate a substantial proportion of long-lived plasma cells following P. falciparum infection giving rise to a long 
lasting antibody response.  
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Chapter 7. Simulation of the effectiveness and cost-
effectiveness of RTS,S vaccination in combination with 
insecticide treated nets 
 
In the earlier chapters of this thesis I discussed issues underlying the measurement of naturally acquired pre-
erythrocytic immunity and vaccine efficacy in field trials, and immunological correlates of protection from P. 
falciparum infection. Drawing from insights on vaccine-induced immune responses on the individual level, I use 
mathematical models to simulate the impact of vaccination campaigns on the population level. Using the published 
summary results from the Phase II and Phase III RTS,S trials I estimate the impact on the clinical epidemiology of 
malaria of RTS,S/AS01 delivered through the Expanded Program on Immunization (EPI) or via mass vaccination 
campaigns . In addition, using data from a systematic review of the costs and cost-effectiveness of malaria control 
interventions [328] I estimate the cost-effectiveness of vaccination with RTS,S/AS01 in combination with long-lasting 
insecticide treated nets (LLINs). 
 
7.1. Introduction 
Should RTS,S be approved for licensure upon completion of Phase III trials, a number of questions will need to be 
addressed before vaccination of children in sub-Saharan Africa can commence [329]. The efficacy of RTS,S/AS01 
against clinical and severe malaria has been well characterised on time scales of up to three years following 
vaccination [15, 136, 139, 203], but the duration of protection and the interaction with naturally acquired immunity 
remain poorly understood. Improved understanding of the biological properties of RTS,S will help to determine 
whether vaccination is likely to have a long term public health benefit. The decision to deploy the vaccine will then 
depend on economic factors, primarily the cost per dose of vaccine and the cost per case of malaria or disability 
adjusted life year (DALY) averted. Using published data from Phase II and Phase III trials of RTS,S and knowledge of 
malaria epidemiology encapsulated in models of malaria transmission we attempt to address these questions.  
The efficacy of RTS,S/AS01 against first episodes of clinical malaria has been estimated as 55.8% (97.5% CI, 50.6% – 
60.4%) in a cohort of 6000 children followed for 14 months in a Phase III trial [15]. There have been no direct 
estimates of the efficacy of RTS,S/AS01 against P. falciparum infection in African children, although Kester et al [129] 
have shown that RTS,S/AS01 has 50% (95% CI, 32.9% – 67.1%) infection-blocking efficacy in malaria-naïve adults 
when challenged with the bites of five P. falciparum infectious mosquitoes. Analysis of data on clinical episodes of 
malaria from extended follow-up of participants in Phase II trials shows that a reduction in estimates of vaccine 
efficacy can be detected for both RTS,S/AS01 and RTS,S/AS02 within three years [136, 139, 203], although these 
trials were not sufficiently powered to estimate the rate of waning of vaccine efficacy. 
Vaccination with RTS,S may delay the acquisition of naturally acquired immunity to clinical malaria. Bejon et al [330] 
observed that young children vaccinated with RTS,S/AS01 had lower blood-stage antibody titres than unvaccinated 
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children, however they found that blood-stage antibodies were significantly associated with increased risk of clinical 
malaria – a finding attributable to heterogeneity in exposure causing blood-stage antibodies to act as a marker for 
exposure [204]. However, conditional upon becoming parasite positive, both LLIN use and vaccination with 
RTS,S/AS01 were significantly associated with increased odds of clinical malaria compared to asymptomatic 
infection. In contrast to Bejon’s findings, Campo et al [331] found no significant differences in blood-stage antibody 
titres between children vaccinated with RTS,S/AS02 and unvaccinated children. However when stratified by age, the 
vaccine group had lower blood-stage antibody concentrations than the control group in younger children (< 2 years, 
comparable with the children in Bejon’s study), but not in older children (≥ 2 years). The evidence to date is 
consistent with RTS,S delaying the acquisition of blood-stage immunity in younger but not in older children. Strong 
blood-stage immune responses induced following small infectious doses of merozoites [332] could provide a 
plausible biological mechanism for the similar levels of blood-stage antibodies in the vaccine and control cohorts 
despite the reduction in the force of infection in vaccinated children. 
The long term public health benefit of vaccination will depend on the biological properties of the vaccine and the 
epidemiology of malaria transmission. Given an understanding of these biological properties, the cost-effectiveness 
of vaccination can be estimated using mathematical models. There have been several modelling studies of both the 
effectiveness [63, 64, 172] and cost-effectiveness [178, 179, 333] of RTS,S vaccination campaigns, most notably by a 
group at the Swiss Tropical and Public Health Institute who have estimated that RTS,S/AS02 administered through 
the EPI would have a substantial impact on malaria morbidity and mortality, but have negligible effects on malaria 
transmission at levels of endemicity typical of sub-Saharan Africa [169]. However, the cost-effectiveness of vaccines 
in the context of other ongoing interventions has not been considered, in particular the rapid scale-up of LLINs that 
has occurred in the last decade [334]. We add to the existing published literature by describing a model for 
estimation of the cost-effectiveness of RTS,S vaccination as part of a package of malaria control interventions across 
a range of epidemiological settings.  
 
7.2. Methods 
7.2.1. Transmission model 
The impact of vaccination on the clinical epidemiology of malaria is investigated using a model of malaria 
transmission which captures key aspects of the P. falciparum lifecycle and its transmission between humans and 
mosquitoes [63]. The model has been validated by statistical fitting to data on parasite prevalence and clinical 
incidence from a variety of malaria endemic settings. Model details and validation have been described elsewhere 
[63], so only a brief summary is presented here and in Figure 7.1. Individuals begin life susceptible (S) to infection but 
with partial maternal immunity which decays in the first months of life. Individuals become infected at a rate 
determined by the force of infection (Λ) which depends on the number of mosquitoes per person, the proportion of 
infectious mosquitoes, and the person’s level of pre-erythrocytic immunity. Once infected, a person passes through 
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the pre-patent (liver) stage of infection, and then progresses to develop clinical disease (D) or asymptomatic (A) 
infection, depending on their level of clinical immunity φ. A proportion fT of those with clinical disease will be treated 
(T). Individuals with clinical disease recover to the asymptomatic stage at a rate rD, and treated individuals recover at 
a rate rT after which they are afforded a period of prophylactic protection (P) with average duration 1/rP. 
Asymptomatic individuals (patent infection – detectable by microscopy) will move to a sub-patent stage of infection 
(U) at a rate rA, from which they eventually return to susceptible at a rate rU. Clinical immunity is acquired at a rate h 
proportional to the force of infection. Increased clinical immunity will reduce φ, the probability of experiencing an 
episode of clinical malaria following infection. 
Malaria is transmitted from human to human by Anopheles mosquitoes. Our model also incorporates the effects of 
insecticide treated nets on mosquitoes and malaria transmission [335]. We assume the vector population has the 
behavioural traits of the indoor and night-time biting Anopheles gambiae s. s. mosquito. LLINs are assumed to have 
three effects on the adult mosquito population: (i) directly killing mosquitoes that land on nets; (ii) repelling and 
possibly diverting mosquitoes to an animal blood host due to either insecticide irritation or the physical barrier of 
the net; and (iii) lengthening of the gonotrophic cycle leading to a reduced frequency of biting. 
 
Figure 7.1: Flow diagram and parameters of a malaria transmission model used to investigate the effects of vaccination. Pre-erythrocytic 
vaccination reduces the force of infection Λ, highlighted in green. Full details are available in Griffin et al [63]. 
 
7.2.2. Pre-erythrocytic vaccination 
Vaccination with the infection-blocking RTS,S/AS01 vaccine can be incorporated into models of malaria transmission 
[63, 169, 178]. In our model simulations we assume that RTS,S has infection-blocking efficacy 50%VE waning 
exponentially with a half-life of 5 years. We assume that vaccination partially reduces the rate of acquisition of 
immunity. In the notation of Griffin et al [63] the rate of acquisition of clinical immunity h  in unvaccinated children is 
proportional to the force of infection , i.e. h . In vaccinated children, a proportion VE of infections are 
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prevented, and the force of infection is reduced to (1 )VE . As vaccination was associated with lower blood-stage 
antibody titres in younger children [330] but not in older children [331], we assumed that the acquisition of 
immunity in vaccinated children was proportional to the force of infection partially reduced by vaccination, 
1
2
(1 )h VE . The outcomes of vaccines causing a full reduction in the rate of acquisition of immunity, i.e.
(1 )h VE , were also simulated for comparison. Unless otherwise stated, the model with partial reduction in 
acquisition of immunity is used in this analysis. 
The characteristics of study sites for Phase II trials of RTS,S/AS01 in sub-Saharan African infants and children are 
summarised in Table 7.1. The transmission intensity at each site at the time of the trial isn’t known precisely, but 
estimates of the EIR can be obtained from previous entomological studies at these sites [61, 336-339], although 
some of these measurements were made before the decline in malaria transmission due to expanded coverage of 
bed nets. These estimates of EIR span a wide range of transmission intensities, from 22 – 600 ibppy. The low levels of 
clinical incidence in children in the control group suggest that during the vaccine trials, transmission was lower than 
reported. For example, in studies of the relationship between EIR and clinical incidence in Senegalese villages [59], it 
was estimated that when EIR ≈ 200 ibppy the expected clinical incidence is 3 – 6 episodes per year in young children, 
and when EIR ≈ 20 ibppy the expected clinical incidence is 2 – 3 episodes per year. In contrast in the control groups 
of the vaccine trials we observe clinical incidence of 0.03 – 0.55 episodes per year suggesting much lower 
transmission intensity. Alternatively, the difference between these estimates of clinical incidence could be due to 
different definitions of an episode of clinical malaria or a reduction in transmission due to the improved access to 
healthcare associated with large scale clinical trials. Using our transmission model, we estimated the EIR that would 
result in the observed clinical incidence in children in the control group with LLIN coverage equal to that reported in 
trials. A comparison of the entomologically measured EIRs, and EIR estimated from clinical incidence are shown in 
Table 7.1.  
 
Table 7.1: Characteristics of Phase II trial sites of RTS,S/AS01. *Incidence rates per person year of observation refer to first episodes of clinical 
malaria in the control group according to the surveillance method used in each study. **In the Bagamoyo Tanzania, Gabon and Ghana studies 
of RTS,S/AS01 no information on bed nets was available, so coverage was set to 75%, equal to that obtained in the Phase III trial of 
RTS,S/AS01.PfPR is the parasite rate in children aged 2 – 10 years in 2007 as reported in the Malaria Atlas Project [340]. Measured EIR is 
derived from entomological studies, and estimated EIR is derived from the reported clinical incidence. 
Site N Median age 
(IQR), months 
Incidence 
person year* 
LLIN 
use** 
PfPR measured 
EIR (ibppy) 
estimated 
EIR (ibppy) 
Reference 
Bagamoyo Tanzania  209 1.8m  
(1.7-1.9) 
0.3 75% 0.35 80 – 600  5 [336, 341] 
Gabon 215 1.5m  
(1.4-1.7) 
0.032 75% 0.2 23 – 61 1 [337, 341] 
Ghana 81 1.6m 
 (1.5-1.8) 
0.55 75% 0.7 269 10 [61, 341] 
Kenya Kilifi 447 11m 
 (8-14) 
0.29 59% 0.25 22 – 53 2 [338, 342, 343] 
Korogwe Tanzania  447 12m  
(9-15) 
0.15 52% 0.15 90 1 [339, 342] 
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7.2.3. Simulation of extended follow-up of vaccine trials 
Extended follow up of Phase II trials of RTS,S has shown sustained protection from clinical malaria for up to three 
years, although efficacy appears to decline over time, for example Guinovart et al [136] observed that children 
vaccinated with RTS,S/AS02 had 35.4% (95% CI, 4.5 – 56.3%) efficacy against clinical malaria in the first 6 months, 
and 9% (95% CI, -30.6% – 36.6%) in the following 12 months.  Apparent reductions in  vaccine efficacy over time 
could be due to biologically mediated waning in vaccine-induced antibody titres [342] and a corresponding reduction 
in the vaccine’s infection-blocking efficacy; heterogeneity in exposure [344]; or faster acquisition of immunity in the 
control cohort. To compare these hypotheses for the reduction of efficacy the outcome of vaccine trials with 
extended follow up are simulated. Trials are simulated for a sample of the study sites described in Table 7.1, namely 
vaccination of infants with RTS,S/AS01 in Gabon and Ghana [130], at both the lower estimates of EIR corresponding 
to the observed clinical incidence in the control groups, and the higher estimates of EIR from entomological studies 
[61, 337].  
 
7.2.4. Cost-effectiveness 
The cost-effectiveness of a package of malaria control interventions can be estimated using model predictions of the 
number of episodes of clinical malaria averted, the cost per unit intervention and the savings on treatment. Using 
transmission model derived estimates of the number of episodes of clinical malaria averted by packages of malaria 
control interventions, a decision tree similar to that described by Shillcutt et al [345] and Coleman et al [346] can be 
used to estimate the number of DALYs and deaths averted. The decision tree, shown in Figure 7.2, follows the 
possible outcomes of a patient experiencing an episode of clinical malaria. We assume that a fixed proportion of 
patients are treated with artemisinin combination therapy (ACT) and fully recover unless they fail to adhere to the 
treatment regimen [347, 348] or treatment fails [349]. If treatment fails, patients will progress to either 
uncomplicated or severe malaria. A fixed proportion of patients with uncomplicated malaria will seek outpatient 
treatment in health centres or hospitals, and the rest will fully recover naturally. A fixed proportion of patients with 
severe malaria will require and be able to access inpatient care in hospitals. There are assumed to be three possible 
outcomes following an episode of severe malaria: full recovery, neurological sequelae, and death [350]. The 
parameter values for the decision tree and their uncertainty distributions are given in Table 7.2.   
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Figure 7.2: Decision tree for estimation of the outcome of an episode of clinical malaria. Progression through the decision tree is determined 
by the probabilities P given in Table 7.2. 
 
First-line treatment was assumed to be with an ACT paid for at the patient’s expense. The costs of LLIN distribution 
and treatment, either of uncomplicated malaria as an outpatient or severe malaria as a hospital inpatient were taken 
from a systematic review of the costs of malaria control interventions [328]. All costs are in 2009 US dollars (USD). 
The costs of vaccine delivery are based on data collected by Hutton and Tediosi [351] for EPI vaccination in a 
Tanzanian setting. The cost of vaccination with RTS,S/AS01 was assumed to be USD 5.00 per dose. Prices in the range 
USD 2.00 – 10.00 were also considered as part of the sensitivity analysis.  
Discounted Years of Life Lost (YLL) due to death are estimated as 27.47 years for children (age < 5 years) and 24.83 
years for adults (age ≥ 5 years) [346]. Disability weights used for estimation of Years Lost due to Disability (YLD) are 
taken from Murray et al [352].   Disability Adjusted Life Years are calculated with and without discounting at a rate of 
3% per year [353]. All parameters and their distributions are shown in Table 7.2. Incremental Cost-Effectiveness 
Ratios (ICER) per DALY averted are calculated from a societal perspective. Costs incurred by patients self-treating for 
an episode of clinical malaria are included. We do not account for loss of earnings due to illness or time taken off 
work to care for sick children [354]. A ten year time frame was used for analysis – costs incurred and cases averted 
after ten years were not included. 
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Parameters for the decision tree and costs of treatment and preventive interventions were sampled from the 
distributions in Table 7.2 using 10,000 Monte Carlo simulations. Estimates of ICER per DALY averted were calculated 
for each sample, and the median and 95% sampling interval (SI) presented. ICERs per DALY averted were compared 
against several ceiling ratios [355]: USD 100.00, USD 260.00 (corresponding to the estimate of 150.00 in 1990 USD at 
which an intervention is considered cost-effective in low-income countries [352]), USD 500.00, and USD 2191 (equal 
to the mean gross domestic product per capita for sub-Saharan Africa based on estimates from the WHO CHOICE 
project [356]).   
 
Table 7.2: Decision tree parameters, costs of interventions and treatment and disability weights. All costs are in 2009 USD. 
Parameter Description Value Lower 
limit 
Upper 
limit 
Distribution Source 
Decision tree parameters 
P1 Proportion self-treated 0.60 0.07 0.94 triangular [357] 
P2 Adherence 0.75 0.59 0.90 triangular [347, 348] 
P3 ACT cure rate  0.85 0.78 0.95 triangular [349] 
P4 Probability of severe disease after 
treatment failure– under 5 
0.05 0.03 0.07 triangular [346, 358] 
P5 Probability of severe disease after 
treatment failure – over 5 
0.01 0.005 0.015 triangular [346, 358] 
P6  Proportion seeking inpatient care for 
severe malaria 
0.48 0.19 0.88 triangular [346, 358] 
P7 Proportion seeking outpatient care for 
uncomplicated malaria 
0.48 0.19 0.88 triangular [346, 358] 
P8 Severe malaria leads to neurological 
sequelae – under 5 
0.0132 0.0041 0.0224 triangular [350, 358] 
P9 Severe malaria leads to neurological 
sequelae – over 5 
0.005 0.0025 0.0075 triangular [350, 358] 
P10 Severe malaria leads to death in inpatients 
– under 5 
0.192 0.1 0.3 triangular [346, 358] 
P11 Severe malaria leads to death in inpatients 
– over 5 
0.10 0.075 0.125 triangular [346, 358] 
P12 Severe malaria leads to death with no 
formal care – under 5 
0.50 0.40 0.60 triangular [346, 358] 
P13 Severe malaria leads to death with no 
formal care – over 5 
0.25 0.20 0.30 triangular [346, 358] 
       
Costs of treatment and preventive interventions 
C1 Cost of ACT self-treatment (USD) 0.14 0.13 0.19 triangular [359] 
C2 Cost of outpatient treatment for 
uncomplicated malaria (USD) 
5.84 2.36 23.65 triangular [328] 
C3 Cost of inpatient treatment for severe 
malaria (USD) 
30.26 15.64 137.87 triangular [328] 
C4 Vaccine price per dose (USD) 5.00  2.00 10.00 triangular – 
C5  Vaccine delivery cost per course (USD) 1.02  0.81 1.23  triangular [178, 351] 
C6 LLIN cost (USD) 7.03  2.97 10.00 triangular [328] 
 
 
141 
 
Table 7.2 (contd.): Decision tree parameters, costs of interventions and treatment and disability weights. All costs are in 2009 USD. 
Parameter Description Value Lower 
limit 
Upper 
limit 
Distribution Source 
Disability weights 
D1 Disability weight: uncomplicated malaria 0.21 – – fixed [352] 
D2 Disability weight: severe malaria 0.25 – – fixed 
 
[352] 
D3 Disability weight: neurological sequelae  0.47 – – fixed 
 
[352] 
D4  Duration of uncomplicated untreated 
malaria (days) 
4  – – fixed 
 
[346] 
D5 Duration of uncomplicated treated malaria 
(days) 
2  – – fixed 
 
[346] 
D6 Duration of severe malaria for inpatients 
(days) 
4.5 2 10 triangular 
 
[358] 
D7 Duration of neurological sequelae (years) 35.4  – – fixed [352] 
D8 Discount rate (per year) 3% – – fixed [353] 
D9 Discounted YLL due to child death (years) 27.47  – – fixed [346] 
D10 Discounted YLL due to adult death (years) 24.83 – – fixed [346] 
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7.3. Results 
 
 
Figure 7.3: Simulated outcome of a trial comparing a cohort of 1,000 children vaccinated with RTS,S/AS01 with a control cohort. For the 
Ghanaian and Gabonese sites, simulations are presented at the lower estimates of EIR derived from clinical incidence observed in the control 
groups, and the higher estimates of EIR from entomological studies. Vaccine efficacy against clinical malaria and number of episodes averted 
for (a – b) a vaccine with exponentially waning efficacy and no reduction in immune acquisition; (c – d) a non-waning vaccine that reduces the 
rate of acquisition of immunity; and (e – f) a waning vaccine that reduces the rate of acquisition of immunity. In panels c – f the solid lines 
represent the outcomes of simulations with partial reduction in the rate of acquisition of immunity 12(1 )h VE , and the dashed 
lines the outcome with full reduction in the rate of acquisition of immunity (1 )h VE .        
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Figure 7.3 shows estimates of vaccine efficacy against clinical malaria (in the left-hand column) and the number of 
episodes of clinical malaria averted (in the right-hand column). Vaccine efficacy is estimated from the reduction in 
the incidence of clinical malaria in the vaccine group compared to the control group at a fixed point in time – this is 
the vaccine efficacy that would be measured in a field trial if there was no bias due to heterogeneity in exposure 
[344]. If vaccine efficacy falls below zero, it indicates a rebound effect where the incidence of clinical malaria is 
higher in the vaccinated group than in the control group [360, 361]. A more serious prospect than a rebound effect is 
the possibility of the cumulative number of cases averted becoming negative, i.e. if vaccination causes a long-term 
increase in cases of malaria. Vaccine efficacy against clinical malaria was simulated under three scenarios for waning 
of efficacy against infection and reduction in the rate of acquisition of immunity: 
 Figure 7.3 a – b: if efficacy against infection wanes exponentially with a 5 year half-life, but vaccination 
doesn’t reduce the rate of acquisition of immunity, then a rebound isn’t predicted and a positive number of 
cases will be averted. 
 Figure 7.3 c – d: if efficacy against infection doesn’t wane, but vaccination reduces the rate of acquisition of 
immunity, then the measured efficacy against clinical malaria will wane over time as the control group 
acquire clinical immunity at a faster rate than the vaccinated group. The reduction in the rate of acquisition 
of immunity was assumed to be partial (solid lines) or full (dashed lines).The model predicts a rebound effect 
at high transmission settings, but not at the low transmission settings. A net increase in episodes of clinical 
malaria is predicted only at high transmission settings if there is full reduction in immune acquisition. 
 Figure 7.3 e – f: if efficacy against infection wanes exponentially and vaccination reduces the rate of 
acquisition of immunity then vaccine efficacy against clinical malaria decreases to near zero, possibly even 
causing a small rebound in sites with low transmission. 
Under our model for the acquisition of naturally acquired immunity [63], the waning of efficacy observed in Phase II 
trials [136, 203] cannot be explained by the differential acquisition of immunity in the vaccine and control cohorts 
alone. Thus some biological waning of efficacy appears to be necessary to reproduce the patterns observed in these 
trials. The model simulations suggest that rebound effects may occur in high transmission settings, although RTS,S 
has yet to be tested in very high transmission settings in the absence of other interventions. Even if there is a 
rebound effect the cumulative number of episodes of malaria averted is still estimated to be positive, because when 
infants are vaccinated the period at which the vaccine is most efficacious coincides with the period when infants are 
most at risk of clinical malaria. If there is a rebound effect it will be experienced in older children who have acquired 
some degree of partial immunity despite being vaccinated. Thus a rebound effect may be acceptable if it occurs in 
older children subjected to lower incidence. However a potential cause for concern is the possibility of a rebound 
effect causing a net increase in the number of episodes of malaria – an outcome observed in Figure 7.3f when there 
is full reduction in the rate of acquisition of immunity (dashed lines) in high transmission sites (red and orange). This 
possibility, however slight, will need to be ruled out by analysis of extended follow up data from Phase II and Phase 
III trials, and a greater understanding of the interaction between vaccination and naturally acquired immunity. 
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7.3.1. Epidemiological impact of vaccination campaigns  
Simulation of the impact of vaccination in transmission settings similar to the trial sites described in Table 7.1 
suggests that vaccination of young children through EPI campaigns will cause a negligible reduction in malaria 
transmission (Figure 7.4a). Although EPI vaccination will only cause minor reductions in clinical incidence at the 
population level (Figure 7.4b), there will be a substantial reduction in episodes of malaria amongst vaccinated 
children, in agreement with Maire et al’s predictions [169].  
Simulation of mass vaccination campaigns suggests that short term reductions in transmission intensity and 
incidence of clinical malaria can be obtained (Figure 7.4 c,d), although transmission intensity will return to initial 
levels after vaccine efficacy has waned, and there may even be an increase in clinical incidence as a consequence of 
the reduced immunity in the population.  
 
 
Figure 7.4: Simulation of the effect of EPI vaccination at 90% coverage in a population of size 1,000 on EIR and total clinical incidence (a,b).   
Simulation of the effect of mass vaccination at 80% coverage in a population of size 1,000 on EIR and clinical incidence (c,d).  
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7.3.2. The mass effect of vaccination and interaction with insecticide treated nets 
Vaccination campaigns can reduce incidence of malaria by preventing infection in vaccinated individuals (the direct 
effect) and by reducing malaria transmission in the population (the mass effect). A comparison of the number of 
episodes of malaria averted due to the direct effect of vaccination alone and the combined direct and mass effect is 
shown in Figure 7.5 a-b for mass vaccination and EPI vaccination campaigns. At low transmission intensities mass 
vaccination can reduce transmission to an extent that a substantial additional benefit is obtained from the mass 
effect. However at high transmission intensities, the mass effect can actually be detrimental to the success of the 
vaccination campaign as vaccine-induced reductions in transmission can lead to lower population level immunity. 
We estimate that above EIR ≈ 50 ibppy mass vaccination may lead to an increase in the incidence of clinical malaria.  
Vaccination via EPI results in very limited reductions to transmission intensity, and as such the mass effect will be 
beneficial only at low to moderate transmission intensities (EIR < 20 ibppy). Model simulations suggest that EPI 
vaccination will be most effective in areas of moderate transmission (EIR ≈ 10 ibppy). EPI vaccination becomes less 
effective in high transmission settings, possibly even causing an increase in clinical incidence at very high 
transmission settings (EIR > 250 ibppy). 
Although the decrease in effectiveness of vaccination at high transmission intensities may not agree with our 
intuition, it can be explained by considering the number of P. falciparum infectious bites. For example, in a setting 
with EIR = 100 ibppy, an unvaccinated child may become infected 20 times over a transmission season. A child 
receiving a 50% efficacious vaccine may still be infected 10 times, more than enough to experience incidence of 
clinical malaria comparable to an unvaccinated child. 
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Figure 7.5: Estimated number of episodes of malaria averted in a population of size 1,000 by the direct effect alone and the combined direct 
and mass effect for a mass vaccination campaign (a) and an EPI vaccination campaign (b). The estimated impact of mass vaccination (c) and EPI 
vaccination campaigns (d) combined with ITNs at different levels of coverage. The reported EIR is the baseline value before introduction of 
vaccines or bed nets. (c) and (d) show only the number of clinical episodes averted due to vaccination.  
 
Partially efficacious pre-erythrocytic vaccines are unlikely to be deployed in isolation; in the recent Phase III trials of 
RTS,S, approximately 75% of vaccinated children were reported as sleeping under bed nets [15]. The impact of 
vaccination must therefore be considered as part of a package of malaria control interventions – in particular ITNs. 
Figure 7.5 c-d shows the expected number of clinical episodes of malaria averted in a population of size 1,000 due to 
EPI vaccination in combination with ITNs – only the cases averted by vaccines over and above those averted by ITNs 
are shown. In low transmission settings increased ITN coverage will result in fewer episodes of malaria being averted 
by mass vaccination campaigns as malaria transmission will have been suppressed by ITNs. In higher transmission 
settings, increasing ITN coverage will reduce transmission to levels where mass vaccination can become more 
effective. Combining EPI vaccination with ITN distribution will make vaccination less effective in low transmission 
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settings (because bed nets alone will be so effective) and more effective in high transmission settings because bed 
nets will reduce transmission to a level where vaccination can become effective. 
 
7.3.3. Cost-effectiveness of RTS,S/AS01 delivered through the Expanded Program on 
Immunisation 
Estimates of the ICER per discounted DALY averted by EPI vaccination in the absence and presence of LLINs are 
shown in Figure 7.6. In the absence of LLINs, vaccination is estimated to be most cost-effective in moderate to low 
transmission settings with an ICER of USD 253 (95% sampling interval (SI), 93 – 696) when EIR = 10 ibppy. In 
comparison the ICER per DALY averted by LLINs at 80% coverage is estimated to be USD 33 (95% SI, 5.50 – 140) when 
EIR = 10 ibppy (this estimate is in good agreement with the median value of USD 27 per DALY averted by bed nets 
derived from a systematic literature review [328]). Vaccination will cease to be cost effective above an EIR ≈ 250 
ibppy as vaccination is predicted to cause a net increase in the incidence of clinical malaria over a ten year time 
frame. The distribution of LLINs in low transmission settings will cause malaria vaccination to be less cost-effective as 
malaria transmission will have been reduced by LLINs. Against a baseline of 80% LLIN coverage in a setting with pre-
intervention EIR = 10 ibppy, the cost-effectiveness of vaccines will be reduced with an ICER per DALY averted of USD 
787 (95% SI, 289 – 2312). 
In contrast, at high transmission settings vaccines will become more cost-effective when combined with LLINs. When 
EIR = 50 ibppy, the ICER per DALY averted by EPI vaccination alone is estimated to be USD 793 (95% SI, 312 – 2095), 
but when vaccination is administered against a baseline of 80% LLIN coverage the ICER per DALY averted drops to 
USD 391 (95% SI, 145 – 1081). For comparison, the ICER per DALY averted in the absence of vaccines by LLINs at 80% 
coverage is estimated to be USD 250 (95% SI, 102 – 676).  
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Figure 7.6: Incremental cost-effective ratio per discounted DALY averted by EPI administered RTS,S/AS01 in a setting with no LLINS (a) and in a 
setting with 80% LLIN coverage (b). The shaded regions represent 95% sampling intervals estimated from Monte Carlo sampling of the cost-
effectiveness parameters.  
 
The estimates of cost-effectiveness presented in Figure 7.6 only consider costs incurred and episodes averted in a 
ten year window. However an infant vaccinated in the ninth year of the vaccination campaign will continue to be 
partially protected after the ten year window for analysis even though the entire cost of vaccination will be captured 
in the analysis. EPI vaccination is therefore likely to be more cost-effective in the long term than the estimates 
presented in Figure 7.6. The ICERs presented in Figure 7.6 are for discounted DALYs, undiscounted DALYs will result 
in lower ICER estimates. For example, presenting undiscounted instead of discounted ICERs per DALY averted will 
cause an approximately two-fold improvement in cost-effectiveness, with the cost per ICER by vaccination when EIR 
= 10 ibppy dropping from USD 253 (95% SI, 93 – 696) to USD 114 (95% SI, 42 – 319). 
Upon evaluation of the cost-effectiveness of an intervention, the decision to deploy it can be informed by comparing 
the ICER per DALY averted with a ceiling ratio [355] – if the ICER per DALY averted is less than the ceiling ratio then 
the intervention is declared to be cost-effective. Although the choice of ceiling ratio is somewhat arbitrary, it is still a 
useful tool for assessing cost-effectiveness. The probability that vaccination is cost-effective when compared to a 
number of ceiling ratios of incremental cost per DALY averted is shown in Figure 7.7. In the absence of LLINs, RTS,S is 
most likely to be cost-effective at low transmission intensities (EIR ≈ 10 ibppy).In the presence of LLINs at 80% 
coverage, vaccination is likely to be most cost-effective in higher transmission settings around EIR ≈ 50 ibppy. 
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Figure 7.7: Probability that an EPI vaccination campaign is cost-effective at different thresholds for the cost per DALY averted in the absence of 
ITNs (a) and in the presence of LLINs at 80% coverage (b). 
 
7.4. Discussion 
In this analysis we have validated the findings of other modelling groups that vaccination with RTS,S/AS01 can cause 
substantial reductions in morbidity and mortality in young African children, although it is unlikely to cause major 
reductions in malaria transmission. In the absence of other interventions, vaccination is estimated to be most 
effective at low transmission intensities. Combining vaccination with other malaria control interventions may change 
the settings at which vaccines are most effective. For example in low transmission settings LLINs will suppress 
malaria transmission, reducing the number of cases of malaria that can be averted by vaccination. In contrast, in 
regions of high transmission (EIR ≈ 50 ibppy) vaccines will become more effective when combined with LLINs. 
RTS,S/AS01 delivered through the EPI is estimated to be most cost-effective in low transmission settings (EIR ≈ 10 
ibppy) with an estimated ICER per DALY averted of USD 253 (95% SI, 93 – 696). This is significantly more expensive 
than the estimated ICER per DALY averted by LLINs of USD 33 (95% SI, 5.50 – 140). Thus LLINs should remain the first 
choice preventive intervention, although vaccination may still be useful after LLIN distribution but with an increased 
ICER per DALY averted of USD 787 (95% SI, 289 – 2312). Although LLINs reduce the cost-effectiveness of vaccines in 
low transmission settings, they actually improve it in high transmission settings as LLINs can reduce malaria 
transmission to the optimal range for vaccines. For example at an EIR = 50 ibppy, the ICER per DALY averted by 
vaccines alone is USD 793 (95% SI, 312 – 2095), but when administered against a background of LLINs at 80% 
coverage, the ICER per DALY averted drops to USD 391 (95% SI, 145 – 1081).  
150 
 
The simulations presented in this analysis are dependent on two key assumptions of the biological properties of the 
RTS,S vaccine: the duration of efficacy and the interaction with naturally acquired immunity. Extended follow up of 
Phase II trials over a three year time scale indicates that there is reduction in vaccine efficacy against clinical malaria 
over time, although these trials do not have sufficient statistical power to estimate rates of waning. More accurate 
estimates of the duration of protection can be obtained from pooled analyses of data from Phase II trials (P. Bejon, 
M. White et al – in preparation) or extended follow up of Phase III trials. Alternatively, if an accurate immunological 
correlate of vaccine-induced protection from infection such as anti-CSP antibody titre or number of CSP-specific T 
cells can be established [232, 279] then the rate of waning of efficacy could be estimated in terms of the rate of 
change of immune correlates. 
Estimates of effectiveness and cost-effectiveness are particularly sensitive to assumptions regarding the interaction 
between vaccination and naturally acquired immunity – an area that remains poorly understood. The consequences 
of delaying the acquisition of immunity could be most severe in high transmission settings, with reduced levels of 
clinical immunity in vaccinated children leading to a rebound effect with increased incidence of clinical malaria after 
vaccine efficacy has waned. The possibility of a rebound effect in vaccinated children has been suggested before 
[361, 362], although fortunately no such effect has been observed so far, despite some evidence for a reduced 
blood-stage antibody response in young children [330]. However an increase in incidence of clinical malaria has been 
detected in a trial of seasonal malaria chemoprophylaxis in young Ghanaian children in the post intervention period 
[363]. Trials of RTS,S have been undertaken across sites of varying transmission intensities, but not in areas of very 
high transmission in the absence of other malaria control interventions. Although model simulations can provide 
estimates of the outcome of vaccination in high transmission settings, they are no substitute for results from well 
conducted trials.  
The model of cost-effectiveness utilised in this analysis has a number of limitations. Incidence of severe malaria and 
malaria associated deaths are assumed to be proportional to incidence of clinical malaria, however it has long been 
recognised that immunity to severe malaria is acquired at a faster rate than immunity to clinical malaria [55]. Future 
iterations of the transmission model will incorporate the acquisition of immunity to severe malaria [57, 63], allowing 
more accurate estimation of the incidence of severe malaria and its associated costs. 
At present model estimates of the cost-effectiveness of vaccination are dependent on the assumed cost per dose of 
vaccine. In this analysis we assumed a cost of USD 5.00 (range 2.00 – 10.00) per dose, the same as Maire et al’s [178] 
estimate, although we have chosen more conservative values for the biological parameters describing efficacy and 
duration of protection. To date there have been no indications of the cost per dose of RTS,S, although 
GlaxoSmithKline have declared that the vaccine will be sold at a price of 5% above the cost of manufacture [364]. 
Until the time when the cost per dose of RTS,S is known, cost-effectiveness models will not be able to estimate the 
cost-effectiveness of vaccines, but they will be able to identify transmission settings and age groups where 
vaccination has the highest probability of being cost-effective. 
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When evaluating the cost-effectiveness of vaccination with RTS,S it is important to consider the interaction with 
other malaria control interventions, in particular bed nets. We found that vaccination combined with LLINs was less 
cost-effective per DALY averted than vaccination alone, except in regions of high transmission intensity. Our 
approach to estimating the cost-effectiveness of vaccines combined with LLINs was conservative, as only the 
episodes of malaria averted by vaccination in addition to those averted by LLINs were included in the DALY 
calculations, that is, we compared the combined package of vaccines and LLINs to the baseline of just LLINs. An 
alternative approach would be to compare the combined package of vaccines and LLINs to a baseline of no 
intervention, and then split the benefits of the intervention package according to the effectiveness of each individual 
intervention. This would lead to a higher estimate of the cost-effectiveness of vaccines as some of the averted DALYs 
attributed to LLINs would be attributed to vaccines. In addition, our analysis may underestimate cost-effectiveness 
as the simple decision tree model does not consider potential economies of scope  achievable through delivery of 
LLINs through the EPI system [365]. 
The combination of a model of the dynamics of malaria transmission and a decision tree for estimating costs has a 
number of advantages over models of cost-effectiveness using decision tress alone such as those described by 
Goodman et al [358], Morel et al [366], and the Lives Saved Tool (LiST model) [367, 368]. Transmission models can 
account for changes in transmission intensity and population-level immunity due to the effects of the intervention 
under evaluation, indirect benefits to those not receiving the intervention due to the mass effect, and the 
interaction between multiple interventions. 
 
7.5. Conclusion 
The effectiveness and cost-effectiveness of vaccination with RTS,S/AS01 will depend on the transmission intensity of 
P. falciparum malaria and the coverage of other malaria control interventions, most notably insecticide treated nets. 
Model estimates of cost-effectiveness will be dependent on assumptions regarding key knowledge gaps, in particular 
the duration of vaccine-induced protection, the interaction with naturally acquired immunity, and the cost per dose 
of vaccine. Despite these limitations, we estimate that RTS,S/AS01 delivered through the Expanded Program on 
Immunisation, across a range of transmission settings, can be cost-effective when compared to a range of ceiling 
ratios.  
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Chapter 8. Discussion 
 
Malaria vaccines: where malaria meets vaccines 
The much-welcomed progress in the malaria vaccine development effort has thrust a number of challenging 
problems onto the research agendas of such diverse fields as immunology, clinical trials, malaria epidemiology, 
vaccine logistics and health economics. Addressing these challenges requires bringing together the previously 
disjoint spheres of malariology and vaccinology. Throughout this thesis I have used mathematical models as tools to 
investigate a number of the problems that need to be tackled as part of the wider malaria vaccine development 
effort. 
 
8.1. Summary of findings 
 
In Chapter 2, I investigated the effects of unaccounted for heterogeneity in exposure and vaccine response on the 
interpretation of results from clinical trials of malaria vaccines. I demonstrated that heterogeneity in exposure, when 
some people are bitten more frequently than others, can cause vaccine efficacy to be underestimated in clinical field 
trials. In contrast, heterogeneity in vaccine response, where some vaccinees receive a higher level of protection than 
others, can cause vaccine efficacy to be overestimated. The possibility of waning vaccine efficacy poses an additional 
problem when analysing results from clinical trials. A reduction in observed vaccine efficacy over time could be due 
to decay of vaccine-induced immune responses, differential acquisition of immunity in the vaccine and control 
cohorts, or a consequence of the effects of heterogeneity in exposure. 
Most of the malaria vaccines currently undergoing clinical development rely on boosting some element of the 
naturally acquired pre-erythrocytic immune response [104]. However, the association between markers of pre-
erythrocytic immunity and protection from infection remains poorly understood. To address this knowledge gap, I 
undertook a systematic review of the published literature which is described in Chapter 3. A potential reason for the 
lack of consensus on the effect of the pre-erythrocytic immune response is that trials to evaluate the association 
between markers of the pre-erythrocytic immunity and protection from infection have been underpowered to 
detect statistically significant effects. By analysing existing published studies, I identified a number of factors which 
can improve the power of a study, namely, increasing the size of the study, performing longitudinal follow-up, 
analysing immune response data as a continuous as opposed to a binary variable, and using Cox proportional 
hazards for statistical analysis. 
Conventional statistical tests such as Cox proportional hazards or logistic regression are somewhat limited tools for 
investigating the association between markers of pre-erythrocytic immunity and protection from infection as they do 
not naturally account for non-linear effects such as thresholds for protection [231]. In Chapter 4 I used a 
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mathematical model based on dose-response curves to estimate the association between antibodies to the pre-
erythrocytic antigens CSP, TRAP and LSA-1 and protection from infection in a cohort Kenyan adults under natural 
exposure to P. falciparum infection [237]. Using the dose-response curves for naturally acquired pre-erythrocytic 
antibodies I estimated that a vaccine that boosts anti-CSP antibodies in adults is likely to prevent approximately 50% 
of infections. The addition of a TRAP component to a CSP-based vaccine is estimated to increase infection-blocking 
vaccine efficacy to approximately 75%. 
In Chapter 5, using data from an artificial challenge study of RTS,S in malaria-naïve adults [129], I investigated the 
association between vaccine-induced anti-CSP antibodies and CSP-specific CD4+ T cells and protection from infection. 
In the cohort under investigation, 50% (95% CI, 33% - 67%) and 32% (95% CI, 18% - 48%) of volunteers vaccinated 
with RTS,S/AS01 and RTS,S/AS02, respectively, were protected from infection. Mathematical models based on dose-
response curves suggest that approximately 2/3 of this protection is attributable to vaccine-induced anti-CSP 
antibodies and 1/3 to CSP-specific T cells. Using a within-host model of the pre-erythrocytic stages of P. falciparum 
infection I estimated that vaccination with RTS,S causes a 97.7% (95% CI, 96.3% – 98/7%) reduction in the number of 
parasites entering the blood stream from the liver. 
In Chapter 6, I extended my focus beyond static measures of immunity to consider the dynamics of antibody 
responses under natural exposure to malaria. Simple models of antibody kinetics and the underlying cellular 
processes responsible for antibody generation were developed and fitted to longitudinal data from cohorts of young 
Ghanaian and Gambian children [303, 311].  In the models of antibody kinetics it was assumed that antibody is 
generated by populations of short-lived and long-lived antibody secreting cells (ASC). In the younger Ghanaian 
cohort, 2% – 11% of ASCs generated following exposure to P. falciparum antigens were estimated to be long-lived, 
with a half-life of 303 – 469 days. In contrast, the older Gambian children were estimated to produce a larger 
proportion of long-lived cells (13% – 26%) with a half-life of 374 – 503 days, suggesting age dependent development 
of the antibody response to malaria infection. 
In Chapter 7, I used a previously published mathematical model of malaria transmission [63] to estimate the 
effectiveness and cost-effectiveness of vaccination with RTS,S/AS01. I demonstrated that model predictions of the 
long term impact of vaccination are dependent on assumptions regarding the interaction between vaccination and 
naturally acquired immunity. In particular, if vaccination reduces the rate of acquisition of immunity there is the 
potential of a rebound effect with vaccinated children experiencing a higher incidence of clinical malaria than 
unvaccinated children. However, if a rebound effect does occur it is likely to be in older children experiencing a 
lower incidence of clinical malaria. We estimated that delivery of RTS,S/AS01 through the expanded program on 
immunisation will be most effective at moderate transmission settings (EIR ≈ 10 ibppy). When combined with 
widespread distribution of LLINs, vaccination is estimated to be most effective in regions of higher baseline 
transmission intensity (EIR ≈ 50 ibppy).  
Although estimates of the cost-effectiveness of vaccination are entirely dependent on the assumed cost per dose of 
vaccine, it is still useful to identify the scenarios where vaccination has the highest probability of being cost-effective. 
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With an average cost per dose of USD 5.00, RTS,S/AS01 delivered through the EPI was estimated to be significantly 
less cost-effective than mass distribution of LLINs with an estimated ICER per DALY averted of USD 253 (95% 
sampling interval (SI), 93 – 696) for vaccines compared to USD 33 (95% SI, 5.50 – 140) for LLINs at moderate 
transmission intensities.      
 
8.2. Limitations of methods and results 
 
The results presented throughout this thesis must be interpreted in terms of the underlying data and the methods 
used for data analysis. A lack of critical assessment of the limitations of the data and models can lead to results being 
over-interpreted. A discussion of some of the limitations of the data and models used to produce the results in each 
of the chapters of this thesis is presented below. 
 
8.2.1. Limitations of Chapter 2 
The findings in Chapter 2 that heterogeneity in malaria exposure and vaccine response can cause estimates of 
vaccine efficacy from Phase II/III field trials to be underestimated or overestimated, respectively, is not based on trial 
data but rather on a theoretical model of a vaccine trial carried out with a treatment re-infection study design. This 
model makes a number of assumptions: each individual is subjected to a constant, non-seasonal force of infection, 
and that all infections are detected immediately with perfect sensitivity and specificity. 
The simulated examples in Chapter 2 consider the effects of heterogeneity in exposure and vaccine response 
separately. In reality, we would expect both of these sources of heterogeneity to act at the same time as well as 
waning of efficacy. Finally, the findings of Chapter 2 are most robust when infection with malaria is the endpoint of 
interest, and not episodes of clinical malaria which is the primary endpoint in the ongoing Phase III trial of 
RTS,S/AS01 [15]. 
 
8.2.2. Limitations of Chapter 3 
The review in Chapter 3 of the association between markers of pre-erythrocytic immunity and protection from 
infection or clinical malaria was undertaken using a systematic search of the published literature. Using the full 
methodology of a systematic review would no doubt improve the quality of the gathered evidence. Although based 
on metrics used with success in clinical medicine [229], the Power Score devised for assessing quality of evidence 
from a study is somewhat arbitrary, as its components were manually selected. Despite this drawback, the Power 
Score still succeeds in giving an approximate measure of a study’s power to detect an effect of a pre-erythrocytic 
immune response.  
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Simulations of treatment re-infection trials were undertaken using a model where probability of infection was 
dependent on pre-erythrocytic antibody titre according to an exponential dose-response curve. Although the exact 
outcome of these simulations is dependent on model assumptions for the dose-response relationship between 
antibody titre and protection from infection, they still give qualitative insights for the interpretation of the results of 
studies for evaluating the effects of pre-erythrocytic immune responses. In the model simulations we assumed that 
there was a true association between antibodies and protection from infection. We did not consider the ‘inverse’ 
problem whereby an antibody with no true association with protection from infection may appear significantly 
correlated with protection. Furthermore, we did not explicitly consider the role that antibodies may play as markers 
for exposure. 
 
8.2.3. Limitations of Chapter 4 
In Chapter 4, data on antibody titres and time to detection of P. falciparum parasites from a study of Kenyan adults 
[237] was combined with a model of the relationship between antibody titres and probability of infection to 
estimate the efficacy of antibody-mediated malaria vaccines. Firstly, the results are dependent on the data used. 
Antibodies to the pre-erythrocytic antigens CSP, TRAP and LSA-1 were measured before follow-up of volunteers, 
thus in this dataset it is only possible to measure associations between these three antibodies and protection. If 
there is significant correlation between different arms of the immune response, and if protection from infection is 
really mediated by cellular or early blood-stage immune responses, then this combination of data and model could 
result in misleading conclusions. 
Secondly, the results are dependent on the choice of model. The model for estimating vaccine efficacy as a function 
of antibody titre makes the assumption that the dose-response relationship between naturally-acquired antibodies 
and protection from infection is the same as that between vaccine-induced antibodies and protection from infection. 
Furthermore, the prediction of vaccine efficacy at high antibody titres assumes that the dose-response curves 
estimated at low naturally-acquired antibody titres can be extrapolated to higher vaccine-induced antibody titres. 
 
8.2.4. Limitations of Chapter 5 
In Chapter 5, a mechanistic model of sporozoite infection was combined with data from a Phase II challenge trial of 
the RTS,S/AS01 and RTS,S/AS02 malaria vaccines [129] to investigate the association between vaccine-induced 
immune responses and protection from infection. The model assumes that each sporozoite successfully developing 
within the liver releases an average number of 20,000 merozoites into the blood stream, an estimate derived from 
observations of cross-sections of the livers of chimpanzees infected with P. falciparum [28]. Revised model 
formulations will allow the number of merozoites per sporozoite to be fitted to the data as there is likely to be 
correlation between the mean number of inoculated sporozoites and the number of merozoites per sporozoite. 
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In addition, infection is assumed to be detected only once blood-stage parasites increase to densities where they can 
be detected by slide microscopy. This density was assumed to be 50 million parasites/mL based on studies by Bejon 
et al [295]. Variation in either threshold for detection of parasites by microscopy or the parasite multiplication rate 
per generation [369] will lead to variation in the estimated number of parasites emerging from the liver. More 
frequent measurements of parasite density using quantitative PCR (which has a sensitivity of 20 parasites/mL) would 
provide valuable additional data. 
A number of markers for the vaccine-induced cell-mediated immune response were available in the dataset: CSP-
specific CD4+ T cells producing the cytokines TNF-α, IL-2, IFN-γ and the co-stimulatory molecule CD40L, or CSP-
specific CD4+ T cells producing at least two cytokines. A more detailed analysis would include combinations of 
multiple markers of cell-mediated immunity, vaccine-induced anti-CSP antibody titres and protection from infection.    
 
8.2.5. Limitations of Chapter 6 
In Chapter 6 mathematical models of the immunological process underlying the generation of IgG antibody were 
developed and fitted to data from two longitudinal cohorts of African children exposed to malaria. The models were 
fitted using mixed effects methods within a Bayesian framework with Markov Chain Monte Carlo sampling of 
parameter space. The advantage of this method is that it uses all of the data to produce estimates of the mean 
values of parameters determining the duration of antibody response across the cohort of children, and the naturally 
occurring variation between children. Alternative approaches to model fitting would be to fit one set of global 
parameters to the data from all children together, or to fit a set of local parameters to each child separately.  
There are a number of drawbacks to using mixed effects methods for model fitting, the first being the computational 
expense as large numbers of parameter updates are needed to explore the full parameter space. Secondly, mixed 
effects models are composed of two components: the model of antibody kinetics for each child, and the model for 
the distribution of the mixed effects parameters. For quantities such as half-lives which must take on positive values, 
we assume a Log-Normal distribution, and for the proportion of short-lived ASCs we assume a Logit-Normal 
distribution. A poor choice of distribution for the mixed effects parameters will result in a low likelihood. 
As the likelihood of a mixed effects model is comprised of two components, direct model comparison with 
likelihoods is difficult, as we will be comparing the combined likelihood of antibody kinetics model plus mixed effects 
model, and not just the likelihood of the antibody kinetics model. Furthermore, as the number of parameter to be 
estimated in mixed effects models is poorly defined [315], estimates of the Akaike Information Criterion must be 
interpreted with caution. An alternative approach to model comparison would be to take advantage of the fact that 
the models are nested and calculate the probability that a model reduces to a sub-model. 
 
157 
 
8.2.6. Limitations of Chapter 7 
In Chapter 7 the effectiveness and cost-effectiveness of vaccination with RTS,S/AS01 in combination with ITNs was 
investigated using a previously published model of malaria transmission [63]. There are three key knowledge gaps 
which will contribute to the uncertainty of model estimates of the impact of vaccination programmes. The first is the 
cost per dose of vaccine. Until GlaxoSmithKline make a public statement of the likely cost per dose there is very little 
we can do to capture the uncertainty in price other than assume a wide range for the cost per dose of vaccine in the 
sensitivity analysis. Secondly, there is uncertainty in the duration of protection provided by RTS,S/AS01  with no 
estimates of half-life published to date. We assume vaccine efficacy decays with a half-life of 5 years. A more 
detailed sensitivity analysis could explore the effect of varying half-life in the range 1 – 10 years. Another major 
source of uncertainty, and perhaps the hardest to quantify, is the interaction between vaccination and naturally-
acquired immunity. A particular concern has been the potential for a rebound effect whereby vaccinated children 
experience a higher incidence of clinical malaria after vaccine efficacy has waned. In Chapter 7 we considered a 
number of potential scenarios for the interaction between vaccination and the acquisition of immunity. An 
alternative approach would be to use an ensemble of models with different assumptions about the effect of 
vaccination on immunity [171]. 
Although a sensitivity analysis was performed, a potential drawback is that only the uncertainties appearing in the 
decision tree in Figure 7.1. are accounted for, and not the uncertainties in the underlying transmission model. In the 
current model formulation, episodes of severe malaria and death are estimated from the decision tree. The 
parameters for probability of severe malaria are taken from a small number of studies [350, 358]. A more detailed 
sensitivity analysis would consider a wider range of probabilities of progression to severe malaria as provided by 
surveys of expert opinion [370]. Future formulations of the malaria transmission model under development at 
Imperial College will include acquisition of immunity to severe malaria, thus partially bypassing the need to depend 
on expert opinion or estimates from a single study site.      
 
8.3. Implications of research 
 
Many of the methods outlined and results presented in this thesis may have implications for the analysis of the large 
amount of epidemiological, clinical and immunological data being generated by Phase II and Phase III trials of the 
RTS,S malaria vaccine. Given the importance and cost of such large scale clinical trials, it is vital that data is analysed 
so as to produce useful, accurate and unbiased results. A number of steps can be taken to address the possibility of 
heterogeneity in exposure introducing bias to estimates of vaccine efficacy identified in Chapter 2 and the associated 
publication [344].  In a pooled analysis of extended follow-up data from seven Phase II field trials of RTS,S (P. Bejon, 
M. White et al – in preparation), time to event data was analysed using Cox proportional hazards analysis with a 
fitted gamma frailty to account for heterogeneity in exposure.  
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The results of Chapter 5 indicate that RTS,S has a protection profile intermediate between that of a leaky and an all-
or-nothing vaccine, in agreement with the results of extended follow up of Phase II field trials [118, 134]. Both 
vaccine-induced anti-CSP antibodies and CSP-specific CD4+ T cells are strongly associated with protection from 
infection, however, the factors determining the magnitude of vaccine-induced immune responses remain poorly 
understood.  The choice of adjuvant has a well established relationship with vaccine immunogenicity [287], but other 
factors determining immunogenicity such as age, prior exposure and boosting regimen remain poorly understood. 
In the Phase II artificial challenge trial of RTS,S a highly protected subset of volunteers with high levels of anti-CSP 
antibodies and CSP-specific T cells was identified. This suggests that if the immunogenicity of adjuvanted RTS,S can 
be improved, then efficacy against infection can be substantially increased. A collaborative project between 
GlaxoSmithKline and Crucell Holland BV  is currently underway for evaluation of the safety, immunogenicity and 
efficacy of a prime-boost combination vaccine with priming with an adenovirus 35-CSP vaccine followed by boosting 
with RTS,S/AS01 [371]. This combination vaccine has been demonstrated to be significantly more immunogenic than 
RTS,S/AS01 alone in rhesus macaques, inducing high levels of CSP-specific T cells [372]. If this finding can be 
replicated in humans, such that the vaccine-induced immune responses in people receiving the combination vaccine 
are comparable to those on the higher end of the spectrum of RTS,S/AS01 induced responses, then vaccine efficacy 
against infection in excess of 70% may be achievable. 
An alternative route to increasing the efficacy of RTS,S-based vaccines could be the addition of other pre-
erythrocytic or blood-stage antigens to form a multi-component vaccine [284]. Our analysis of the relationship 
between naturally acquired anti-CSP and anti-TRAP antibodies and protection from infection in Chapter 4 suggests 
that the addition of a TRAP component to RTS,S/AS01 may be a worthwhile approach. A combination 
TRAP/RTS,S/AS02 vaccine has already been trialled in a small number of volunteers but failed to provide any 
protection from infection, possibly due to poor presentation of the TRAP antigen [280]. Combining RTS,S with blood-
stage antigens is unlikely to lead to improvements in infection-blocking efficacy but may cause substantial increases 
in efficacy against clinical malaria. A recent trial of FMP2.1/AS02, a vaccine comprised of a recombinant protein 
based on AMA1 and the AS02 adjuvant demonstrated 17.4% efficacy against episodes of clinical malaria, and 64.3% 
efficacy against clinical malaria caused by parasites with AMA1 corresponding to that of the vaccine strain [107]. This 
result suggests that the combination of RTS,S with blood-stage antigens may be a fruitful approach.  
In many studies of the relationship between vaccine-induced immune responses and protection from infection, 
immune responses are assumed to be constant over time [118]. In reality vaccine-induced immune responses will 
decay over time [279], possibly with an associated change in protection. Mathematical models can be used to help 
understand the kinetics of vaccine-induced immune responses. This could be especially useful when evaluating 
changes in immune responses following the booster dose of RTS,S/AS01 that is to be administered to participants in 
Phase III trials 18 months after the third dose [15].  
Mathematical models provide a convenient framework within which to evaluate the effectiveness of vaccination 
campaigns, however they can’t work magic as there are some knowledge gaps which models just can’t bridge 
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without making strong assumptions. Two key knowledge gaps encountered by models of the effects of malaria 
vaccination are the duration of vaccine-induced protection, and the interaction with naturally acquired immunity. 
However models can be used to test various assumptions, and hence aid in the design of experiments or statistical 
tests.  
 
8.4. Conclusion 
 
The long wait for an effective malaria vaccine is almost over, and although many problems in the intersection of 
malariology and vaccinology have been solved by groups from across the world, many problems and knowledge gaps 
remain. Throughout this thesis, I have attempted to contribute to the understanding of several of these problems 
ranging from the interpretation of clinical trial results, to vaccine immunology to the effectiveness of vaccination 
campaigns. There are however many remaining questions which have no easy answers. Will a vaccine that prevents 
approximately one half of clinical episodes malaria be good enough, and will its effects last for long enough? How 
much will it cost and who should pay? Will it even matter against the rapidly changing landscape of malaria control 
where we have seen massive reductions in morbidity and mortality across the globe? Despite these reservations, the 
RTS,S malaria vaccine is set to have completed Phase III clinical trials by 2015, after which important decisions on 
vaccine deployment will need to be made by both scientists and policy makers. 
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